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Dissertation  Advisor:  Professor  John  Quackenbush   Jarupon  Fah  Sathirapongsasuti  
Post-­‐‑Genomic  Approaches  to  Personalized  Medicine:    
Applications  in  Exome  Sequencing,  Microbiome,  and  COPD  
Abstract  
Since  the  completion  of  the  sequencing  of  the  human  genome  at  the  turn  of  the  century,  
genomics  has  revolutionized  the  study  of  biology  and  medicine  by  providing  high-­‐‑throughput  
and  quantitative  methods  for  measuring  molecular  activities.  Microarray  and  next  generation  
sequencing  emerged  as  important  inflection  points  where  the  rate  of  data  generation  
skyrocketed.  The  high  dimensionality  nature  and  the  rapid  growth  in  the  volume  of  data  
precipitated  a  unique  computational  challenge  in  massive  data  analysis  and  interpretation.  
Noise  and  signal  structure  in  the  data  varies  significantly  across  types  of  data  and  technologies;  
thus,  the  context  of  the  data  generation  process  itself  plays  an  important  role  in  detecting  key  
and  oftentimes  subtle  signals.  In  this  dissertation,  we  discuss  four  areas  where  contextualizing  
the  data  aids  discoveries  of  disease-­‐‑causing  variants,  complex  relationships  in  the  human  
microecology,  interplay  between  gene  and  environment,  and  genetic  regulation  of  gene  
expression.    These  studies,  each  in  its  own  unique  way,  have  helped  made  possible  discoveries  
and  expanded  the  horizon  of  our  understanding  of  the  human  body,  in  health  and  disease.  
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Chapter  1:  Introduction  
Background 
The  past  decade  has  seen  the  power  of  genomics  for  biomedical  research.    The  
greatest  impact  of  genomics  has  been  the  ability  to  study  biological  system  in  a  
comprehensive,  unbiased,  hypothesis-­‐‑free  manner.    In  the  study  of  disease,  genomic  
technologies  enable  a  systematic  approach  to  discover  the  genes  and  cellular  pathways  
underlying  disease.    To  date,  the  genomic  approach  has  resulted  in  the  identification  of  
over  2,850  genes  underlying  Mendelian  diseases,  over  1,100  loci  affecting  common  
disorders,  and  hundreds  of  carcinogenic  somatic  mutations  [1].      
The  high-­‐‑throughput  nature  of  genomic  technologies  has  enabled  large-­‐‑scale  
interrogations  of  the  biology  of  genome  and  of  disease.    Several  genetic  epidemiological  
studies  now  include  hundreds,  if  not  thousands,  of  subjects.  The  speed  and  cost  of  
sequencing  technologies  has  been  a  key  driver  of  this  revolution.    As  shown  in  Figure  
1.1,  the  cost  per  base  and  per  genome  of  sequencing  has  dramatically  and  steadily  
dropped  from  over  a  hundred  million  dollars  to  a  few  thousand  dollars1.    As  a  result,  the  
amount  of  genomic  data  produced  has  exponentiated  to  a  point  where  the  bottleneck  is  
analysis  and  interpretation—a  problem  sometimes  called  “the  $1,000  genome,  the  
                                                                                                              
1  http://www.genome.gov/sequencingcosts/  
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$100,000  analysis  [2].”    Thus  efficient  computational  and  statistical  analysis  methods  are  
critical  in  harnessing  the  full  power  and  promise  of  genomic  technologies.  
Through  a  common  platform  of  sequencing  technologies,  many  types  of  genomic  
information  can  be  generated,  for  example  gene  expression,  epigenetic  markings,  DNA  
point  mutations,  structural  variations,  and  microbial  compositions.    With  the  richness  of  
data  types  comes  complexity.    Although  generated  by  a  common  sequencing  platform,  
analyzing  and  interpreting  these  data  often  require  specialized  methods.    This  is  
primarily  because  each  type  of  genomic  data  possesses  unique  signal  and  noise  
characteristics.    In  this  dissertation,  we  explored  unique  characteristic  of  several  types  of  
genomics  data  and  developed  approaches  to  extract  information  and  understanding  
from  them.    The  four  application  areas  are:  exome  sequencing-­‐‑based  copy  number  
variation  detection,  microbial  co-­‐‑occurrence  network  in  the  human  microbiome,  sexual  
dimorphism  in  chronic  obstructive  pulmonary  disease  (COPD),  and  bicluster-­‐‑based  
error  rate  control  procedure  for  expression  quantitative  trait  loci  (eQTL)  analysis.  
     
   3  
A.     
B.     
Figure  1.1:  Reduction  in  sequencing  cost  (A)  per  megabase  and  (B)  per  genome.  
Technology  developments  that  keep  up  with  Moore’s  law  are  considered  to  be  doing  
exceedingly  well.    The  sudden  out-­‐‑pacing  in  2008  corresponds  to  the  transition  from  
Sanger  sequencing  to  next-­‐‑generation  sequencing  technologies.    Source:  
www.genome.gov/sequencingcosts/  
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ExomeCNV:  Exome  Sequencing-­‐‑Based  Copy  Number  Variation  and  Loss  of  
Heterozygosity  Detection  
Exome  sequencing  is  a  strategy  to  selectively  sequence  the  coding  regions  of  the  
genome  as  a  low-­‐‑cost  yet  effective  alternative  to  whole  genome  sequencing.    We  are  
interested  in  detecting  structural  variation,  which  is  a  class  of  large-­‐‑scale  mutation  
commonly  found  in  cancer  genomes.    The  target  enrichment  step  in  the  library  
preparation  process  substantially  biases  the  sequencing  information.    In  addition  to  the  
technical  noise,  heterogeneity  of  the  sample  introduces  an  additional  layer  of  bias.    In  
Chapter  2,  we  detail  the  problems  and  developed  ExomeCNV,  a  structural  variation  
detection  method  that  accounts  for  characteristic  biases  in  exome  sequencing  data.  
Co-­‐‑Occurrence  Relationships  in  the  Human  Microbiome  
The  interplay  between  microbes  and  human  health  has  recently  gained  attention  
in  the  biomedical  field.  The  advancement  in  sequencing  technology  allows  us  to  
interrogate  microbial  composition  of  micro-­‐‑communities  in  the  context  of  human  hosts.    
We  are  interested  in  studying  the  patterns  of  co-­‐‑occurrence  and  co-­‐‑exclusion  between  
microbes.    Assessing  correlation  between  such  compositional  data  turned  out  to  be  quite  
challenging.    As  the  individual  components  in  a  compositional  data  have  to  add  up  to  
one,  spurious  correlation  may  arise  as  a  result  of  normalization.    We  developed  a  
method  called  ReBoot,  which  mitigated  this  compositional  effect  and  aided  discovery  of  
microbial  interactions  in  healthy  human  microbiome.    We  discussed  in  Chapter  3  the  
challenges  and  methods  that  might  help  overcome  the  spurious  correlation  problem.  
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Integrative  Genomics  of  Sexual  Dimorphism  in  COPD  
Chronic  obstructive  pulmonary  disease  (COPD)  is  the  third  leading  cause  of  
death  in  the  US.    The  number  of  women  dying  of  the  disease  has  been  increasing  
drastically  over  the  last  twenty  years  and  now  surpasses  that  of  men.    An  cumulating  
body  of  evidence  suggests  that  women  may  be  biologically  more  susceptible  to  COPD.    
However,  no  study  has  done  a  systematic  screen  of  genes  or  pathways  that  are  
differentially  expressed  between  genders.  Using  a  unique  set  of  data  from  Lung  
Genomics  Research  Consortium,  we  developed  the  sexual  dimorphic  and  COPD  
differential  (SDCD)  analysis,  a  stratification  analysis  that  highlights  the  elusive  sexual  
dimorphic  effects  in  gene  expression  data.    Chapter  4  discusses  the  methods  and  
findings  of  this  work.  
BBER:  Bicluster-­‐‑Based  Error  Rate  Control  for  eQTL  Analysis  
The  availability  of  multiple  genomic  data  types  enables  integrative  approaches  
that  reveal  correlation  information  across  data  types.    Correlating  genotypes  and  gene  
expression  data,  or  expression  quantitative  trait  loci  (eQTL)  analysis,  shed  light  on  the  
genetic  regulation  of  gene  expression.    Because  of  the  ultra-­‐‑high  dimensional  nature  of  
eQTL  analysis,  multiple  hypotheses  testing  adjustment  is  very  critical  in  keeping  the  
number  of  false  positives  at  a  reasonable  rate.    Traditional  approaches  such  as  
Bonferroni  or  Benjamini-­‐‑Hochberg  procedures  assume  independence  between  tests,  but  
in  reality  genetic  markers  are  highly  correlated  and  the  eQTL  tests  are  rarely  
independent.    In  Chapter  5,  we  discussed  the  development  of  BBER  a  technique  to  
cluster  correlated  eQTL  tests  to  improve  sensitivity  of  the  eQTL  analysis.  
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Chapter  2:  Exome  Sequencing-­‐‑Based  Copy-­‐‑Number  Variation    
and  Loss  of  Heterozygosity  Detection:  ExomeCNV  
Abstract  
The  ability  to  detect  copy-­‐‑number  variation  (CNV)  and  loss  of  heterozygosity  (LOH)  
from  exome  sequencing  data  extends  the  utility  of  this  powerful  approach  that  has  mainly  been  
used  for  point  or  small  insertion/deletion  detection.  We  present  ExomeCNV,  a  statistical  
method  to  detect  CNV  and  LOH  using  depth-­‐‑of-­‐‑coverage  and  B-­‐‑allele  frequencies,  from  
mapped  short  sequence  reads,  and  we  assess  both  the  method’s  power  and  the  effects  of  
confounding  variables.    We  apply  our  method  to  a  cancer  exome  resequencing  dataset.    As  
expected,  accuracy  and  resolution  are  dependent  on  depth-­‐‑of-­‐‑coverage  and  capture  probe  
design.  
Introduction  
The  development  of  next-­‐‑generation  sequencing  has  enabled  routine  large-­‐‑scale  
resequencing  projects,  permitting  us  to  perform  increasingly  more  comprehensive  DNA  variant  
analysis.    However,  the  cost  and  analytical  complexity  of  sequencing  still  limit  the  number  of  
whole  genomes  that  can  be  sequenced  in  any  single  project  [1].    In  fact,  the  analysis  of  complete  
human  genome  sequence  often  interprets  DNA  alterations  in  protein  coding  regions  primarily.    
This  is  in  practice  a  reasonable  strategy  since  approximately  85%  of  the  disease-­‐‑causing  
mutations  are  found  in  the  coding  regions  or  canonical  splice  sites  [2].    Thus,  whole-­‐‑exome  
sequencing  presents  an  effective  alternative  to  whole-­‐‑genome  sequencing  and  provides  an  
unbiased,  cost-­‐‑effective,  and  time-­‐‑efficient  tool  for  the  study  of  the  genetic  basis  for  disease.    
        
     
   8  
Following  the  first  successful  application  of  whole-­‐‑exome  sequencing  in  re-­‐‑discovering  the  
cause  of  a  dominantly  inherited  rare  Mendelian  disorder  Freeman-­‐‑Sheldon  syndrome  [3],  a  
number  of  studies  have  reported  similar  successes  [4-­‐‑9].    Although  the  cost  of  both  genome  and  
exome  sequencing  continues  to  fall  at  a  rapid  pace,  whole-­‐‑exome  sequencing  has  a  number  of  
advantages,  including  a  lower  cost,  more  straight-­‐‑forward  data  analysis  and  interpretation,  and  
significantly  greater  depth  of  coverage  with  a  corresponding  overall  improvement  in  data  
quality.    Exome  sequencing  is  rapidly  becoming  a  fundamental  tool  for  genetic  and  functional  
genomic  research  laboratories  and  a  diagnostic  tool  in  clinics.    At  present  the  main  applications  
of  targeted  exonic  sequencing  is  for  the  determination  of  single  nucleotide  variants  (SNVs)  or  
small  indel  variants  but  not  structural  variation.  
Structural  variation,  especially  copy-­‐‑number  variation  (CNV)  or  loss  of  heterozygosity  
(LOH),  is  an  important  class  of  genetic  variability  in  Mendelian,  common  inherited  diseases,  
and  cancer  [10-­‐‑17].    As  is  true  of  SNVs,  there  are  population-­‐‑specific,  common  CNVs  and  rare,  
disease-­‐‑causing  CNVs  [18,19].    Many  large-­‐‑scale  projects  [20-­‐‑22]  and  technological  platforms  
[23,24]  have  been  devised  to  estimate  the  prevalence  and  impact  of  CNV.    Array  Comparative  
Genomic  Hybridization  (CGH)[23]  and  SNP  genotyping  arrays  have  been  widely  used  as  
standard  methods  to  detect  CNV  and  LOH.    However,  with  the  rapid  increase  in  genomic  and  
exomic  sequence,  there  is  growing  interest  in  the  use  of  these  data  to  detect  CNVs.  
While  methods  have  been  developed  for  CNV  estimation  in  whole-­‐‑genome  sequencing  
[25,26],  these  methods  make  key  assumptions  that  fail  to  hold  in  the  exome  sequencing  setting.    
For  example,  Yoon  et  al.  [26]  assumes  random,  unbiased  distribution  of  sequence  reads,  such  
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that  read  depth  can  be  modeled  as  a  normal  distribution  across  the  genome,  and  deviation  from  
the  background  indicates  the  presence  of  CNV.    This  random  read  distribution  assumption  
breaks  down  in  the  context  of  exome  capture  as  the  probes  have  variable  specificity  and  
efficiency  for  the  targeted  exonic  regions.    The  discrete  nature  of  exome  sequences  also  presents  
problems  to  existing  methods.    Many  whole-­‐‑genome  CNV  detection  tools  use  segmentation  
algorithms  that  assume  continuity  of  search  space  and  do  not  function  properly  when  given  
discontinuous  and  variable  length  exome  sequencing  data.    SegSeq  [25],  for  example,  merges  
windows  of  a  fixed  length  based  on  a  log-­‐‑ratio  difference  statistic.    Lastly,  because  exons  are  
generally  smaller  than  insert  sizes  for  paired-­‐‑end  sequencing  (200-­‐‑500  bp),  paired-­‐‑end  based  
CNV  detection  methods  are  not  generally  applicable  to  exome  data.  
Here  we  present  ExomeCNV,  which  uses  depth-­‐‑of-­‐‑coverage  and  B-­‐‑allele  frequencies  
from  mapped  short  sequence  reads  to  estimate  copy  number  variation  (Figure  2.1,  left  side)  and  
loss  of  heterozygosity  (Figure  2.1,  right  side).    We  describe  an  assessment  of  its  validity,  
sensitivity,  specificity,  and  limitations  through  an  analysis  of  a  melanoma  tumor  and  a  matched  
normal  sample.    Important  model  assumption  and  the  effect  of  important  confounding  factor  
such  as  sample  admixture  rate  are  also  considered.  
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Figure  2.1  Overview  of  ExomeCNV  analysis  workflows.  Two  workflows  are  present:  CNV  
detection  and  LOH  detection.  Each  involves  similar  steps  of  exon/position/segment-­‐‑wise  
CNV/LOH  calling,  Circular  Binary  Segmentation,  and  interval  merging.  User  inputs  and  
parameters  are  listed  at  each  step.  
Methods  
Correlation  of  Depth-­‐‑of-­‐‑Coverage  
To  plot  the  correlation  of  depth-­‐‑of-­‐‑coverage,  we  used  the  internal  exome  data  that  were  
captured  by  the  same  Agilent  SureSelect  Human  All  Exon  Kit  and  sequenced  on  the  Illumina  
GAIIx.    Samples  1  through  4  were  generated  by  2  lanes  of  76bp  single-­‐‑end  sequencing,  sample  5  
was  generated  by  3  lanes  of  76bp  single-­‐‑end  sequencing  and  sample  6  was  generated  by  1  lane  
of  76+76bp  paired-­‐‑end  sequencing.    For  each  sample,  the  average  depth-­‐‑of-­‐‑coverage  per  exon  
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was  normalized  by  dividing  the  average  coverage  by  the  overall  exome  average  coverage  and  
then,  the  normalized  depth-­‐‑of-­‐‑coverage  were  compared  between  15  pairs  of  samples.  
The  CNV  and  LOH  Detection  Algorithm  
Power  analysis  of  CNV  Detection  
Consider  an  exon  of  length  L,  let  X  and  Y  denote  the  numbers  of  reads,  each  of  length  w,  
mapped  within  the  exon  in  question  in  case  (e.g.  tumor)  and  control  (e.g.  matched  normal),  
respectively.    The  depth-­‐‑of-­‐‑coverage  is  then  Xw/L  and  Yw/L  for  case  and  control,  respectively.    
Although  we  discuss  our  method  in  terms  of  depth-­‐‑of-­‐‑coverage,  our  method  is  developed  in  
terms  of  the  count  statistics  X  and  Y.    Let  NX  and  NY  be  the  total  numbers  of  aligned  reads  in  
case  and  control,  respectively.    Define  the  read  count  ratio:  
𝑅 = 𝑋/𝑁!𝑌/𝑁! .  
We  divide  the  raw  counts  X  and  Y  by  the  total  number  of  reads  NX  and  NY  to  mitigate  
the  effect  of  overall  increase  in  local  counts  due  to  the  increase  in  total  depth-­‐‑of-­‐‑coverage.    
Finally,  we  adjust  the  ratio  so  that  the  exome-­‐‑wide  median  is  1.    Without  lost  of  generality,  we  
assume  NX  =  NY  and  reduce  R  =  X/Y.    Because  X  and  Y  follow  Poisson  distributions  with  
parameters  λX  and  λY,  respectively,  with  sufficient  depth-­‐‑of-­‐‑coverage  the  Poisson  distributions  
converge  to  a  normal  distribution  with  equal  means  and  variances:  N(λX,  λX)  and  N(λY,  λY).    
Under  the  null  hypothesis  of  no  CNV,  λX  =  λY,  and  under  the  alternative  hypothesis,  λX  =  ρλY  =  
ρλ.    ρ  indicates  the  copy-­‐‑number  ratio;  for  example,  ρ  =  0.5  for  deletion,  and  ρ  =  1.5  for  
duplication.    By  Geary-­‐‑Hinkley  transformation  [27-­‐‑29],  let  
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𝑡(𝜌) = 𝜇!𝑅 − 𝜇!𝜎!!𝑅! + 𝜎!! = 𝜆!𝑅 − 𝜆!𝜆!𝑅! + 𝜆! = 𝜆𝑅 − 𝜌𝜆𝜆𝑅! + 𝜌𝜆 = (𝑅 − 𝜌) 𝜆𝑅! + 𝜌 ,  
and  t(ρ)  follows  the  standard  normal  distribution.    Thus,  the  specificity  and  sensitivity  are  1  –  α  
and  1  –  β  where    
𝛼 = Φ 𝑡 11 − Φ 𝑡 1 if  𝜌 < 1,if  𝜌 ≥ 1   
𝛽 = 1 − Φ 𝑡 𝜌Φ 𝑡 𝜌 if  𝜌 < 1,if  𝜌 ≥ 1   
The  formulas  above  describe  the  achievable  specificity  and  sensitivity  of  a  given  cutoff  
ratio  R.    Considering  values  of  R  from  zero  to  infinity,  we  can  plot  the  receiver  operating  
characteristic  (ROC)  curve  (Appendix  2).    In  practice,  we  may  wish  to  identify  a  cutoff  r(ρ)  
which  yields  the  desired  minimum  specificity  and/or  sensitivity  for  testing  a  particular  copy-­‐‑
number  ratio  ρ  at  an  exon  with  certain  depth-­‐‑of-­‐‑coverage  and  length.    This  can  be  achieved  by  
solving  above  equations,  and  an  appropriate  cutoff  r(ρ)  can  be  chosen  from  a  set  of  solutions  to  
maximize  user-­‐‑selected  quantity  metrics  such  as  specificity,  sensitivity,  or  area  under  curve.  
In  the  presence  of  sample  admixture,  the  “true”  copy-­‐‑number  ratio  will  tend  to  1.    In  
particular,  if  a  fraction  c  of  the  tumor  sample  has  a  normal  copy-­‐‑number  (either  by  
contamination  of  normal  tissue  or  heterogeneity  within  the  tumor),  the  copy-­‐‑number  ratio  of  
this  admixed  sample  will  be  ρ’  =  c  +  ρ(1  –  c).    Thus,  in  heterogeneous  samples,  the  only  change  
to  the  method  described  above  is  the  replacement  of  ρ  by  ρ’.    The  admixture  rate  c  can  be  
estimated  from  data  by  back-­‐‑calculating  c  from  empirical  ρ’  in  LOH  regions  (see  Appendix  2).  
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Segmentation  and  Sequential  Merging  
We  used  the  circular  binary  segmentation  (CBS)  algorithm[30],  as  implemented  in  the  R  
package  DNAcopy  [31],  to  subdivide  the  genome  (exome).    For  each  segment  we  combined  the  
coverage  by  direct  sum,  and  used  mean  coverage  log  ratio  as  the  segment’s  log  ratio  log(R).    
Log  ratio  is  used  here  to  satisfy  the  input  requirement  of  CBS  algorithm.    CNV  call  proceeds  on  
each  segment  in  the  same  manner  as  described  above.  
In  order  to  achieve  the  most  sensitive  segmentation,  we  chose  to  start  CBS  with  
parameters  that  produce  a  large  number  of  small  segments,  call  CNV  on  the  segments,  and  
repeat  the  process  with  a  smaller  number  of  larger  segments.    We  then  merge  the  CNV  
segments  sequentially,  from  finest  segmentation  to  coarsest.    By  nature  of  CBS,  finer  segments  
are  contained  within  coarser  segments,  and  in  merging  step,  we  need  to  resolve  conflicting  
CNV  calls  between  finer  segments  within  a  larger  segment.    If  a  finer  (smaller)  segment  has  
sufficient  coverage  to  call  a  CNV  event,  the  call  persists.    However,  if  it  does  not  have  sufficient  
coverage  to  reject  the  null  hypothesis  (i.e.  not  being  called,  or  being  called  as  copy-­‐‑number  
neutral),  a  positive  CNV  call  in  a  larger  segment  overrides  the  negative  calls.    An  illustration  of  
this  sequential  merging  algorithm  is  given  in  the  Appendix  2.  
LOH  Detection  
First,  we  consider  all  polymorphic  positions  in  the  exome  of  the  control  sample,  and  for  
each  of  the  positions,  the  B-­‐‑allele  count  Bi  is  the  number  of  reads  with  non-­‐‑reference-­‐‑  or  B-­‐‑allele  
at  that  position.    For  a  polymorphic  position  i,  let  Ni  be  the  total  number  of  reads  mapped  to  
that  position  (i.e.  depth-­‐‑of-­‐‑coverage);  thus  the  B-­‐‑allele  count  Bi  follows  a  binomial  distribution  
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Binomial  (pi,  Ni).    A  binomial  that  rejects  the  null  hypothesis:  pi  =  0.5  can  be  used  to  detect  LOH  
at  each  polymorphic  position.  
Segmentation  is  done  using  CBS  algorithm  based  on  the  absolute  difference  in  B-­‐‑allele  
frequencies  |BAFi,case  –  BAFi,control|,  where  BAFi  =  Bi/Ni.    Within  each  segment,  based  on  the  
realization  that  B-­‐‑allele  frequencies  deviate  from  the  null  value  of  0.5  under  LOH,  an  F-­‐‑test  for  
equality  of  variance  is  used  to  detect  significance  increase  in  variance  of  BAFcase  from  that  of  
BAFcontrol  (other  statistics  were  also  considered,  see  Appendix  2).    Finally,  the  LOH  calls  are  
merged  sequentially  as  described  above.  
Exome  Sequencing  and  Data  Analysis  
Exome  Sequencing  
High  molecular  weight  whole  genomic  DNA  from  matched  skin  and  tumor  pair  
samples  of  a  melanoma  patient  were  sequenced  on  the  Illumina  Genome  Analyzer  (GAIIx).    The  
UCLA  Institutional  Review  Board  (IRB)  approved  the  collections  of  the  DNA  samples.    The  
libraries  were  generated  following  the  Agilent  SureSelect  Human  All  Exon  Kit  version  1.0.1  
protocol,  and  the  Illumina  Genome  Analyzer  (GAIIx)  flowcell  was  prepared  according  to  the  
manufacturer’s  protocol.    We  performed  three  and  four  lanes  of  single-­‐‑end  sequencing  for  each  
of  the  skin  and  tumor  samples,  respectively,  within  the  UCLA  Center  of  High-­‐‑throughput  
Biology  (CHTB).    The  base-­‐‑calling  was  performed  by  the  real  time  analysis  (RTA)  software  
(version  1.6)  provided  by  Illumina.  
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Sequence  Data  Analysis  
Novoalign  from  Novocraft  Short  Read  Alignment  Package  
(http://www.novocraft.com/index.html)  was  used  to  align  each  lane’s  QSEQ  file  to  the  reference  
genome.  Human  Genome  reference  sequence  (hg18,  March  2006,  build  36.1),  downloaded  from  
the  UCSC  genome  database  located  at  http://genome.ucsc.edu  and  mirrored  locally,  was  
indexed  using  novoindex  program  (–k  14  –s  3).  The  output  format  was  set  to  SAM  and  default  
settings  were  used  for  all  options.  Using  SAMtools  (http://samtools.sourceforge.net/),  the  SAM  
files  of  each  lane  were  converted  to  BAM  files,  sorted  and  merged  for  each  sample  and  potential  
PCR  duplicates  were  removed  using  Picard  (http://picard.sourceforge.net/)[32].  To  retrieve  the  
depth  of  coverage  information  of  each  base,  we  generated  a  PILEUP  file  for  each  sample  using  
SAMtools  and  calculated  the  average  coverage  per  capture  interval  using  a  custom  script.  Here,  
we  used  processed  BAM  files  that  were  used  to  call  the  single  nucleotide  variants  (SNVs)  while  
reducing  the  likelihood  of  using  spuriously  mismapped  reads  to  call  the  variants:  the  last  5  
bases  were  trimmed  and  only  the  reads  lacking  indels  were  retained  [33].  The  detailed  
description  of  the  mutational  landscape  of  this  tumor  sample  is  in  preparation.  
Genome-­‐‑wide  SNP  Genotyping  
Both  the  skin  and  the  tumor  samples  were  submitted  to  the  Southern  California  
Genotyping  Consortium  (SCGC)  at  UCLA  for  genotyping  on  the  Illumina  Omni-­‐‑1  Quad  
BeadChip,  which  consists  of  1,140,419  SNPs  (1,016,423  genotyping  probes  and  123,996  CNV  
probes)  distributed  across  the  genome.  The  Illumina  GenomeStudio  V2010.1  Genotyping  
Module  version  1.6.3  was  used  to  calculate  the  B-­‐‑allele  frequency  (BAF)  values  and  the  log  R  
ratio  (LRR)  for  each  probe  and  the  copy  number  aberration  (CNA)  and  loss  of  heterozygosity  
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(LOH)  of  the  autosomes  were  inferred  from  these  values  using  the  genoCN  R  package  [34].  The  
genoCNA  function  was  used  with  the  default  parameters.  
Copy-­‐‑Number  Analysis  using  ERDS  (Estimation  by  Read  Depth  with  SNVs)  
The  same  PILEUP  file  we  used  to  generate  the  average  coverage  per  capture  interval  
was  used  to  run  ERDS  [35].  The  SNV  file  that  is  required  by  ERDS  was  generated  by  using  
SAMtools  varFilter  tool  default  parameters  and  SVA  (Sequence  Variant  Analyzer)  snp_filter.pl  
script.  The  result  file  generated  by  ERDS  was  summarized  using  the  SVA  software  
(http://people.genome.duke.edu/~dg48/sva/index.php).  
Comparison  between  CNV  Calling  Methods  
In  assessing  performance  of  ExomeCNV,  we  used  all  mapped  exons  as  the  sample  space.    
CNV  calls  on  other  platforms  were  mapped  to  the  exons  and  compared  to  calls  by  ExomeCNV.    
Thus  specificity  is  the  proportion  of  copy-­‐‑neutral  exons  correctly  identified  by  ExomeCNV,  
while  sensitivity  is  the  proportion  of  amplified  (or  deleted)  exons  correctly  identified.    Similarly,  
LOH  performance  is  assessed  using  all  polymorphic  positions  as  the  sample  space.  
Results  
ExomeCNV  for  CNV  and  LOH  Detection  
ExomeCNV  uses  a  normalized  depth-­‐‑of-­‐‑coverage  ratio  approach  to  identify  CNV  and  
LOH  from  exome  sequencing  information  of  paired  case/control  samples  (for  example,  paired  
tumor/normal)  in  a  way  that  optimizes  sensitivity  and  specificity.    We  begin  by  assuming  that  
although  there  are  potentially  exon-­‐‑specific  biases  due  to  laboratory  capture  methods  and  
sequence-­‐‑specific  biases,  these  are  independent  of  sample  and  so  are  nearly  uniform  for  a  
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particular  exon  across  samples.    As  a  result,  simply  assessing  the  ratio  of  depth-­‐‑of-­‐‑coverage  of  
each  exon  reduces  such  bias  (see  Appendix  2).  
  
Figure  2.2  Correlation  of  Depth-­‐‑of-­‐‑Coverage  across  exome  sequencing  samples.    To  
demonstrate  the  consistency  of  capture  and  sequencing  efficiency  of  individual  exons  
represented  by  the  depth-­‐‑of-­‐‑coverage  per  exon,  the  normalized  individual  exon  coverage  in  all  
pairs  of  6  independent  exomes  were  plotted.  All  six  samples  were  captured  using  the  Agilent  
SureSelect  Human  All  Exon.  Samples  1-­‐‑5  had  mean  base  coverages  of  36~39X  as  a  result  of  2  
(samples  1-­‐‑4)  or  3  (sample  5)  lanes  of  GAIIx  single-­‐‑end  sequencing  per  sample.  Sample  6  had  
mean  base  coverage  of  60X  as  a  result  of  1  lane  of  GAIIx  paired-­‐‑end  sequencing  and  
demonstrates  substantially  different  biases  in  individual  exonic  depth-­‐‑of-­‐‑coverage.  
To  establish  validity  of  this  fundamental  assumption,  we  compared  depth-­‐‑of-­‐‑coverage  
of  exons  across  five  independent  samples  from  five  different  subjects  (Samples  1-­‐‑5  in  Figure  
2.2).    All  samples  were  captured  using  the  same  probe  set  (Agilent  SureSelect  Human  All  Exon  
G3362)  and  sequenced  at  mean  base  coverages  of  36-­‐‑39X  as  a  result  of  two  (Samples  1-­‐‑4)  or  
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three  (Sample  5)  lanes  of  GAIIx  single-­‐‑end  sequencing  per  sample  (see  Methods).    As  shown  in  
Figure  2.2,  a  high  correlation  was  observed  among  the  five  samples  (Pearson  correlation  0.908-­‐‑
0.975,  mean=0.947,  sd=0.027),  arguing  for  the  validity  of  our  assumption.      
  
Figure  2.3  Examples  of  the  power  of  ExomeCNV  to  detect  segmental  duplication,  deletion,  
and  LOH  based  on  an  analytical  calculation.    Power  is  plotted  relative  to  mean  depth-­‐‑of-­‐‑
coverage  in  the  genomic  segment,  setting  false  positive  to  1  per  genome  based  on  an  analytical  
model  of  genome-­‐‑wide  power  of  detection  at  different  window  sizes  (inset,  panel  a-­‐‑d).  
Windows  are  the  total  length  of  a  given  sequence  at  a  given  exon  or  the  sum  of  length  of  exons  
adjacent  to  each  other  in  the  genome.    The  effect  of  admixture  (rate  of  30%)  on  the  power  to  
detect  deletions  and  single  copy  duplications  are  shown  in  (c)  and  (d),  respectively.  Panel  (e)  
plots  the  power  of  LOH  detection  versus  depth-­‐‑of-­‐‑coverage  of  individual  polymorphic  position  
(single  base  pair)  with  variable  admixture  rates  (inset).  The  periodicity  of  the  power  curve  is  
due  to  discrete  nature  of  the  binomial  test.    The  35x  depth  of  coverage  is  chosen  because  it  is  a  
typical  minimal  average  depth  of  coverage  for  exome  sequencing  and  is  thus  a  conservative  
view  of  power  within  typical  exome  sequencing  datasets.  
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The  same  level  of  consistency  was  not  observed  when  single-­‐‑end  data  were  compared  
with  paired-­‐‑end  data  (Sample  6;  Pearson  correlation  0.855-­‐‑0.877,  mean=0.871,  sd=0.009)  due  to  
the  lack  of  independence  between  pairs  of  reads  in  paired-­‐‑end  data.    Thus,  care  must  be  taken  
to  ensure  consistency  of  library  preparation  and  sequencing  method  between  samples  used  in  
analysis.    Here,  all  of  our  analyses  used  exome  sequencing  data  from  a  melanoma  (Sample  5)  
and  a  matched  normal  skin,  both  processed  and  sequenced  in  the  same  manner  (see  Methods).  
Analytic  power  calculation  of  exonic  CNV  and  LOH  detection  
For  each  exon,  the  number  of  sequencing  reads  aligning  within  it  appears  to  follow  a  
Poisson  with  mean  directly  proportional  to  the  size  of  the  exon  and  the  copy-­‐‑number  (see  
Appendix  2),  but  assuming  that  we  have  sufficiently  deep  coverage,  we  can  approximate  this  by  
a  normal  distribution  with  mean  equal  to  variance.    We  apply  the  Geary-­‐‑Hinkley  
transformation  [27-­‐‑29],  which  converts  a  ratio  of  two  normally  distributed  variables  to  a  
standard  normal  distribution,  and  a  CNV  is  identified  by  a  significant  deviation  of  the  
transformed  ratio  from  the  null,  standard  normal  distribution  (see  Methods).    Allowing  only  
one  false  positive  per  genome,  we  analytically  determine  the  statistical  power  of  this  CNV  
detection  approach  for  different  depth-­‐‑of-­‐‑coverage,  and  the  results  are  shown  in  Figure  2.3A-­‐‑B.    
For  detecting  deletions,  95%  power  is  achieved  for  segments  of  size  500  bp  or  more  (Figure  
2.3A),  while  detection  of  a  single  copy  duplication  is  achieved  with  95%  power  for  segments  of  
size  1,000  bp  or  more  (Figure  2.3B)  with  a  mean  segmental  base  coverage  of  35x.    We  note  that  
the  power  of  the  method  improves  substantially  with  higher  depth-­‐‑of-­‐‑coverage,  and  an  
individual  exons  deletion/duplication  status  would  be  more  powerfully  observed  by  including  
additional  flanking  intronic  sequence  in  the  capture  probe  design.    Genomic  DNA  admixture,  as  
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expected,  diminishes  power,  but  even  with  35x  coverage  of  a  given  exon,  a  length  of  greater  
than  1000bp  is  observed  over  95%  of  the  time.    Exons  or  segments  captured  with  500bp  at  target  
sequence  are  observed  at  95%  power  only  with  greater  than  55x  base  coverage.    A  more  
thorough  consideration  of  specificity  and  receiver  operating  characteristic  (ROC)  curves  are  
produced  in  the  Appendix  2.  
To  estimate  LOH,  we  focused  on  the  non-­‐‑reference-­‐‑allele  or  “B-­‐‑allele”  frequency  (BAF)  
of  polymorphic  positions  in  the  sequenced  regions.    The  observed  B-­‐‑allele  count  at  a  
polymorphic  position  can  be  modeled  by  a  binomial  distribution  with  depth-­‐‑of-­‐‑coverage  as  
sample  size  and  the  probability  of  observing  a  B-­‐‑allele  proportional  to  the  B-­‐‑allele  copy-­‐‑number,  
which  is  equivalent  to  the  LOH  state.    Because  the  expected  value  of  BAF  at  a  normal  (non-­‐‑
LOH)  polymorphic  position  is  0.5,  a  significant  deviation  of  BAF  from  0.5  identifies  LOH.    With  
sufficient  depth-­‐‑of-­‐‑coverage,  LOH  can  be  detected  at  a  single  polymorphic  position.  
The  effect  of  sample  admixture  
The  specificity  and  sensitivity  of  this  CNV  detection  method  depends  not  only  on  the  
depth-­‐‑of-­‐‑coverage  but  also  the  rate  of  admixture,  whereby  non-­‐‑mutated  genomes  contaminate  
mutated  genomes  in  the  sampled  tissue/cells.    In  the  absence  of  admixture,  the  average  depth-­‐‑
of-­‐‑coverage  ratio  is  0.5  for  deletion,  1.5  for  one-­‐‑copy  duplication,  and  the  BAF  at  an  LOH  site  is  
either  0  or  1;  however,  in  cancer  biopsy  sequencing,  this  is  rarely  observed  in  practice  due  to  
admixture  with  normal  or  non-­‐‑mutated  tumor  cells.    Thus,  we  assess  the  effect  of  admixture  
ranging  from  10-­‐‑70%,  which  is  frequently  observed  in  tumor  samples  (Figure  2.3E).    With  
admixture,  the  depth-­‐‑of-­‐‑coverage  ratio  and  the  BAF  will  tend  to  the  null  values  of  1  and  0.5,  
        
     
   21  
respectively,  making  the  CNV  and  LOH  detection  harder.    Figure  2.3C-­‐‑D  show  a  reduction  of  
power  in  detecting  deletion  (c)  and  one-­‐‑copy  duplication  (d)  as  a  result  of  30%  admixture.    
There  is  an  approximate  two-­‐‑fold  increase  in  the  size  of  the  exonic  sequence  detectable  in  the  
presence  of  30%  non-­‐‑mutated  genomic  DNA.    Capping  the  false  positive  rate  at  0.001  and  
assuming  35x  mean  depth-­‐‑of-­‐‑coverage,  a  power  curve  (Figure  2.3E)  shows  0.95  sensitivity  of  
detecting  LOH  at  a  single  polymorphic  position  with  admixture  up  to  30%.  
Using  circular  binary  segmentation  to  merge  exonic  CNV/LOH  
Because  CNV  and  LOH  can,  and  usually  do,  span  multiple  exons,  we  extended  our  
method  above  to  call  CNV/LOH  on  larger  segments  derived  from  summing  data  of  sequentially  
spaced  exons  in  the  human  genome.    We  apply  circular  binary  segmentation  (CBS)  [30,31]  to  
subdivide  the  genome  and  then  combine  depth-­‐‑of-­‐‑coverage  of  exons  and  BAF  of  polymorphic  
positions  within  each  segment,  composed  of  arbitrary  number  of  individual  exons,  to  search  for  
larger  CNV  and  LOH.    In  the  case  of  CNV,  since  reads  are  independent  of  each  other,  the  sum  
of  depth-­‐‑of-­‐‑coverage  of  all  exons  in  a  segment  constitutes  the  segment’s  depth-­‐‑of-­‐‑coverage,  and  
the  CNV  test  can  be  performed  as  described  above.    In  the  case  of  LOH,  since  B-­‐‑alleles  are  not  
always  on  the  same  chromosome,  BAF  cannot  be  combined  by  direct  summation.    Instead,  since  
BAF  deviates  from  the  null  value  0.5  under  LOH,  a  significance  increase  in  variance  of  BAF  
from  control  (F-­‐‑test  for  equality  of  variances)  indicates  LOH  (several  other  statistics  were  also  
considered,  see  Appendix  2).    Finally,  we  repeated  the  process  of  CBS  and  CNV/LOH-­‐‑calling,  
ranging  granularity  of  segmentation  from  finest  to  coarsest,  and  merged  the  CNV/LOH  calls  by  
prioritizing  positive  calls  of  finer  segments  over  coarser  ones  (see  Methods  for  details).    In  the  
case  of  our  melanoma  sample,  we  performed  CBS/sequential  merging  at  five  levels  of  
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granularity  and  observed  165,130  merging  events  in  the  first  iteration  followed  by  121,  79,  105,  
and  66  in  the  subsequent  iterations  for  a  total  of  165,501  merging  events.  
Validation  
To  test  the  performance  of  ExomeCNV  we  analyzed  exome  sequencing  data  from  a  
melanoma  and  a  matched  normal  skin  (Appendix  2);  the  average  depth-­‐‑of-­‐‑coverage  of  the  data  
is  42.8x  for  the  tumor  and  37.5x  for  the  normal  sample,  which  are  sufficient  to  achieve  at  least  
90%  sensitivity  and  specificity  based  on  the  power  calculation  above.    We  first  estimated  the  
false  positive  rate  of  the  algorithm  by  calling  CNVs  on  two  sequencing  lanes  of  the  same  normal  
tissue  library,  treating  one  as  case  and  the  other  as  control;  any  CNV  call  from  this  would  be  
false  positive.    Our  method  correctly  called  most  exons  as  non-­‐‑CNV.    In  particular,  setting  p-­‐‑
value  thresholds  to  ensure  minimum  specificity  of  0.9,  0.99,  and  0.999,  we  observed  specificity  
of  0.916,  0.995,  and  1.0,  respectively  (Appendix  2).    Furthermore,  we  tested  the  sensitivity  of  
ExomeCNV  by  analyzing  copy-­‐‑number  of  sex  chromosomes  in  a  pair  of  male  and  female  exome  
data  that  were  available  internally  (see  Methods).    Using  the  male  exome  as  control,  ExomeCNV  
correctly  identified  female  chromosome  X  as  being  “duplicated”  and  chromosome  Y  as  being  
“deleted”  (Appendix  2)  with  no  false  negatives.  
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Figure  2.4  Analysis  of  Melanoma  and  Paired  Normal  Samples.  Interpretation  of  deletion,  
duplication,  and  LOH  from  exonic  sequence  data  using  ExomeCNV  and  plotted  with  Circos.  
The  most  outer  ring  shows  the  chromosome  ideograms  in  a  pter-­‐‑qter  orientation,  clockwise  
with  the  centromeres  in  red.  From  inside  to  outside,  each  data  track  represents  (A)  B-­‐‑allele-­‐‑
frequency  (BAF)  from  Omni-­‐‑1  genotyping  array  with  the  region  of  LOH  highlighted  in  blue  
underneath  the  track;  (B)  Log  R  Ratio  (LRR)  from  genotyping  array  with  the  region  of  gain  
highlighted  in  red  and  the  region  of  loss  highlighted  in  green;  (C)  BAF  from  ExomeCNV  output  
from  ~40x  depth-­‐‑of-­‐‑coverage  exome  sequencing  with  the  region  of  LOH  highlighted  in  blue;  (D)  
log  ratio  of  tumor  and  normal  depth-­‐‑of-­‐‑coverage  with  the  segment  mean  in  red  line,  the  region  
of  gain  highlighted  in  red  and  the  region  of  loss  highlighted  in  green.  The  LOH  and  CNV  for  
the  chromosome  Y  were  not  called  for  the  genotyping  data  as  genoCN  (the  algorithm  used  to  
call  CNV  from  Omni-­‐‑1)  is  not  designed  to  analyze  chromosome  Y.  The  table  in  the  middle  
summarizes  best  achievable  specificity  and  sensitivity  of  ExomeCNV  in  detecting  CNV  and  
LOH  relative  to  CNV/LOH  calls  from  Omni-­‐‑1  array  assessment.  
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We  then  used  ExomeCNV  to  predict  CNV  and  LOH  in  the  melanoma  samples  and  
compared  our  results  to  those  obtained  from  Illumina  Omni-­‐‑1  Quad  Beadchip  genotyping  array  
assessment  of  the  same  samples  (Figure  2.4  and  Appendix  2).    The  sizes  of  the  CNV  segments  
from  ExomeCNV  range  from  single  exon  (120bp)  to  whole  chromosome  (chr  10  and  18)  (size  
distribution  of  CNV  calls  is  presented  in  the  Appendix  2).    Treating  calls  from  the  genotyping  
array  experiment  as  a  standard,  ExomeCNV  had  97%  specificity  and  86%  sensitivity  for  
detecting  deletions,  92%  specificity  and  88%  sensitivity  for  detecting  amplifications,  and  88%  
specificity  and  68%  sensitivity  for  detecting  LOH  even  though  there  is  substantial  variability  
across  the  genome.    Higher  depth-­‐‑of-­‐‑coverage  from  the  sequence  data  for  each  exome  would  
likely  further  improve  concordance.    We  note  that  this  is  a  dramatic  improvement  over  the  
ERDS  [35]  CNV  caller  which,  when  applied  to  these  data,  achieves  16%  sensitivity  and  83%  
specificity  for  deletion  and  50%  sensitivity  and  56%  specificity  for  amplification  (see  Circo  plot  
showing  results  from  the  three  methods  in  the  Appendix  2).    For  CNV  segments  called  by  
ExomeCNV  but  not  by  the  genotyping  arrays,  we  found  that  most  lie  within  regions  in  which  
there  is  a  low  density  of  genotyping  markers;  thus  the  false  positive  rates  (and  the  associated  
specificity)  for  ExomeCNV  here  may  in  fact  be  lower.      
Discussion  
The  resolution  of  CNV  detection  with  ExomeCNV  is  limited  largely  by  the  probe  design.    
The  CNV  segments  identified  by  our  method  range  from  120bp  (single  exons  with  higher  than  
average  coverage)  to  240Mb  in  size  (whole  chromosomes);  however,  the  true  breakpoint  can  be  
anywhere  in  the  space  between  the  terminal  exon  called  within  a  CNV  region  and  the  adjacent  
exon  in  a  non-­‐‑CNV  region.    Hence,  although  a  given  CNV  event  can  be  detected  at  a  single  exon  
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in  some  instances,  the  absolute  resolution  of  our  method  is  in  fact  limited  to  the  inter-­‐‑exon  
distance  around  an  exon,  which  can  be  as  small  as  125bp  or  as  large  as  22.8Mb  with  the  median  
of  5kb  (statistics  based  on  SureSelect  Human  All  Exon  Kit  G3362).  
Although  ExomeCNV  relies  on  the  availability  of  matched  control  samples,  we  can  also  
derive  a  matched  control  sample  from  a  pool  of  other  samples  which  then  serves  as  an  effective  
control.    This  is  useful  for  the  identification  of  germline  inherited  or  de  novo  CNVs  in  an  
individual.    Because  the  expected  copy  number  in  the  reference  population  is  constant  (usually  
two),  by  the  law  of  large  numbers,  averaging  depth-­‐‑of-­‐‑coverage  from  sufficiently  many  samples  
yields  a  good  control  set,  assuming  that  they  are  all  captured  using  the  same  probe  set  and  
capture  method  and  sequenced  in  the  same  manner.    This  may  limit  the  application  of  
ExomeCNV  to  data  generated  at  a  given  site  with  a  given  protocol.    Calling  CNVs  using  this  
pooled  sample  as  background  will  generate  CNV  calls  that  are  present  in  the  case  sample  but  
not  the  control  population.    Also,  by  the  central  limit  theorem,  pooling  independent  samples  
helps  reduce  variance  in  depth-­‐‑of-­‐‑coverage  and  increases  precision  of  our  method.    We  have  
pooled  as  few  as  8  samples  and  have  observed  that  this  is  indeed  the  case  (Appendix  2).    
However,  it  is  important  to  note  that  using  pooled  sample  as  control  imposes  a  strong  
assumption  that  the  samples  do  not  share  common  CNV  regions  and  that  the  population  has  an  
average  genomic  copy  number  of  two.    Other  potential  challenges  of  using  the  pooled  sample  as  
control  are  discussed  in  the  Appendix  2.  
Because  ExomeCNV  depends  on  an  estimate  of  the  admixture  rate  c,  misspecification  of  
c  would  affect  its  performance.    We  performed  sensitivity  analysis  and  found  that  
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misestimating  c  would  have  a  strong  effect  on  sensitivity  and  specificity  of  CNV  detection.    
Fortunately,  LOH  detection  provides  some  data  to  directly  estimate  c,  as  LOH  detection  does  
not  depend  on  a  prior  knowledge  of  c  (Appendix  2).    For  the  melanoma  sample,  our  estimate  of  
30%  admixture  rate  matches  that  from  genotyping  arrays,  confirming  the  validity  of  this  
approach.    However,  there  are  advantages  to  slightly  overestimating  c  as  it  makes  the  method  
more  conservative  and  reduces  false  positives.  
As  we  have  shown,  CNV  and  LOH  detection  is  readily  possible  from  exome  sequencing  
data,  extending  the  utility  of  this  powerful  approach.    The  fundamental  basis  that  makes  this  
approach  possible  is  the  consistency  of  depth-­‐‑of-­‐‑coverage  of  each  exon  (and  BAF  by  extension)  
across  multiple  samples  for  each  individual  exon,  as  demonstrated  in  5  samples  performed  in  
our  lab  (Appendix  2,  Figure  2.2).    This  consistency  permits  reliable  parametric  modeling  of  the  
shift  in  depth-­‐‑of-­‐‑coverage  and  BAF  distributions,  hence  accurate  identification  of  CNV  and  
LOH.    However,  we  do  not  observe  the  same  level  of  consistency  when  comparing  depth-­‐‑of-­‐‑
coverage  across  different  library  types.    For  instance,  a  sixth  sample  was  performed  using  a  
paired-­‐‑end  approach  which  results  in  very  different  coverage  of  each  exon  (Figure  2.2),  and  as  a  
result,  ExomeCNV  does  not  perform  well  when  the  control  sample  library  is  of  one  type  and  the  
case  is  of  another,  or  when  the  case  and  control  have  significantly  different  coverage  levels.    
Resolving  these  issues  is  a  work-­‐‑in-­‐‑progress.  
From  the  analytical  power  calculations,  assuming  35x  coverage  (which  is  the  lower  end  
of  a  reasonable  amount  of  sequence  for  variant  calling  and  easy  to  generate  with  a  variety  of  
technologies),  CNV  detection  has  a  limit  of  about  500bp  (in  transcript  coordinates),  which  is  
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typically  equivalent  to  2-­‐‑3  exons  and  spans  about  10kb  of  genomic  space  on  average.    Increased  
depth-­‐‑of-­‐‑coverage,  which  is  likely  to  become  the  norm  as  sequencing  costs  decrease,  reduces  the  
interval  size  that  is  reliably  detectable  and  should  push  the  method  to  single  exonic  deletion  
resolution.    Currently,  CNV  and  LOH  information  should  be  detectable  in  whole-­‐‑exome  
sequencing  data  at  a  resolution  that  is  almost  equivalent  to  what  one  can  obtain  from  a  dense  
SNP  genotyping  array.      
ExomeCNV  is  available  as  a  CRAN  package  “ExomeCNV”.  
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Chapter  3:  Microbial  Co-­‐‑Occurrence  Relationships  in  the  Human  Microbiome  
Abstract  
The  healthy  microbiota  show  remarkable  variability  within  and  among  individuals.  In  
addition  to  external  exposures,  ecological  relationships  (both  oppositional  and  symbiotic)  
between  microbial  inhabitants  are  important  contributors  to  this  variation.  It  is  thus  of  interest  
to  assess  what  relationships  might  exist  among  microbes  and  determine  their  underlying  
reasons.  The  initial  Human  Microbiome  Project  (HMP)  cohort,  comprising  239  individuals  and  
18  different  microbial  habitats,  provides  an  unprecedented  resource  to  detect,  catalog,  and  
analyze  such  relationships.  
Here,  we  applied  an  ensemble  method  based  on  multiple  similarity  measures  in  
combination  with  generalized  boosted  linear  models  (GBLMs)  to  taxonomic  marker  (16S  rRNA  
gene)  profiles  of  this  cohort,  resulting  in  a  global  network  of  3,005  significant  co-­‐‑occurrence  and  
co-­‐‑exclusion  relationships  between  197  clades  occurring  throughout  the  human  microbiome.  
This  network  revealed  strong  niche  specialization,  with  most  microbial  associations  occurring  
within  body  sites  and  a  number  of  accompanying  inter-­‐‑body  site  relationships.  Microbial  
communities  within  the  oropharynx  grouped  into  three  distinct  habitats,  which  themselves  
showed  no  direct  influence  on  the  composition  of  the  gut  microbiota.  Conversely,  niches  such  
as  the  vagina  demonstrated  little  to  no  decomposition  into  region-­‐‑specific  interactions.  Diverse  
mechanisms  underlay  individual  interactions,  with  some  such  as  the  co-­‐‑exclusion  of  
Porphyromonaceae  family  members  and  Streptococcus  in  the  subgingival  plaque  supported  by  
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known  biochemical  dependencies.  These  differences  varied  among  broad  phylogenetic  groups  
as  well,  with  the  Bacilli  and  Fusobacteria,  for  example,  both  enriched  for  exclusion  of  taxa  from  
other  clades.  Comparing  phylogenetic  versus  functional  similarities  among  bacteria,  we  show  
that  dominant  commensal  taxa  (such  as  Prevotellaceae  and  Bacteroides  in  the  gut)  often  compete,  
while  potential  pathogens  (e.g.  Treponema  and  Prevotella  in  the  dental  plaque)  are  more  likely  to  
co-­‐‑occur  in  complementary  niches.  This  approach  thus  serves  to  open  new  opportunities  for  
future  targeted  mechanistic  studies  of  the  microbial  ecology  of  the  human  microbiome.  
Introduction  
In  nature,  organisms  rarely  live  in  isolation,  but  instead  coexist  in  complex  ecologies  
with  various  symbiotic  relationships  [1].  As  defined  in  macroecology,  observed  relationships  
between  organisms  span  a  wide  range  including  win-­‐‑win  (mutualism),  win-­‐‑zero  
(commensalism),  win-­‐‑lose  (parasitism,  predation),  zero-­‐‑lose  (amensalism),  and  lose-­‐‑lose  
(competition)  situations  [2-­‐‑4].  These  interactions  are  also  widespread  in  microbial  communities,  
where  microbes  can  exchange  or  compete  for  nutrients,  signaling  molecules,  or  immune  evasion  
mechanisms  [4-­‐‑6].  While  such  ecological  interactions  have  been  recently  studied  in  
environmental  microbial  communities  [7-­‐‑10],  it  is  not  yet  clear  what  the  range  of  normal  
interactions  among  human-­‐‑associated  microbes  might  be,  nor  how  their  occurrence  throughout  
a  microbial  population  may  influence  host  health  or  disease  [11].  
Several  previous  studies  have  identified  individual  microbial  interactions  that  are  
essential  for  community  stability  in  the  healthy  commensal  microbiota  [12-­‐‑15],  and  many  are  
further  implicated  in  dysbioses  and  overgrowth  of  pathogens  linked  to  disease  [16].  Each  
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human  body  site  represents  a  unique  microbial  landscape  or  niche  [17,18],  and  relationships  
analogous  to  macroecological  "ʺcheckerboard  patterns"ʺ  [3]  of  organismal  co-­‐‑occurrence  have  
been  observed  due  to  competition  and  cooperation  [19-­‐‑22].  For  example,  dental  biofilm  
development  is  known  to  involve  complex  bacterial  interactions  with  specific  colonization  
patterns  [23-­‐‑25].  Likewise,  disruption  of  relationships  among  the  normal  intestinal  microbiota  
by  overgrowth  of  competitive  pathogenic  species  can  lead  to  diseases,  e.g.  colonization  of  
Clostridium  difficile  in  the  gut  [26].  However,  no  complete  catalog  of  normally  occurring  
interactions  in  the  human  microbiome  exists,  and  characterizing  these  co-­‐‑occurrence  and  co-­‐‑
exclusion  patterns  across  body  sites  would  elucidate  both  their  contributions  to  health  and  the  
basic  biology  of  their  ecological  relationships.  Thus,  characterizing  key  microbial  interactions  of  
any  ecological  type  within  the  human  body  would  serve  as  an  important  first  step  for  studying  
and  understanding  transitions  among  various  healthy  microbial  states  or  into  disease-­‐‑linked  
imbalances.  
As  has  been  also  been  pointed  out  in  macroecology,  however,  the  analytical  
methodology  needed  to  comprehensively  detect  such  co-­‐‑occurrence  relationships  is  
surprisingly  complex  [27].  Most  existing  studies  employ  simple  measures  such  as  Pearson’s  or  
Spearman'ʹs  correlation  to  identify  significant  abundance  relationships  [13,15,28].  These  methods  
are  suboptimal  when  applied  without  modification  to  organismal  relative  abundances  [29].  
Since  absolute  microbial  counts  are  not  known  and  measurements  depend  on  sampling  and  
sequencing  depth,  an  increase  in  one  relative  abundance  must  be  accompanied  by  a  
compositional  decrease  in  another,  leading  to  spurious  correlations  among  non-­‐‑independent  
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measurements  [30].  In  addition,  sparse  sequence  counts  can  cause  artefactual  associations  for  
low-­‐‑abundance  organisms  with  very  few  non-­‐‑zero  observations    [29].  Conversely,  association  
methods  such  as  log-­‐‑ratio  based  distances  [31]  that  have  been  developed  specifically  for  such  
compositional  data  are  difficult  to  assign  statistical  significance,  a  vital  consideration  in  high-­‐‑
dimensional  microbial  communities  containing  hundreds  or  thousands  of  taxa.  
Here,  we  have  addressed  these  issues  to  catalog  a  baseline  of  normal  microbial  
interactions  in  the  healthy  human  microbiome.  The  Human  Microbiome  Project  (HMP)  [32]  
sampled  a  disease-­‐‑free  adult  population  of  239  individuals,  including  18  body  habitats  in  five  
areas  (oral,  nasal,  skin,  gut,  and  urogenital),  providing  5,026  microbial  community  compositions  
assessed  using  16S  rRNA  gene  taxonomic  marker  sequencing  [32].  We  have  developed  a  suite  of  
methods  to  characterize  microbial  co-­‐‑occurrence  and  co-­‐‑exclusion  patterns  throughout  the  
healthy  human  microbiome  while  suppressing  spurious  correlations.  Specifically,  these  were  1)  
an  ensemble  approach  including  multiple  similarity  and  dissimilarity  measures,  and  2)  a  
compendium  of  generalized  boosted  linear  models  (GBLMs)  describing  predictive  
relationships,  both  assessed  nonparametrically  for  statistical  significance  while  mitigating  the  
effects  of  compositionality.  Together,  these  methods  provide  a  microbiome-­‐‑wide  network  of  
associations  both  among  individual  microbes  and  between  entire  microbial  clades.  
Among  the  726  taxa  and  884  clades  in  the  HMP  data,  we  examined  both  intra-­‐‑body  site  
and  inter-­‐‑body  site  relationships  as  a  single  integrated  microbial  co-­‐‑occurrence  network.  Each  
relationship  represents  co-­‐‑occurrence/co-­‐‑exclusion  pattern  between  a  pair  of  microbes  within  or  
between  body  sites  among  all  subjects  in  the  HMP  (in  contrast  to  studies  within  single  subjects  
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of  microbial  co-­‐‑occurrences  across  biogeography,  e.g.  [33,34]).  This  ecological  network  proved  
to  contain  few  highly  connected  (hub)  organisms  and  was,  like  most  biological  networks,  scale-­‐‑
free.  Co-­‐‑occurrence  patterns  of  the  human  microbiome  were  for  the  most  part  highly  localized,  
with  most  relationships  occurring  within  a  body  site  or  area,  and  there  were  proportionally  few  
strong  correspondences  spanning  even  closely  related  body  sites.  Each  pair  of  organisms  was  
assessed  for  positive  (e.g.  cooperative)  or  negative  (e.g.  competitive)  associations,  and  in  many  
cases  these  patterns  could  be  explained  by  comparing  the  organisms'ʹ  phylogenetic  versus  
functional  similarities.  In  particular,  taxa  with  close  evolutionary  relationships  tended  to  
positively  associate  at  a  few  proximal  body  sites,  while  distantly  related  taxa  with  functional  
similarities  tended  to  compete.  The  resulting  network  of  microbial  associations  thus  provides  a  
starting  point  for  further  investigations  of  the  ecological  mechanisms  underlying  the  
establishment  and  maintenance  of  human  microbiome  structure.  
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Table  3.1:  16S  rRNA  gene  sequencing  data  from  the  Human  Microbiome  Project  used  to  
assess  microbial  co-­‐‑occurrence  relationships  in  the  human  microbiome.  We  considered  
microbial  associations  in  a  total  of  5,026  samples  from  the  Human  Microbiome  Project  (HMP)  
comprising  18  body  sites  in  239  individuals  recruited  at  two  clinical  centers  (Baylor  College  of  
Medicine,  Houston,  TX  and  Washington  University  at  St.  Louis,  MO),  which  in  total  contained  
726  reliably  detectable  bacterial  phylotypes.  For  details  of  HMP  samples  and  data  processing,  
see  [32].  
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Figure  3.1:  Methodology  for  characterizing  microbial  interactions  using  a  compendium  of  
similarity  measures.  16S  data  from  the  Human  Microbiome  Project  (HMP)  were  collected  from  
18  body  sites  in  a  cohort  of  239  healthy  subjects  and  assessed  using  16S  rRNA  gene  sequencing.  
We  analyzed  microbial  co-­‐‑occurrence  and  co-­‐‑exclusion  patterns  in  these  data  by  developing  
two  complementary  approaches:  a  compendium  of  Generalized  Boosted  Linear  Model  (GBLMs)  
and  an  ensemble  of  similarity  and  dissimilarity  measures.  Each  approach  produced  a  network  
in  which  each  node  represented  a  microbial  taxon  within  one  body  site,  and  each  edge  
represented  a  significant  association  between  microbial  or  whole  clade  abundances  within  or  
across  body  sites.  The  resulting  association  networks  produced  by  each  individual  method  were  
merged  as  p-­‐‑values  using  Simes  method,  after  which  FDR  correction  was  performed.  
Associations  with  FDR  q-­‐‑values  >0.05,  inconclusive  directionality,  or  fewer  than  two  supporting  
pieces  of  evidence  were  removed.  This  provided  a  single  global  microbial  association  network  
for  taxa  throughout  the  healthy  commensal  microbiota.  
     
   38  
Methods  
Two  complementary  approaches,  an  ensemble  of  multiple  similarity/dissimilarity  
measures  and  a  compendium  of  generalized  boosted  linear  models  (GBLMs),  were  used  to  
interrogate  significant  associations  between  microbial  abundances.  These  were  drawn  from  18  
body  sites  assayed  by  the  Human  Microbiome  Project  at  two  clinical  centers  using  16S  rRNA  
gene  sequencing.  Simes  method  and  Benjamini-­‐‑Hochberg-­‐‑Yekutieli  false  discovery  rate  (FDR)  
correction  were  used  to  combine  the  resulting  networks.  From  this  merged,  global  network,  we  
summarized  overall  network  properties  (degree  distribution,  modularity,  etc.),  assessed  
patterns  of  microbial  connectivity  within  and  among  body  sites,  and  identified  highly  
connected  (hub)  microbes.  Phylogenetic  and  functional  distances  were  calculated  based  on  16S  
rRNA  gene  sequence  similarity  and  shared  orthologous  gene  families,  respectively,  and  
combined  with  the  network.  
Please  see  Appendix  3  for  an  extensive  discussion  of  the  methodology  used  to  assess  
relationship  significance  in  compositional  data,  which  is  presented  in  summary  below.  
16S  data  acquisition  and  processing  
The  16S  rRNA  gene-­‐‑based  dataset  of  the  normal  (healthy)  human  microbiome  was  made  
available  through  the  Human  Microbiome  Project  (HMP)  and  is  detailed  in  [32].  Briefly,  it  
consists  of  454  FLX  Titanium  sequences  spanning  the  V1  to  V3  and  V3  to  V5  variable  regions  
obtained  for  239  healthy  subjects  enrolled  at  clinical  sites  in  Houston,  TX  and  St.  Louis,  MO.  
These  cover  18  body  sites  covering  five  areas:  the  oral  cavity  (nine  sites:  saliva,  tongue  dorsum,  
palatine  tonsils,  keratinized  gingiva,  hard  palate,  buccal  mucosa,  throat,  and  sub-­‐‑  and  
   39  
supragingival  plaques),  the  gut  (one  site:  stool),  the  vagina  (three  sites:  introitus,  mid-­‐‑vagina,  
and  posterior  fornix),  the  nasal  cavity  (one  sample:  anterior  nares),  and  the  skin  (four  sites:  left  
and  right  antecubital  fossae  and  retroauricular  creases).  Sequences  of  both  16S  windows  were  
processed  separately  using  mothur  [35]  into  phylotypes  using  the  RDP  taxonomy  as  described  
in  [32]  and  [36],  with  full  protocols  also  available  on  the  HMP  DACC  website  
(http://hmpdacc.org/HMMCP).  Genus  level  and  above  phylotypes  were  used  for  this  analysis,  
for  which  the  datasets  from  both  windows  were  combined.  
This  resulted  in  more  than  5,000  samples  comprising  910  taxa  made  available  as  part  of  
the  HMP  (http://hmpdacc.org/HMMCP).  These  were  further  processed  for  this  study  by  
excluding  any  phylotype  not  supported  by  at  least  two  sequences  in  at  least  two  samples.  
Samples  were  removed  as  suspect  if  the  most  abundant  taxon  was  detected  by  fewer  than  1%  of  
the  sequences  supporting  it  in  the  sample  in  which  it  was  most  abundant,  and  counts  for  the  
remaining  726  taxa  were  converted  to  relative  abundances  in  each  of  the  resulting  5,026  
samples.  Due  to  potential  differences  between  clinical  centers,  the  dataset  was  conservatively  
split  into  two  subsets  for  further  analysis,  subjects  recruited  in  Houston  (3,296  samples)  and  
those  recruited  in  St.  Louis  (1,730  samples).  
Generalized  Boosted  Linear  Models  
GBLM  definition  and  construction  
For  each  resulting  dataset,  a  compendium  of  generalized  boosted  linear  models  
(GBLMs)  was  constructed  by  selecting  all  324  combinations  of  source  body  sites  ss  and  target  
sites  ts.  Each  GBLM  was  fit  using  the  abundances  of  all  source  taxa  st  within  the  source  site  to  
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predict  the  abundance  of  each  target  taxon  tt  within  the  target  site  using  a  sparse  linear  model  
of  the  form:  
∑+=
st
ssstsssttstttstttstt xxx ,,,,,, β   
All  additional  non-­‐‑leaf  clades  in  the  RDP  [37]  taxonomy  (i.e.  families,  orders,  etc.  up  to  
the  bacterial  and  archaeal  domains)  were  included  as  source  and  target  taxa.  For  ss  equal  to  ts,  
i.e.  predicting  the  abundance  of  a  taxon  tt  when  the  abundances  of  all  taxa  in  the  same  body  site  
are  known,  the  abundances  of  all  parent  and  descendant  clades  of  tt  were  excluded  from  the  
available  source  taxa  st.  That  is,  when  ss=ts  and  tt  was  of  the  form  domain|phylum|class|...|clade,  
all  source  taxa  of  the  form  domain,  domain|phylum,  domain|phylum|class,  etc.  or  of  the  form  
domain|phylum|class|...|clade|subclade,  domain|phylum|class|...|clade|subclade|subsubclade,  etc.  
were  excluded  from  the  source  taxa  st.  This  prevented  the  abundances  of  xtt,ts  from  being  
predicted  using  abundances  xst,ss  on  which  they  were  directly  dependent,  while  allowing  the  
detection  of  predictive  relationships  between  distinct  clades  within  the  same  body  site.  
The  linear  model  was  generalized  to  include  binary  categorical  target  taxa  (in  this  case  
only  gender  and  ethnicity)  using  standard  logistic  regression:  
∑+=
st
ssstsssttstttstttstt xxx ,,,,,, )(logit β   
As  this  is  clearly  an  extremely  high-­‐‑dimensional  problem,  multiple  a  priori  and  post  hoc  
steps  were  taken  to  enforce  model  sparsity  and  to  avoid  overfitting  for  each  (ss,  ts,  tt)  tuple.  The  
first  of  these  was  to  exclude  from  the  available  st  any  taxon  not  correlating  with  tt  at  a  
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Spearman  correlation  of  nominally  p<0.05.  The  second  was  to  boost  linear  model  fitting  rather  
than  attempt  to  fit  all  βtt,ts,st,ss  simultaneously  [38].  Boosted  linear  models  retain  the  usual  L2  least  
squares  penalty,  but  are  constructed  in  a  manner  similar  to  sparse  forward  variable  selection  or  
the  LASSO  [39].  βs  are  considered  for  inclusion  in  the  model  one  at  a  time  and  the  parameter  
minimizing  sum  of  squared  error  selected  and  included.  However,  each  subsequent  round  of  
parameter  fitting  operates  on  the  residuals  of  all  previous  rounds,  thus  "ʺupweighting"ʺ  poorly  fit  
examples,  and  the  inclusion  of  further  non-­‐‑zero  βs  stops  after  a  fixed  number  of  iterations.  
This  tuning  parameter  and  the  model  fitting  process  was  10-­‐‑fold  cross-­‐‑validated  and  
selected  from  the  most  accurate  (by  root  mean  square  error  for  continuous  tt  and  AUC  for  
binary)  of  50,  100,  or  150  boosting  iterations  using  the  caret  [40]  and  mboost  [41]  R  packages.  
This  resulted  in  a  compendium  of  7±4.9  non-­‐‑zero  parameters  β,  each  evaluated  with  a  10x  cross-­‐‑
validated  R2/AUC  and  a  nominal  R2/AUC  on  the  full  dataset.  Final  model  quality  scores  were  
assigned  by  A)  subtracting  AUCs  below  0.5  from  one,  since  caret  does  not  calculate  AUCs  
directionally,  and  B)  retaining  the  minimum  of  the  cross-­‐‑validated  and  nominal  R2/AUC.  Any  








nRAR ),  parameters  p,  training  samples  n)  was  discarded  
(55,424  retained).  
GBLM  filtering  and  significance  
Even  from  cross-­‐‑validated  goodness-­‐‑of-­‐‑fit  scores,  the  compositional  structure  of  relative  
abundance  data  prevents  straightforward  assessment  of  model  significance  (see  Appendix  3).  
We  thus  additionally  fit  twenty  models  per  (ss,  ts,  tt)  tuple  after  bootstrap  re-­‐‑sampling  the  
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values  of  tt  across  samples.  The  AR2/AUC  of  these  bootstrap  models  provided  a  confidence  
interval  around  the  observed  AR2/AUC.  Any  model  for  which  the  90%  confidence  interval  
failed  to  include  the  observed  AR2/AUC  was  discarded.  To  construct  the  null  distribution  of  
associations  due  to  compositionality  alone,  we  fit  twenty  additional  models  after  permuting  the  
values  of  tt  across  samples  and  renormalizing  them  sample-­‐‑wise,  thus  retaining  compositional  
effects  but  breaking  true  associations.  The  GBLM  was  re-­‐‑fit  and  the  resulting  null  distribution  of  
AR2/AUC  values  used  to  assess  significance  of  the  true  model.  The  mean  and  standard  
deviation  of  the  bootstrap  distribution  was  z-­‐‑tested  against  this  null  distribution  using  the  
jointly  pooled  standard  deviation,  providing  one  p-­‐‑value  per  model  per  clinical  center.  Any  
model  with  FDR  adjusted  p-­‐‑value  greater  than  0.05  was  discarded  (18,286  retained).  
Ensemble  scoring  
Data  preprocessing  
The  16S  data  described  above  were  first  normalized  by  dividing  each  sample  by  its  total  
phylotype  sum.  Mislabeled  samples  were  removed  [42]  and  samples  were  again  processed  as  
two  subsets,  one  per  clinical  center  (Houston  and  St.  Louis).  These  were  encoded  as  a  matrix  in  
which  each  row  represented  a  phylotype  in  a  specific  body  site  and  each  column  represented  an  
individual  during  one  sampling  visit.  Rows  with  more  than  2/3  zero  counts  were  removed,  
leaving  matrices  of  1,217  (Houston)  and  1,408  (St.  Louis)  phylotype-­‐‑bodysite  composite  features  
collected  for  248  and  144  subject-­‐‑visit  points,  respectively.  
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Ensemble  score  calculation  
We  built  on  composite  co-­‐‑occurrence  scores  as  described  in,  for  example,  [43]  (for  
protein  functions)  and  [20]  (graph  clustering)  to  find  groups  of  microbial  lineages  co-­‐‑existing  
across  a  large  number  of  environments.  Specifically,  we  combined  four  diverse  measures  in  
order  to  overcome  two  major  challenges  in  the  inference  of  co-­‐‑occurrence  networks,  particularly  
appropriateness  of  scoring  measures  to  sparse  count  data  and  determination  of  statistical  
significance.  The  first  is  exemplified  by  the  double-­‐‑zero  problem,  in  which  a  zero  indicates  
either  that  an  organism  is  absent  or  that  it  is  below  detection  limit  [27];  Pearson  and  Spearman  
correlations  are  sensitive  to  this,  while  the  Bray  Curtis  dissimilarity  is  not.  The  latter  issue  arises  
from  the  need  to  normalize  across  samples  with  unknown  absolute  abundances,  either  by  
relativizing  or  by  downsampling;  either  procedure  results  in  constrained  sample  sums,  which  
introduce  artificial  correlations  [29].  
We  thus  employed  an  ensemble  approach  combining  four  diverse  measures:  two  
measures  of  correlation  (Pearson  and  Spearman)  and  two  measures  of  dissimilarity  (Bray-­‐‑Curtis  
(BC)  and  Kullback-­‐‑Leibler  (KLD)).  For  BC  and  KLD  calculations,  rows  were  divided  by  their  
sum  prior  to  computation.  Additional  measures  were  considered  for  our  ensemble,  including  
the  Hellinger,  Euclidean,  variance  of  log-­‐‑ratios  and  other  measures,  but  these  proved  to  be  well-­‐‑
represented  by  the  smaller  final  ensemble  (see  Supplemental  Figure  3.6-­‐‑3.7).    
Ensemble  network  building  
After  running  each  of  the  above  measures  on  the  two  16S  data  matrices,  one  per  clinical  
center,  we  set  measure-­‐‑specific  thresholds  as  a  pre-­‐‑filter  such  that  each  measure  contributed  
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1,000  top-­‐‑ranking  and  1,000  bottom-­‐‑ranking  edges  to  the  network.  Edge  scores  were  computed  
only  between  clade  pairs  without  parent-­‐‑descendant  relationship  (e.g.  without  pairs  of  the  type  
Actinobacteridae|Actinomycetales  or  Actinomycetales|Propionibacterineae)  for  clades  in  the  
same  body  site.  To  assign  statistical  significance  to  the  resulting  differently-­‐‑scaled  scores,  we  
first  computed  edge-­‐‑  and  measure-­‐‑specific  permutation  and  bootstrap  score  distributions  with  
1,000  iterations  each.  In  order  to  address  the  compositionality  issues  discussed  above  [29],  we  
re-­‐‑normalized  the  data  in  each  permutation,  providing  a  null  distribution  that  captures  the  
similarity  introduced  by  compositionality  alone  (see  Appendix  3).  We  then  computed  the  p-­‐‑
value  as  above  by  z-­‐‑scoring  the  permuted  null  and  bootstrap  confidence  interval  using  pooled  
variance.  P-­‐‑values  were  tail-­‐‑adjusted  so  that  low  p-­‐‑values  correspond  to  co-­‐‑presence  and  high  
p-­‐‑values  to  exclusion.  For  BC  and  KLD,  we  did  not  compute  re-­‐‑normalized  permutations,  
because  these  measures  are  intrinsically  robust  to  compositionality  [30].  Instead,  we  calculated  
their  p-­‐‑values  using  the  bootstrap  interval  compared  to  a  point  null  value  that  was  computed  
by  permutation.    
Finally,  to  remove  unstable  edges,  we  removed  all  edges  whose  score  was  not  within  the  
95%  confidence  interval  (limited  by  the  2.5  and  97.5  percentiles)  of  the  bootstrap  distribution.  
Additionally,  a  small  number  of  Bray-­‐‑Curtis  scores  were  manually  curated  and  removed  after  
generating  erroneous  negative  relationships  when  applied  to  abundance  profiles  including  only  
one  extreme  outlier.  This  affected  only  the  clades  for  St.  Louis:  Actinomycetales  in  stool,  
Corynebacterium  and  Corynebacteriaceae  in  the  tonsils,  Lactobacillus  and  Lactobacillaceae  in  the  
anterior  nares  and  for  Houston:  an  unclassified  Neisseria  in  the  left  retroauricular  crease.  
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Mitigating  the  compositional  effect  in  relative  abundance  analysis  
Data  summarized  as  relative  abundances  are  referred  to  as  compositional  [30].    Because  
they  sum  to  one,  their  elements  are  not  independent  and  may  exhibit  spurious  correlations  
regardless  of  the  true  underlying  relationship.  To  mitigate  this  effect,  we  assessed  the  
significance  of  our  ensemble  scores  and  GBLMs  as  described  above,  each  by  comparing  a  
bootstrap  confidence  interval  around  the  observed  score  with  a  permuted  null  distribution  that  
includes  repeated  renormalization  to  account  for  compositional  effects  alone.  In  each  
permutation,  only  the  target  taxon  row  was  randomized  and  all  samples  subsequently  
renormalized  to  a  constant  sum.  Because  permutation  breaks  correlation  structure  while  
renormalization  reintroduces  compositionality,  a  null  distribution  coupling  these  elements  
induces  correlation  from  compositional  structure  alone.  Comparing  this  null  distribution  to  a  
standard  bootstrap  confidence  interval  around  the  observed  value  provided  a  straightforward  
nonparametric  test  of  association  accounting  for  compositionality.  Simulation  studies  showed  
that  the  bootstrap-­‐‑renormalization  scheme  was  successful  in  discounting  compositional  effects  
while  preserving  true  correlations  (see  Appendix  3).  
Network  merging  by  Simes  method  and  FDR  correction  
Simes  method  was  used  to  combine  all  ten  networks  (5  methods  x  2  study  centers)  into  
one  final  network,  as  it  is  robust  against  non-­‐‑independent  tests  [44].  A  strict  intersection  of  the  
two  clinical  centers'ʹ  networks,  rather  than  a  p-­‐‑value  combination,  was  also  examined  and  found  
to  be  over-­‐‑stringent  due  to  systematic  differences  in  the  data  (Supplemental  Figure  3.8).  After  
merging,  p-­‐‑values  on  each  final  edge  were  corrected  to  FDR  q-­‐‑values  using  the  Benjamini-­‐‑
Hochberg-­‐‑Yekutieli  method  and  a  q-­‐‑value  cutoff  of  0.05  was  applied.  The  positivity  or  
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negativity  of  each  relationship  was  determined  by  consensus  voting  over  all  integrated  data  
sources,  ranging  from  -­‐‑10  (most  negative)  to  10  (most  positive,  see  Figure  3.2).    Edges  with  
indeterminate  directionality  (direction  score  of  zero)  were  removed.    Finally,  only  edges  with  at  
least  two  (out  of  ten)  supporting  pieces  of  evidence  were  retained.  
Computation  of  network  modularity  
The  formula  by  Clauset  et  al.  [45]  compares  the  fraction  of  edges  within  input  clusters  
with  the  fraction  of  within-­‐‑cluster  edges  that  would  be  expected  for  a  randomized  network.  We  
clustered  the  network  using  the  Markov  cluster  algorithm  (MCL)  [46]  and  computed  network  
modularities  for  a  range  of  inflation  parameters.  The  strongest  modularity  (0.28)  was  measured  
for  an  inflation  of  1.3  and  is  slightly  below  the  cut-­‐‑off  recommended  by  Clauset  et  al..  This  
modularity  was,  however,  higher  than  any  measured  for  100  randomized  networks  (which  
preserved  node  and  edge  number,  but  in  which  edges  were  randomly  re-­‐‑assigned)  and  was  
therefore  retained  as  significant.  
Assessment  of  significant  connectivity  density  within  and  among  body  sites  and  classes  
To  assess  whether  specific  body  sites  were  more  connected  than  expected  by  chance,  we  
repeatedly  (1,000  times)  selected  as  many  nodes  as  a  body  site  contains  from  the  global  network  
at  random  and  counted  their  edge  number.  This  resulted  in  a  distribution  of  edge  numbers  for  
random  node  sets.  To  retain  only  plausibly  significant  edges  for  further  calculation,  we  
corrected  for  multiple  testing  by  multiplied  the  nominal  p-­‐‑value  from  this  distribution  with  the  
number  of  tests  carried  out  and  retaining  values  below  0.05.  We  repeated  this  test  separately  for  
positive,  negative,  intra-­‐‑  and  cross-­‐‑edges.  For  visualization,  the  network  itself  was  also  
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separated  into  within-­‐‑site,  within-­‐‑area,  and  between-­‐‑area  subsets  for  further  inspection  
(Supplemental  Figure  3.9).  
Assessment  of  relationships  between  body-­‐‑site-­‐‑specific  and  class-­‐‑specific  clade  groups    
To  assess  the  interaction  strength  between  body  site  and  clade  groups  (Figures  3.4  and  
3.5),  the  number  of  relationships  between  nodes  in  each  group  pair  was  counted  and  
normalized  by  the  group  member  product,  which  represents  the  number  of  links  two  groups  
can  potentially  form.  This  was  repeated  in  1,000  randomized  networks  (generated  as  described  
for  the  computation  of  network  modularity).  A  p-­‐‑value  was  computed  from  the  count  
distribution  and  node  group  relationships  with  p-­‐‑values  above  0.05  were  discarded,  retaining  
only  the  fractions  of  total  possible  relationships  which  were  significantly  higher  than  that  
expected  by  chance.  
Phylogenetic  and  functional  similarity  scores  
Phylogenetic  distances  
Genome  sequences  of  1,107  organisms  were  retrieved  from  NCBI  
(http://www.ncbi.nlm.nih.gov/genomes/lproks.cgi,  December  2010)  and  16S  sequences  were  
extracted.  These  16S  sequences  were  aligned  using  MUSCLE  3.8.31  [47]  and  a  full  phylogenetic  
tree  reconstructed  by  maximum  likelihood  using  FastTree  2.1  [48].  A  matrix  of  all  pair-­‐‑wise  
distances  was  created  from  this  cladogram  and  distances  between  any  two  nodes  (e.g.  families,  
orders,  etc.)  calculated  by  taking  the  median  of  all  distances  (as  provided  in  units  from  
FastTree)  between  all  pairs  of  leaf  taxa  descending  from  the  two  nodes.  
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Functional  distances  
Functional  complements  of  the  same  genomes  were  summarized  using  COG  [49]  
families  as  assigned  by  NCBI  annotations.  This  resulted  in  an  abundance  matrix  with  4,685  
columns  (corresponding  to  COG  families)  and  one  row  per  genome.  Columns  summing  to  less  
than  10%  of  the  number  of  genomes  were  removed,  resulting  in  3,514  usable  COG  families.  
Pairwise  scores  between  genomes  were  calculated  using  Jaccard  index,  with  distances  for  
higher-­‐‑level  clades  computed  using  medians  in  the  same  manner  as  described  above.  Final  
functional  distances  were  represented  as  the  Jaccard  index  of  non-­‐‑shared  COG  families  between  
pairs  of  genomes.  
Results  
We  inferred  a  microbiome-­‐‑wide  microbial  interaction  network  by  analyzing  5,026  
samples  from  the  Human  Microbiome  Project  (HMP)  comprising  18  body  sites,  239  individuals  
recruited  at  two  clinical  centers,  and  726  bacterial  phylotypes  detected  by  16S  rRNA  gene  
sequencing  (Table  1).  Our  study  aimed  to  determine  co-­‐‑occurrence  and  co-­‐‑exclusion  
relationships  among  the  relative  abundances  of  microbial  taxa  across  all  individuals,  potentially  
indicative  of  their  ecological  relationships.  We  thus  combined  two  complementary  approaches,  
namely  an  ensemble  of  multiple  similarity  and  dissimilarity  measures  (henceforth  “ensemble  
approach”)  and  a  compendium  of  generalized  boosted  linear  models  (GBLMs,  henceforth  
“GBLM  approach”).  Both  methods  were  applied  to  the  HMP  data  to  produce  microbial  
interaction  networks  in  which  each  node  represented  a  microbial  clade  (taxon  or  group  of  taxa)  
connected  by  edges  that  were  weighted  by  the  significance  of  their  association  (positive  or  
negative).  Spurious  correlations  due  to  compositional  structure  of  relative  abundance  data  [29]  
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were  prevented  by  a  novel  bootstrap  and  re-­‐‑normalization  approach  assessing  the  degree  of  
association  present  beyond  that  expected  by  compositionality  alone.  We  used  Simes  method  
followed  by  Benjamini-­‐‑Hochberg-­‐‑Yekutieli  false  discovery  rate  (FDR)  correction  to  combine  the  
resulting  networks  (Figure  3.1).  A  detailed  final  network  is  provided  in  Supplemental  Figure  
3.1,  with  a  comparison  of  all  networks  in  Supplemental  Figure  3.7  and  additional  information  in  
Methods.  This  provided  a  single  global  microbial  interaction  network  capturing  3,005  
associations  among  197  phylotypes,  spanning  all  available  body  sites  from  the  human  
microbiome  (Figure  3.2).  
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Figure  3.2:  Significant  co-­‐‑occurrence  and  co-­‐‑exclusion  relationships  among  the  abundances  
of  clades  in  the  human  microbiome.  A  global  microbial  interaction  network  capturing  1,949  
associations  among  452  clades  at  or  above  the  order  level  in  the  human  microbiome,  reduced  
for  visualization  from  the  complete  network  in  Supplemental  Figure  3.1.  Each  node  represents  a  
bacterial  order,  summarizing  one  or  more  genus-­‐‑level  phylotypes  and  family-­‐‑level  taxonomic  
groups.  These  are  colored  by  body  site,  and  each  edge  represents  a  significant  co-­‐‑occurrence/co-­‐‑
exclusion  relationship.  Edge  width  is  proportional  to  the  significance  of  supporting  evidence,  
and  color  indicates  the  sign  of  the  association  (red  negative,  green  positive).  Self-­‐‑loops  indicate  
associations  among  phylotypes  within  an  order;  for  a  full  network  of  all  phylotypes  and  clades,  
see  Supplemental  Figure  3.1.  A  high  degree  of  modularity  is  apparent  within  body  areas  (skin,  
urogenital  tract,  oral  cavity,  gut,  and  airways)  and  within  individual  body  sites,  with  most  
communities  forming  distinct  niches  across  which  few  microbial  associations  occur.          
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A  global  network  of  microbial  co-­‐‑occurrence  and  mutual  exclusion  within  and  among  body  site  
niches  of  the  human  microbiome  
Global  properties  of  the  microbiome-­‐‑wide  network  of  microbial  associations  are  
summarized  in  Figures  3.2  and  3.3.  A  dominant  characteristic  of  the  network  was  its  habitat-­‐‑
specific  modularity.  After  grouping  the  18  body  sites  into  five  broad  areas  (oral,  skin,  nasal,  
urogenital,  and  gut),  the  large  majority  of  edges  were  found  clustered  within  body  areas  
(98.54%),  and  these  clusters  were  sparsely  connected  through  a  minority  of  edges  (1.46%).  This  
is  confirmed  by  the  network'ʹs  high  modularity  coefficient  of  0.28  (as  defined  by  [45])  and  
Markov  clustering  of  the  network  (see  Methods  and  Supplemental  Figure  3.2).  It  has  long  been  
observed  that  sites  within  the  human  microbiome  are  distinct  in  terms  of  microbial  composition  
[50],  and  this  proved  to  be  true  of  microbial  interactions  as  well:  microbial  relationships  within  
each  body  area'ʹs  community  were  largely  unique  (Table  2).  The  microstructure  of  interaction  
patterns  -­‐‑  and  thus  in  the  underlying  ecology  -­‐‑  was  different  for  different  areas,  however.  For  
example,  all  vaginal  sites  within  the  urogenital  area  were  interrelated  in  a  single  homogeneous  
community,  whereas  interactions  within  the  oral  cavity  suggested  microbial  cross-­‐‑talk  among  
three  distinct  habitats  [51].  This  can  be  observed  quantitatively  based  on  the  proportions  of  
microbial  interactions  spanning  body  sites  within  each  area,  e.g.  69.57%  among  the  vaginal  sites  
and  53.19%  among  the  oral  sites,  both  exceeding  the  microbiome-­‐‑wide  baseline.  The  skin  was  
further  unique  in  that  the  large  amount  (57.65%)  of  its  associations  related  microbes  in  
corresponding  left  and  right  body  sites  (left  and  right  antecubital  fossae  and  retroauricular  
creases),  reflecting  consistent  maintenance  of  bilateral  symmetry  in  the  skin  microbiome.  
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Table  3.2:  Summary  statistics  of  microbial  associations  in  the  normal  human  microbiota.  
Microbial  co-­‐‑occurrence  and  co-­‐‑exclusion  relationships  summarized  within  the  five  major  body  
areas  and  relationships  spanning  different  body  sites  within  these  areas.  Percentages  are  
fractions  of  the  total  number  of  edges  in  the  network,  while  percentages  in  parentheses  
represent  fractions  of  edges  within  each  body  area.  
  
We  began  decomposing  the  network  by  categorizing  microbial  associations  within  each  
body  area  into  body-­‐‑site-­‐‑specific  relationships  of  two  types:  cross-­‐‑site  and  within-­‐‑site  
interactions.  On  average,  these  two  classes  make  up  53.11  and  46.89  percent  of  the  total  edges,  
respectively  (Table  3.2).  First  focusing  on  cross-­‐‑site  associations,  a  majority  (66.10%)  of  such  
relationships  were  co-­‐‑occurrences  between  the  same  or  taxonomically  related  clades  in  
proximal  or  bilateral  body  sites.  This  reflects  coordinated  community  structure  among  
ecologically  related  niches,  such  as  similar  dental  plaques,  vaginal  sites,  and  bilateral  skin  sites.  
Body  sites  specifically  connected  by  many  positive  associations  were  either  in  direct  contact  
(e.g.  tongue  and  saliva),  proximal  (e.g.  sub-­‐‑  and  supragingival  plaques),  or  similar  in  terms  of  
environmental  exposure  (e.g.  bilateral  skin  sites),  thus  providing  mechanisms  to  support  
comparable  microbiota  and  exhibiting  high  levels  of  microbial  co-­‐‑occurrence.  This  pattern  held  
true  for  the  minority  (33.90%)  co-­‐‑exclusions  as  well,  with  many  occurring  between  bilateral  skin  
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sites  or  within  subgroups  of  the  oral  cavity  ([51],  see  also  Figure  3.5).  This  suggested  that  the  
first  level  of  hierarchical  co-­‐‑occurrence  structure  in  this  network  corresponded  with  groups  of  
body  sites  representing  distinct  microbial  habitats.  
Conversely,  within-­‐‑site  relationships  showed  a  much  more  balanced  ratio  of  microbial  
co-­‐‑occurrence  (48.26%)  vs  co-­‐‑exclusion  (51.74%)  interactions.  Many  of  the  negative  within-­‐‑site  
relationships  were  associated  with  the  abundant  signature  organisms  characteristic  of  each  
body  site  [52],  for  example  Streptococcus  in  the  oral  cavity  and  Bacteroides  in  the  gut.  The  relative  
abundances  of  these  signature  taxa  varied  greatly  among  individuals,  in  some  cases  (e.g.  
Bacteroides)  spanning  from  1%  to  97%  within  a  body  site  across  the  HMP  population.  It  is  
generally  very  difficult  to  determine  from  relative  abundance  measurements  alone  whether  
these  negative  associations  represent  true  anti-­‐‑correlation  (e.g.  one  organism  out-­‐‑competing  
another)  or  overgrowth  of  one  organism  while  the  rest  of  the  population  remains  unchanged  
(resulting  in  a  negative  correlation  due  to  compositionality  of  these  data).  This  problem  has  a  
long  history  in  quantitative  ecology  [29,30,53].  Our  methods  generally  determine  these  
relationships  in  the  human  microbiome  to  be  stronger  than  what  would  be  expected  from  
compositionality  alone  (see  Methods  and  Supplemental  Methods),  and  the  negative  interactions  
detected  here  are  thus  likely  biologically  informative.  This  is  supported  by  the  fact  that  they  are  
strongest  in  cases  where  distinct  alternative  dominant  community  members  occurred  among  
different  individuals  (e.g.  Prevotellaceae  vs.  Lactobacillaceae  in  the  vaginal  area  [54]  or  
Propionibacterium  vs.  Staphylococcus  on  the  skin  [52,55]).  The  increase  in  negative  interactions  
within  habitats  is  also  in  line  with  the  fact  that  most  competitive  mechanisms  require  proximity  
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or  physical  contact  [56],  whereas  positive  interactions  are  likely  to  also  occur  from  microbiome-­‐‑
wide  shared  environmental  exposures.  
Association  properties  globally  and  within  body  sites  demonstrate  the  basic  ecological  
organization  of  the  human  microbiota  
We  further  assessed  several  other  measures  of  network  community  structure.  Globally  
speaking,  the  network  followed  a  scale-­‐‑free  degree  distribution  typical  of  biological  systems,  
meaning  that  most  clades  possessed  few  interactions  but  a  few  clades  possessed  many  (Figure  
3.3A  [57]),  The  network  had  a  low  average  path  length  of  three  (contrasted  with  six  in  
randomized  networks),  meaning  that  short  paths  existed  between  most  clades  [58],  and  it  
possessed  a  low  average  per-­‐‑node  cluster  coefficient  (0.1)  measuring  the  local  density  of  
connections.  Together,  these  values  indicate  that  the  microbial  association  network  is  structured  
to  be  scale-­‐‑free  and  thus  robust  to  random  disruption  [57],  with  only  sparse  local  multi-­‐‑
organism  clusters.  Since  these  data  only  describe  phylotypes  at  approximately  the  genus  level,  it  
remains  to  be  seen  whether  a  greater  degree  of  locally  clustered  functional  associations  emerges  
among  Operational  Taxonomic  Units  (OTUs),  species,  or  strains  within  these  phylotypes.  As  the  
cluster  coefficient  distribution  was  not  well  described  by  the  inverse  node  degree  distribution  
[59],  the  network  possesses  no  strong  hierarchical  modularity  despite  its  scale-­‐‑freeness,  in  
contrast  to  the  strong  habitat-­‐‑centric  modularity.  
The  diversity  of  microbial  interactors  (i.e.  number  of  unique  phylotypes)  within  each  
body  site  also  proved  to  directly  dictate  its  interaction  density  (Figure  3.3B).  That  is,  
communities  with  a  greater  number  of  different  organisms  had  a  proportionally  greater  number  
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of  positive  and  negative  associations.  Within  these  sites,  the  number  of  relationships  scaled  
directly  with  the  number  of  unique  phylotypes  (adjusted  R2  of  0.75),  the  only  body  site  with  
more  interactions  than  expected  for  its  diversity  being  the  tongue.  This  site  also  harbored  the  
top-­‐‑ranking  hub  phylotype  (Firmicutes,  see  Figure  3.3A).  In  combination  with  the  behavior  of  
specific  microbial  hubs  as  discussed  below,  this  might  argue  that  most  microbial  taxa  form  
strong  metabolic  or  functional  associations  with  adjacent  taxa  inhabiting  the  same  body  site  
habitat,  allowing  consortia  to  specialize  within  highly  localized  microbial  niches  [50].    
When  randomizing  between  rather  than  within  body  sites,  no  body  site  pairs  possessed  
more  cross-­‐‑site  associations  than  expected  (with  the  slight  exception  of  tongue  dorsum),  
whereas  most  body  sites  were  significantly  enriched  for  within-­‐‑site  relationships  (the  only  
exceptions  being  posterior  fornix,  mid-­‐‑vagina,  and  antecubital  fossae,  which  tended  toward  too  
few  phylotypes  to  reach  significance;  see  Figure  3.3D),  again  confirming  the  microbiome'ʹs  
habitat-­‐‑driven  modularity.  When  calculating  network  properties  in  a  body-­‐‑area-­‐‑specific  
manner,  we  found  that  the  overall  average  path  length  between  nodes  in  the  oral  cavity,  which  
contributes  most  of  the  samples,  was  much  larger  (~3.4)  than  those  of  the  other  body  areas  
(ranging  from  ~1.1  to  ~2.0).  In  addition  to  supporting  the  aforementioned  degree  of  inter-­‐‑site  
habitat  formation  in  the  oral  cavity,  this  intriguingly  suggests  that  other  body  sites  in  which  
fewer  samples  are  currently  available  (see  Table  3.1)  have  not  yet  exhausted  the  detection  of  
microbial  relationships  in  the  human  microbiome.  More  samples  and  greater  sequencing  depth  
may  further  improve  detection  power.  
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Key  taxa  including  members  of  the  Firmicutes  act  as  network  hubs  coordinating  many  
relationships  throughout  the  microbiome  
We  next  examined  the  associations  of  individual  clades  with  respect  to  interaction  
degree,  observing  highly  connected  "ʺhub"ʺ  clades  to  be  found  within  each  body  area.  Two  
classes  of  hubs  appeared  in  the  association  network:  clades  highly  connected  within  one  body  
site,  and  clades  acting  as  "ʺconnectors"ʺ  between  multiple  body  sites.  Hubs  included  both  specific  
taxa  (e.g.  Porphyromonas,  see  Figure  3.3A)  and  larger  taxonomic  groupings  (e.g.  the  phylum  
Firmicutes).  Within-­‐‑site  hubs  were  often,  although  not  always,  abundant  signature  taxa  
(detailed  below),  high-­‐‑degree  exceptions  including  Atopobium  on  the  tongue  (28  total  
associations,  16  within-­‐‑site)  and  Selenomonas  on  both  tooth  plaques  (20  total/19  within  and  7  
total/3  within  for  supra-­‐‑  and  subgingival,  respectively).  The  latter  provides  a  striking  example  
of  the  niche-­‐‑specificity  of  these  low-­‐‑abundance  within-­‐‑site  interactors,  as  Selenomonas  averages  
only  1.1%  and  1.2%  of  the  sub-­‐‑  and  supragingival  plaque  communities,  respectively,  but  
associates  preferentially  (20  of  27,  74%)  with  members  of  the  greater  oxygen  availability  
supragingival  community.  The  clade'ʹs  detection  as  a  within-­‐‑site  hub  thus  corresponds  with  the  
ecology  that  might  be  expected  of  an  organism  known  to  be  oxygen-­‐‑sensitive,  fastidious,  and  
grown  best  in  co-­‐‑culture  [60].  
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Figure  3.3:  Global  network  properties  summarizing  key  microbial  hubs  and  interaction  
patterns.  A)  Node  degree  distributions  of  overall,  co-­‐‑occurrence,  and  co-­‐‑exclusion  associations  
in  the  human  microbiome.  This  is  well-­‐‑fit  by  a  power  law  with  slope  -­‐‑1,7  (dotted  red  regression  
line,  adjusted  R2=0.9).  Node  degree  indicates  the  number  of  links  that  connect  a  node  to  others  
in  the  network.  Power  law  degree  distributions,  referred  to  as  scale-­‐‑free,  mean  that  most  nodes  
have  only  a  few  edges  and  are  often  connected  by  a  few  high-­‐‑degree  hub  nodes,  The  top  five  
most  connected  hubs  as  indicated  in  callouts,  mainly  signature  oral  taxa  including  
Porphyromonas  in  the  tongue  dorsum.  B)  and  C)  Node  proportions  after  division  of  the  network  
into  body  sites  (B)  or  classes  (C).  Both  pie  charts  show  that  the  composition  of  the  network  (in  
agreement  with  underlying  data)  is  skewed  towards  the  oral  cavity  (B)  and  its  constituent  
Firmicutes  (including  Bacilli  and  Clostridia)  (C).  (B)  further  agrees  with  published  measures  of  
body  sites'ʹ  alpha  diversity  [61].  D)  and  E)  Composition  of  relationships  among  microbes  
grouped  according  to  body  site  (D)  and  taxonomic  class  (E).  In  E),  the  first  two  bars  (green  and  
red)  include  the  fraction  of  all  possible  edges  incident  to  at  least  one  node  representing  a  class  
or  one  of  its  members  (root  scaled  for  visualization).  The  second  two  bars  (lime  and  orange)  
only  include  pairs  of  microbes  that  are  members  of  the  same  class,  again  normalized  as  a  
fraction  of  total  possible  interactions  and  root  scaled.  The  Bacilli,  Bacteroidia,  and  Fusobacteria  
contain  significantly  more  negatively  associated  microbes  than  expected  by  permutation  testing,  
and  classes  overall  are  depleted  for  negative  associations,  indicating  that  members  of  the  same  
class  tend  not  to  compete  strongly  with  each  other  in  these  communities.  
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Between-­‐‑site  hubs  typically  operated  among  body  sites  within  the  same  area  as  
described  above,  with  two  of  the  five  most  connected  hub  clades  in  the  network  falling  into  this  
connector  category  linking  multiple  body  sites,  Firmicutes  and  Proteobacteria  on  the  tongue  
(see  Figure  3.3A).  The  Firmicutes  and  Porphyromonas  (phylum  Bacteroidetes)  hubs  in  the  tongue  
also  had  the  largest  numbers  of  negative  connections  among  all  phylotypes,  and  all  of  these  
highly  interactive  clades  centered  on  the  tongue  and  spanned  multiple  related  oral  habitats.  
Signature  clades  such  as  the  Firmicutes  are  of  course  highly  functionally  diverse,  and  this  
network  suggests  that  the  few  abundant  members  in  any  one  habitat  [52]  might  instead  serve  as  
"ʺinformation  processors"ʺ  throughout  a  body  area.  In  contrast  to  the  low-­‐‑abundance  within-­‐‑site  
hubs,  this  would  allow  them  to  provide  baseline  functionality  complemented  by  distinct,  less  
abundant  clades  with  which  they  co-­‐‑occur  within  differing  body  site  habitats.  
Correspondingly,  Firmicutes  and  other  inter-­‐‑site  hub  nodes  showed  a  higher  
connectivity  than  the  clades  with  highest  intra-­‐‑site  degree  (e.g.  Bacteroidales  in  the  subgingival  
plaque).  Such  clades  with  unusually  frequent  inter-­‐‑site  associations  are  thus  outliers  relative  to  
the  network'ʹs  overall  habitat-­‐‑specific  trend  and  suggest  that  inter-­‐‑site  hubs  are  particularly  
critical  for  associating  similar  sites  within  the  same  body  area.  In  the  oropharynx,  for  example,  
Streptococcus  spp.  with  a  modest  degree  of  functional  variation  might  be  present  throughout  the  
habitat,  interacting  with  distinct,  more  specialized  clades  within  each  body  site  [13].  Almost  all  
such  high-­‐‑connectivity  hubs  occurred  among  oral  sites  (e.g.  Porphyromonas,  Streptococcus,  
Veillonella,  and  others),  the  first  notable  exception  being  the  Propionibacterium  hub  on  skin  sites  
(left  and  right  retroauricular  crease).  All  of  these  follow  the  same  pattern,  however,  in  which  
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abundant  phylotypes  likely  possessing  within-­‐‑clade  functional  diversity  are  distributed  among  
related  habitats  within  each  individual.  
Marked  differences  in  ecological  behavior  between  phylogenetic  clades  
We  additionally  examined  the  phylogenetic  rather  than  biogeographical  distribution  of  
these  associations,  testing  whether  clades  tended  to  support  more  phylogenetically  related  
(within-­‐‑clade)  or  diverse  (between-­‐‑clade)  interactions.  We  first  investigated  purely  quantitative  
degree  distributions  by  summarizing  clades  at  the  class  level.  Associations  were  summarized  as  
the  fraction  of  all  possible  interactions  that  were  observed  to  occur,  separated  into  positive  and  
negative  bins  (Figure  3.3E).  In  addition,  clade-­‐‑specific  over-­‐‑representation  of  these  bins  was  
tested  for  significance  by  randomization  (see  Methods).  The  only  classes  that  showed  
significantly  more  negative  (and,  simultaneously,  cross-­‐‑clade)  associations  than  expected  were  
the  Bacteroidia,  Bacilli,  and  Fusobacteria.  Most  of  the  common  classes  in  the  human  microbiome  
had  more  intra-­‐‑clade  edges  than  expected  by  chance  (Actinobacteria,  Bacilli,  Bacteroidia,  
Betaproteobacteria,  Clostridia,  Epsilonproteobacteria,  Fusobacteria,  Gammaproteobacteria,  
Mollicutes,  and  Spirochaetes),  most  of  which  also  have  high  cluster  coefficients  (Supplemental  
Figure  3.3).  Taken  together  with  the  biogeographical  interactions  assessed  above,  the  
enrichment  for  within-­‐‑class  associations  likely  indicates  a  phylogenetic  aspect  of  the  same  
behavior.  Specifically,  if  one  member  of  such  a  class  is  abundant  in  one  body  site  within  an  
individual,  it  (or  closely  related  class  members)  also  tends  to  be  enriched  in  related  body  sites.  
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Figure  3.4:  Co-­‐‑occurrence  of  microbial  clades  within  and  among  body  areas.  Nodes  represent  
microbial  classes  colored  by  phylum,  with  edges  summarizing  aspects  of  their  interactions  over  
all  body  sites.  Classes  are  linked  when  the  number  of  edges  between  them  is  significantly  larger  
than  expected  (randomization  p<0.05,  see  Methods).  Edge  type  (solid  or  dashed)  indicates  the  
body  area  contributing  the  most  edges  to  the  total  interactions  between  two  classes,  with  the  
label  specifying  the  percentage  contributed  by  this  dominant  body  area.  For  instance,  80%  of  the  
edges  between  Bacilli  and  Actinobacteria  come  from  skin  sites.  Green  indicates  co-­‐‑occurrence,  
red  exclusion.  Most  inter-­‐‑class  interactions  occur  in  the  mouth,  with  the  Actinobacteria  and  
Bacilli  forming  negative  hubs.  
We  next  considered  relationships  between  class-­‐‑level  clades  throughout  the  microbiome,  
summarized  in  Figure  3.4.  Surprisingly,  the  Actinobacteria  and  Bacilli  form  only  co-­‐‑exclusion  
relationships  with  other  classes,  most  strongly  with  Bacteroidia  and  Fusobacteria,  and  primarily  
within  the  oral  cavity.  These  clades  (which  include  the  extremely  abundant  streptococci)  might  
thus  be  largely  self-­‐‑sufficient  in  the  functional  diversity  needed  to  maintain  an  oral  community,  
excluding  other  clades  when  appropriately  supported  by  e.g.  environmental  factors.  Although  a  
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few  classes  were  linked  by  positive  as  well  as  negative  interactions  (e.g.  Clostridia  and  
Bacteroidia),  none  of  these  reached  significance  on  randomization,  although  such  behavior  
might  suggest  either  that  the  clades  exhibit  co-­‐‑occurrence  only  in  some  environments  or  that  
some  members  of  the  two  classes  co-­‐‑occur  while  others  co-­‐‑exclude.  As  the  oral  communities  are  
both  the  most  data-­‐‑rich  and  the  most  alpha-­‐‑diverse  in  the  human  microbiome  [52],  it  is  not  
surprising  that  most  relationships  are  observed  within  and  among  them.  For  instance,  97%  of  
the  specific  mutual  exclusions  between  Bacilli  and  Bacteroidia  members  occur  in  oral  sites,  as  do  
81%  of  the  members  of  the  Clostridia  and  Bacteroidia.  The  second  largest  contribution  to  the  
latter  exclusion  (~18%)  comes  from  the  gut,  reflecting  the  frequently  discussed  
Bacteroides/Firmicutes  ratio  observed  in  Western  populations  [15,62],  and  similar  tradeoffs  
(with  few  positive  associations)  were  observed  in  other  habitats  such  as  the  skin  (e.g.  
Staphylococcus  in  the  Bacilli  and  Propionibacterium  in  the  Actinobacteria  [55]).  
Co-­‐‑exclusions  such  as  these  have  previously  been  observed  in  the  human  microbiota  to  
induce  distinct  alternative  community  configurations,  which  may  differ  across  persons  [15,54]  
as  well  as  time  points  (e.g.  early  and  late  colonizers  in  community  establishment  or  
repopulation  after  disturbance).  Although  our  methodology  does  not  explicitly  describe  
alternative  community  configurations,  co-­‐‑occurrence  networks  can  in  some  cases  capture  them  
as  extreme  exclusion  relationships  between  key  microbial  taxa.  For  instance,  Ravel  et.  al  
reported  five  different  vaginal  communities  in  an  independent  cohort  of    healthy  women,  four  
dominated  by  Lactobacilli  and  the  fifth  diverse  and  featuring  members  of  the  Actinobacteria,  
Clostridia,  Bacteroidia,  and  other  classes.  These  alternative  configurations  occur  as  mutual  
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exclusions  in  our  genus-­‐‑level  phylotypes  between  Lactobacillus  and  members  of  this  fifth  diverse  
community  (particularly  anaerobes  such  as  Anaerococcus  and  the  Prevotellaceae).  Furthermore,  
we  see  a  strong  negative  correlation  in  stool  samples  between  Bacteroides  and  members  of  the  
gut  community,  including  the  Ruminococcaceae  and  other  Firmicutes.  In  other  body  sites,  the  
clade  relationship  network  (Figure  3.4)  features  a  negative  interaction  between  Bacilli  and  
Bacteroidia  classes  that  mostly  occurs  in  the  oral  cavity,  and  oral  Porphyromonas  (a  member  of  
the  Bacteroidia)  is  among  the  most  highly  connected  negative  hubs.  Porphyromonas  is  abundant  
(avg.  3.3%  s.d.  3.9%)  in  oral  habitats  but  not  in  most  cases  the  dominant  clade;  the  clade  also  
includes  potential  oral  pathogens  [63],  and  this  may  be  one  of  the  more  striking  examples  of  
functional  competition  and  co-­‐‑exclusion  occurring  with  a  specific  clade  among  several  oral  
communities.  
Microbial  relationships  within  digestive  tract  niches  including  Fusobacterium  and  Prevotella  
support  known  microbiology  
The  digestive  tract  is  home  to  one  of  the  most  diverse  and  densely  populated  microbial  
communities  in  the  human  body  [11].  Oral  sites  made  up  half  of  the  body  sites  surveyed  here,  
as  well  as  exhibiting  the  greatest  within-­‐‑subject  microbial  diversity  [52].  Correspondingly,  
associations  between  microbes  within  and  among  oral  sites  likewise  comprised  the  majority  
(86.46%)  of  all  edges  in  our  co-­‐‑occurrence  network,  also  forming  its  largest  connected  
component.  This  consisted  of  two  clusters  of  organisms  from  the  mouth  soft  tissues  (gingiva,  
mucosa,  and  palate)  and  distal  areas  (tongue,  throat,  tonsils,  and  saliva);  the  oral  hard  surfaces  
(sub-­‐‑  and  supra-­‐‑gingival  plaques)  formed  an  additional  isolated  habitat  that  showed  
significantly  fewer  microbial  associations  with  the  remainder  of  the  oral  cavity  (Figure  3.5).  A  
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complementary  analysis  of  the  HMP  microbiomes  has  revealed  evidence  of  three  sub-­‐‑habitats  
within  the  oral  cavity  based  on  overall  similarity  of  their  microbial  communities  [51],  and  these  
results  demonstrate  that  the  shared  community  structures  of  these  habitats  were  to  a  lesser  
degree  recapitulated  in  terms  of  specific  microbial  associations  (see  Figure  3.5  below).  
  
Figure  3.5:  Related  microbial  niches  as  determined  by  associations  spanning  habitats  at  
multiple  human  body  sites.  Each  node  represents  a  body  site,  with  edge  width  indicating  
significant  cross-­‐‑site  correlations  (randomization  p<0.05,  see  Methods).  Green  edges  show  co-­‐‑
occurrence,  red  co-­‐‑exclusion.  Skin,  vaginal,  oral  soft  tissue,  and  tooth  plaque  moieties  are  
apparent,  with  the  gut  and  airways  notably  lacking  significant  interactions  with  other  available  
body  site  niches.  However,  most  relationships  between  microbial  relative  abundances  occur  
specifically  within,  rather  than  between,  individual  body  sites.  
Although  the  current  study  is  associative  and  does  not  by  itself  establish  causative  
mechanisms  of  interaction  for  these  microbial  associations,  many  that  we  detect  in  the  oral  
cavity  in  particular  are  supportd  by  known  metabolic  or  biochemical  interactions.    For  instance,  
in  the  context  of  cell  to  cell  interaction,  Fusobacterium  species  are  known  to  be  bridging  
organisms  in  the  development  of  oral  biofilms  by  co-­‐‑aggregation  through  physical  contact  [64].  
This  bridging  occurs  during  biofilm  maturation,  allowing  a  more  complex  use  of  resources  
including  sugars  (the  predominant  carbon  source  for  early  colonizers)  and  proteins  (used  by  
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late  colonizers).  In  the  hard  palate,  for  example,  positive  associations  were  found  between  
Fusobacterium  and  Capnocytophaga,  Peptosptreptococcus,  and    Porphyromonas,  which  are  in  
agreement  with  previously  published  cell-­‐‑to-­‐‑cell  interactions  [65,66],  and  these  predictions  
additionally  implicate  Leptotrichia  and  Parvimonas.  Dental  plaque  associations  included  
Parvimonas,  Prevotella,  and  Treponema,  also  in  agreement  with  existing  evidence  [67].  However,  
those  previously  published  aggregations  are  strain  specific  and,  this  study  may  be  observing  
broader  effects  than  the  direct  cell-­‐‑cell  contact  preferences  in  previously  described  associations.  
Conversely,  metabolic  shifts  may  explain  negative  associations  detected  between  other  
co-­‐‑habiting  microbes,  e.g.  Tannerella  and  Streptococcus  in  the  subgingival  plaque.  The  anaerobic  
Tannerella  requires  a  much  lower  pO2  than  Streptococcus  and  is  proteolytic,  while  Streptococcus  is  
a  saccharolytic  colonizer  of  the  tooth  surface  that  uses  sugars  as  its  primary  source  of  carbon  
and  is  oxygen  tolerant  [68,69].    This  continuous  nutritional,  metabolite  (e.g.  hydrogen  peroxide),  
and  oxygen  gradient  between  the  supragingval  and  the  subgingival  biofilms,  along  with  
differential  exposure  to  host  factors  in  saliva,  is  reflected  through  the  gradual  drop  of  the  
abundance  of  Tannerella  as  the  streptococci  increase  (Supplemental  Figure  3.4).  A  similar  
example  can  be  found  in  the  Prevotella  and  species  from  the  Flavobacteriaceae  (represented  here  
by  Capnocytophaga;  mean  abundance  1.68±2.76%)  in  the  tonsils.  Less  exposed  surfaces  of  
tonsillar  crypts  offer  an  anaerobic  micro-­‐‑environement  favoring  species  like  Prevotella,  while  
other  areas  support  the  growth  of  carbon  dioxide-­‐‑dependant  Capnocytophaga,  a  tradeoff  that  we  
detect  here  as  a  specific  negative  association.  
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Phyla  such  as  the  TM7  and  Synergistetes  have  only  recently  been  characterized  at  the  
genetic  level  in  the  oral  cavity  [70,71],  and  little  is  yet  known  about  their  roles  in  this  microbial  
ecosystem.  We  identified  a  number  of  novel  co-­‐‑occurrences  between  members  of  these  under-­‐‑
characterized  phyla,  including  a  positive  association  between  members  of  the  TM7  phylum  
(mean  abundance  0.62±1.14%)  and  Moryella  genus  members  (mean  abundance  0.29±0.47%)  in  
the  tongue  dorsum  and  a  positive  relationship  between  members  of  the  Synergistetes  phylum  
and  Treponema  in  the  subgingival  biofilm.  Since  limited  data  on  metabolic  byproducts  or  
requirements  for  these  clades  in  the  oral  community  are  available,  these  newly  identified  
putative  interactors  provide  specific  hypothesis  for  follow-­‐‑up  studies  (e.g.  by  co-­‐‑culture  
experiments).  
The  degree  to  which  microbial  shedding  from  the  oral  cavity  along  the  digestive  tract  
might  seed  the  distal  commensal  gut  microbiota  is  as  yet  unclear  [72].  We  found  few  (7)  
relationships  between  organisms  in  the  two  areas  meeting  our  significance  criteria,  none  of  
which  were  consistently  supported  by  a  majority  of  available  data  (Supplemental  Figure  3.5),  
suggesting  no  such  direct  microbial  seeding  within  our  level  of  detection  in  the  healthy  adult  
microbiome.  Interactions  detected  within  the  gut  itself  consisted  primarily  of  negative  
associations  between  Bacteriodes  and  Clostridia,  especially  members  of  the  Ruminococcaceae  
family.    These  negative  relationships  reflect  the  tradeoff  between  Bacteroides  (mean  abundance  
48.79±22.94%,  range  1.47-­‐‑97.14%)  and  Firmicutes  (mean  abundance  27.04±16.52%,  range  1.49-­‐‑
91.78%),  the  two  dominant  gastrointestinal  taxa  and  the  subject  of  previous  close  study  [15,73].  
While  oral  microbial  transit  is  clearly  important  during  founding  of  the  microbiome  in  infancy  
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and  in  extreme  cases  such  as  illness  [74,75],  these  data  suggest  that  it  occurs  at  low  levels  in  the  
normal  adult  microbiome.  In  such  hosts,  the  naturally  dense  microflora  of  the  lower  gut  may  
serve  to  further  exclude  the  few  bacteria  that  survive  gastrointestinal  transit  [72].  
Similarities  among  niches  in  the  microbiome  determined  by  microbial  associations  spanning  
body  sites  
It  is  common  practice  to  group  microbial  communities  by  ecological  similarity  [50,52],  
and  we  extended  this  analysis  method  by  summarizing  relationships  among  similar  habitats  
based  on  microbial  cross-­‐‑talk  (Figure  3.5).  Specifically,  we  organized  pairs  of  body  sites  by  the  
frequency  with  which  they  demonstrated  co-­‐‑occurring  (or  excluding)  microbes  (see  Methods).  
Overall,  this  network  recapitulates  similarities  in  community  structure  among  these  microbial  
habitats  as  assessed  by  beta-­‐‑diversity  [52],  with  the  added  information  of  which  microbes  might  
drive  these  similarities.  Conversely,  co-­‐‑exclusions  spanning  multiple  habitats  might  represent  
cases  in  which  competitive  relationships  or  differing  responses  to  host  environment  might  
bridge  multiple  habitats.  Stool  microbes  (representing  the  gut  microbiota),  as  above,  did  not  
demonstrate  any  detectable  associations  with  inhabitants  of  the  mouth;  the  airways  microbiota  
(nares)  likewise  associated  minimally  with  other  body  site,  although  they  were  detectably  
structurally  similar  to  the  skin  communities.  The  sub-­‐‑  and  supra-­‐‑gingival  plaques  were  distinct  
from  other  mouth  sites,  and  the  vaginal  communities  and  skin  were  again  all  highly  similar.  
The  sparsity  of  this  body  site  network  again  illustrates  that  phylotypes  rarely  participate  in  
detectable  ecological  relationships  spanning  distal  body  site  habitats.  
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Functional  and  phylogenetic  similarities  among  associated  organisms  suggest  competitive  and  
adaptive  explanations  for  interactions  
We  hypothesized  based  on  previous  findings  in  environmental  communities  [20]  that  
patterns  of  microbial  co-­‐‑occurrence  and  exclusion  might  be  explained  by  their  evolutionary  
relatedness  and  functional  similarity.  For  example,  closely  related  microbes  might  compete  for  
limited  resources,  while  functionally  complementary  bacteria  would  exhibit  mutualism.  To  test  
this  hypothesis,  we  compared  two  genomic  properties  of  all  microbial  clades  appearing  in  our  
network,  their  phylogenetic  similarity  (i.e.  evolutionary  relatedness)  and  a  "ʺfunctional"ʺ  
similarity  score  based  on  counting  shared  orthologous  gene  families  (i.e.  a  measure  of  shared  
pathways  and  metabolic  capacity).  Phylogenetic  distances  were  calculated  as  evolutionary  
divergence  based  directly  on  16S  sequence  dissimilarity  between  all  pairs  of  microbes.  We  
compared  this  with  a  "ʺfunctional"ʺ  distance  calculated  as  the  Jaccard  index  of  non-­‐‑shared  COG  
families  between  all  pairs  of  microbial  genomes  (see  Methods).  For  most  pairs  of  microbes,  
these  measures  were  highly  correlated  (Figure  3.6),  not  necessarily  surprising  in  that  both  are  
influenced  by  gradual  sequence  change  driven  by  molecular  evolution.  
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Figure  3.6:  Functional  and  phylogenetic  similarities  between  co-­‐‑occurring  microbes.  
Evolutionary  (phylogenetic)  distances  among  microbial  clades  were  compared  to  the  clades'ʹ  
functional  potentials  as  defined  by  the  Jaccard  index  of  orthologous  gene  (COG)  families  shared  
between  genomes  (see  Methods).  Each  point  represents  a  pair  of  significantly  associated  
microbes  colored  by  direction  of  the  association  (green  positive,  red  negative)  and  shaped  by  
the  type  of  relationship  (triangle:  between  body  sites,  square:  within  site).  Phylogenetic  
distances  were  inferred  by  FastTree  [48]  using  species-­‐‑level  16S  sequences.  Most  interactions  lie  
along  the  diagonal,  reflecting  the  baseline  correlation  between  these  functional  and  
evolutionary  distances,  with  highly  related  clades  co-­‐‑occurring  among  related  habitats  (e.g.  
bilateral  skin  sites,  proximal  oral  sites)  in  the  lower  left.  Off-­‐‑diagonal  examples  include  potential  
competition  among  dominant  gut  signature  taxa  (e.g.  Prevotellaceae/Bacteroides)  and  functional  
complementarity  between  distinct  oral  pathogens  (e.g.  Treponema/Prevotella).  
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However,  several  exceptions  to  this  pattern  were  apparent  among  the  interacting  
organisms  of  our  study.  First,  a  dramatic  separation  of  phylogenetic  and  functional  distances  
occurred  between  positively  and  negatively  associated  clades  (Figure  3.6,  green  lower  left  vs.  
red  upper  right):  positive  associations  were  enriched  for  both  phylogenetic  and  functional  
similarity,  while  negative  associations  showed  the  inverse  pattern.  This  was  partially  explained  
by  the  basic  observation  that  similar  organisms  occupy  similar  niches,  as  most  relationships  
among  similar  organisms  occurred  between  clades  at  different  body  sites  and  often  between  the  
same  clade  at  two  proximal  (e.g.  oral)  or  bilateral  sites  (e.g.  left  and  right  retroauricular  creases).  
Conversely,  the  preference  for  negative  correlations  to  occur  between  phylogenetically  and  
functionally  different  organisms  (top  right)  suggests  that  the  wide  range  of  co-­‐‑exclusion  
mechanisms,  not  only  direct  competition  but  also  toxin  production,  environmental  
modification,  and  differential  niche  adaptation  [76]  required  substantial  time  to  develop  
throughout  evolution.  Furthermore,  interactions  in  the  same  body  site  were  primarily  negative,  
suggesting  that  competition  or  subniche  differentiation  were  more  prevalent  in  these  data  than  
were  collaboration  or  niche  sharing.  
Exceptions  to  both  of  these  trends  did  occur,  however,  in  that  related  organisms  
occasionally  showed  within-­‐‑site  competition,  and  phylogenetically  distant  clades  sometimes  co-­‐‑
occurred.  A  highlighted  example  of  the  former  was  the  negative  association  between  Bacteroides  
and  Prevotellaceae  family  members  (also  phylum  Bacteroidetes)  in  the  gut,  reflecting  the  
recurrent  tradeoff  of  this  genus  with  the  Prevotella  as  previously  linked  to  enterotypes  [15]  
and/or  dietary  patterns  [77].  As  these  organisms  are  closely  related,  this  might  reflect  alternative  
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metabolic  specializations  in  an  otherwise  fairly  similar  gut  environment.  Conversely,  the  
Aggregatibacter  were  positively  associated  with  members  of  the  highly  dissimilar  
Flavobacteriaceae  family  in  the  saliva.  As  mentioned  above,  the  Capnocytophaga  (dominant  
members  of  the  Flavobacteriaceae  in  these  data)  are  highly  metabolically  dependent,  and  
positive  correlations  among  organisms  are  enriched  in  oral  biofilm  associated  organisms  
generally  (see  Figures  3.3  and  3.4).  
In  addition  to  these  on-­‐‑diagonal  outliers  (Figure  3.6),  several  additional  groups  of  
organisms  lay  off  the  trend  of  functional  and  phylogenetic  similarity.  That  is,  some  co-­‐‑
occurring/co-­‐‑exclusive  microbes  were  evolutionarily  distant  but  functionally  more  similar  than  
expected  (below  trend),  while  others  were  evolutionarily  close  but  functionally  distinct  (above  
trend).  Several  relationships  in  the  upper-­‐‑left  represent  single  functionally  diverse  clades  that  
are  also  widely  co-­‐‑distributed  among  bilateral  or  related  body  sites,  such  as  the  Actinobacteria  
(skin)  and  Fusobacteriaceae  (oral).  Such  clades'ʹ  functional  distances  reflect  a  relatively  high  
level  of  within-­‐‑clade  diversity,  raising  the  possibility  that  a  combination  of  environmental  
perturbation  with  a  highly  structured  microenvironment  might  help  to  maintain  a  tension  of  
high  functional  diversity  within  a  limited  phylogenetic  range.  
In  the  oral  cavity,  co-­‐‑occurrence  of  such  outliers,  appearing  off  the  trend  of  functional  
and  phylogenetic  similarity  (Figure  3.6)  was  limited  to  low-­‐‑abundance  community  members,  
with  some  exceptions.  Abundant  signature  taxa  such  as  Streptococcus  and  Neisseria  often  
excluded  clades  with  more  stringent  environmental  oxygen  requirements  regardless  of  their  
specific  degree  of  relatedness.  Prevotella  -­‐‑  evolutionarily  distant  from  the  Neisseria  but  sharing  
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much  functional  potential  as  defined  by  orthologous  gene  clusters  -­‐‑  exhibited  a  negative  
association  in  the  tonsil.  Because  of  their  functional  similarity,  particularly  their  shared  
metabolic  requirements  (both  with  varying  degrees  of  saccharolytic  and  proteolytic  activities  at  
the  species  level  [78,79]),  this  strongly  suggests  a  co-­‐‑exclusion  due  to  competition  for  resources,  
again  in  addition  to  their  environmental  oxygen  requirement.  At  the  family  level,  
Pasteurellaceae  (composed  of  Actinobacillus,  Aggregatibacter,  Haemophilus,  and  Pasteurella)  
negatively  correlate  with  several  other  members  of  the  microbiota.  Co-­‐‑occurrence  is  more  
common  with  pairs  of  functionally  similar  microbes  able  to  co-­‐‑exist  through  combinations  of  
complementarity,  commensalism,  and  cross-­‐‑feeding  of  vitamins,  amino  acids,  and  other  
cofactors.  Here,  the  Prevotella  produce  hydrogen,  which  influences  the  growth  of  
Campylobacteria  [80].  Prevotella  can  also  be  supported  by  glycine  and  pyruvate  produced  from  
glutathione  by  Treponema  species  in  the  periodontal  pocket.  The  most  extreme  case  of  organisms  
both  related  and  correlated  were  the  Bacteroides  and  Parabacteroides  in  the  anterior  nares.  While  
these  clades  are  not  always  well-­‐‑resolved  [81],  this  trend  occurred  in  nine  distinct  samples  (of  
282  total),  the  only  ones  in  which  Bacteroides  occurred  nasally  at  >5%  abundance.  While  a  trivial  
explanation  might  be  misclassification  of  a  small  portion  of  Bacteroides,  this  trend  might  instead  
suggest  co-­‐‑occurrence  in  a  metabolic  niche  that  rarely  favors  either  organism  but,  in  the  rare  
occasion  of  favoring  one,  permits  both.  
Discussion  
We  analyzed  ecological  interactions  among  bacteria  in  the  human  microbiome  using  16S  
marker  gene  abundance  data  from  the  Human  Microbiome  Project.  Our  methods  for  building  a  
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microbiome-­‐‑wide  microbial  association  network  combined  two  complementary  approaches:  an  
ensemble  of  similarity/dissimilarity  measures  and  a  compendium  of  generalized  boosted  linear  
models.  Relationship  significance  was  assessed  using  a  novel  nonparametric  approach  to  
compositional  data  analysis,  resulting  in  a  network  of  co-­‐‑occurrence  and  co-­‐‑exclusion  
relationships  representing  potential  microbial  interactions  and  incompatibilities  within  and  
across  body  sites.  Analysis  of  the  network  demonstrated  strong  organization  of  the  human  
microbiota  into  body  area  niches,  mostly  among  closely  related  individual  body  sites  
representing  microbial  habitats.  A  few  "ʺhub"ʺ  microbes  were  observed  to  act  as  signature  taxa  
driving  the  composition  of  each  microcommunity.  Many  of  these  were  also  the  dominant  
species  within  a  body  area,  for  example  Streptococcus  in  the  oral  cavity  and  Bacteroides  in  the  gut,  
and  these  highly  abundant  taxa  also  frequently  co-­‐‑occurred  as  connectors  among  multiple  
related  body  sites.  In  vivo  mechanisms  were  available  from  prior  work  for  many  of  these  
associations,  and  more  generally  the  phylogenetic  and  functional  relatedness  of  pairs  of  co-­‐‑
occurring  microbes  often  explained  their  associations.  In  particular,  phylogenetically  related  
microbes  tended  to  co-­‐‑occur  at  proximal  or  environmentally  similar  body  sites,  while  distantly  
related  microbes  with  shared  functional  capacities  tended  to  compete.  
This  microbial  association  network  was  described  from  observational  data,  and  the  
mechanisms  underlying  any  of  these  putative  interactions  may  be  quite  diverse.  Positive  co-­‐‑
occurrence  association  types  could  include  nutritional  cross-­‐‑feeding,  co-­‐‑aggregation,  co-­‐‑
colonization,  signaling  pathways,  and  co-­‐‑survival  in  similar  environments  [4,82].  Negative  
exclusion  interactions  likewise  might  span  toxin  or  small  molecule  production,  environmental  
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modification  (to  the  detriment  of  microbial  neighbors),  immunomodulation,  or  gross  
overpopulation  of  a  niche.  Ecologically,  these  data  alone  do  not  resolve  variations  of  mutualism,  
commensalism,  amensalism,  or  predator-­‐‑prey  relationships  [4,82].  Further,  all  of  these  
ecological  relationships,  detected  here  based  on  microbial  abundance  patterns  across  many  
subjects,  are  themselves  distinct  from  the  biogeographical  "ʺco-­‐‑occurrence"ʺ  patterns  observed  by  
previous  studies  of  individual  microbes  within  subjects  [33,34].  To  distinguish  between  these,  
future  work  could  include  perturbation  experiments  (e.g.  the  removal  of  a  species  from  a  
defined  habitat  such  as  the  gut  of  a  gnotobiotic  mouse),  as  these  are  becoming  less  difficult  to  
sustain  technically  [83].  Analytic  refinements  might  instead  include  defining  directionality  of  
relationships  in  higher-­‐‑resolution  (e.g.  temporal)  data;  for  instance,  we  expect  a  strict  
mutualistic  relationship  (where  both  partners  cannot  exist  without  the  other)  to  be  symmetric,  
whereas  the  relationship  between  a  prey  and  a  specialized  predator  is  expected  to  be  
asymmetric  (the  prey  can  occur  without  its  predator,  but  not  vice  versa).  Negative  co-­‐‑exclusions  
may  have  fewer  possible  initial  interpretations,  comprising  the  types  of  competition  outlined  
above,  or  they  may  indicate  different,  exclusive  microbial  community  states  occurring  
temporally  or  as  linked  to  host  environment  [15,54,77].    
Methodologically,  it  is  again  important  to  emphasize  that  detecting  significant  co-­‐‑
occurrences  among  members  of  a  population  assayed  as  relative  abundances  can  be  
surprisingly  difficult  due  to  compositionality  [29].  That  is,  an  absolute  increase  in  one  
organism'ʹs  abundance  can  result  in  an  apparent  relative  decrease  of  all  other  abundances,  
leading  to  spurious  correlations.  Extensive  prior  work  has  explained  the  problem  in  microbial  
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and  macroecological  settings  [53,84],  and  we  have  mitigated  potential  issues  in  these  data  
through  our  ensemble  approach  and  by  principled  calculation  of  significance  thresholds  using  
null  distributions  that  incorporate  the  degree  of  similarity  due  solely  to  compositional  effects  
(see  Methods,  Appendix  3).  GBLMs  were  the  most  distinct  method  included  in  this  ensemble  
and  share  some  similarities  with  recently  proposed  genetic  regulatory  network  (GRN)  
reconstruction  techniques  [85].  GBLMs  do  provide  methodology  for  discovering  GRN-­‐‑like  
higher-­‐‑order  interactions  in  microbial  communities,  but  the  accuracy  needed  to  overcome  the  
associated  multiple  hypothesis  testing  problems  is  not  yet  achievable  from  available  16S  data  
[86,87].  We  anticipate  that  future  studies  with  species-­‐‑  or  strain-­‐‑level  classification  of  deep  
shotgun  metagenomic  sequences  may  provide  sufficient  resolution  for  more  detailed  networks  
including  such  cooperative  microbial  associations.    
While  it  might  be  hoped  that  easily  sampled  microbiomes  such  as  the  saliva  would  serve  
as  proxies  for  e.g.  the  broader  oral  microbiome,  these  results  suggest  that  this  is  not  generally  
the  case.  There  are  few  strong  correspondences  among  organisms  even  at  closely  related  body  
sites,  let  alone  distal  sites,  and  very  few  cases  where  microbial  abundance  is  quantitatively  
predictable  from  a  proxy  sample.  In  the  HMP,  this  may  be  a  feature  of  a  healthy  population,  
and  additional  relationships  (or  disruption  of  existing  ones)  might  emerge  in  the  presence  of  
disease.  Environmental  factors  that  strongly  impact  the  healthy  microbiome  may  additionally  
not  be  captured  for  this  population  (e.g.  diet)  and  can  be  further  investigated  by  targeted  
methodology  in  future  cohorts.  
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This  catalog  of  microbial  co-­‐‑occurrence  and  co-­‐‑exclusion  relationships  thus  provides  an  
initial  glimpse  of  potential  mechanisms  of  community  organization  throughout  the  human  
microbiome.  While  this  computational  methodology  can  be  applied  to  any  communities  
assayed  using  marker  gene  sequencing,  it  is  interesting  to  conclude  by  noting  that  the  resolution  
of  the  resulting  network  is  limited  by  the  specificity  of  16S  sequence  binning.  The  network  
discussed  here,  for  example,  leverages  two  specific  hypervariable  regions  for  taxonomic  
classification,  each  with  strengths  and  weaknesses,  and  neither  individually  adequate  for  
sequence  classification  at  the  species  level  [88,89].  Since  it  is  likely  that  additional  microbial  
associations  will  occur  at  the  species  or  strain  level,  we  anticipate  that  further  community  
structure  will  emerge  during  analysis  of  metagenomic  shotgun  sequences  taxonomically  binned  
at  a  finer  level  of  detail.  Community  shotgun  sequencing  will  also  provide  functional  
information  regarding  metabolism,  signaling,  and,  again,  potential  physical  mechanisms  of  
interaction,  which  can  in  turn  be  matched  against  complete  reference  genomes  for  co-­‐‑occurring  
strains.  Perturbation  analyses  in  co-­‐‑culture  or,  eventually,  longitudinal  studies  in  human  
cohorts  will  provide  an  intriguing  means  of  investigating  the  impact  of  these  microbial  "ʺwiring"ʺ  
diagrams  on  human  health.  
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Chapter  4:  Integrative  Genomics  of  Sexual  Dimorphism  in  COPD  
Abstract  
Chronic  Obstructive  Pulmonary  Disease  (COPD)  is  the  third  leading  cause  of  death  in  
the  United  States.  Epidemiologic  studies  report  more  women  than  men  dying  from  COPD  with  
additional  data  suggesting  that  females  may  be  biologically  more  susceptible  to  the  disease.  To  
identify  molecular  pathways  associated  with  sexually  dimorphic  features  of  COPD,  we  used  
lung  tissue  gene  expression  data  from  the  Lung  Genomics  Research  Consortium  to  identify  959  
genes  with  sexually  dimorphic  patterns  of  differential  expression  in  the  presence  of  COPD  
(“sexually  dimorphic  and  COPD  differential”  or  “SDCD”  genes).  Gene  set  enrichment  analysis  
highlighted  processes  including  chemotaxis,  inflammatory  responses,  cell  morphogenesis,  and  
VEGF  signaling.  We  observed  that  a  subset  of  SDCD  genes  are  more  likely  to  be  targeted  by  
progesterone,  vitamin  D,  and  PPAR-­‐‑gamma,  and  their  promoters  contain  an  overrepresentation  
of  estrogen  and  androgen  response  elements.  We  also  observed  sex-­‐‑specific  differential  
methylation  for  one  third  of  the  SDCD  genes.  A  sex-­‐‑stratified  eQTL  analysis  identified  94  SDCD  
genes  with  suggested  genetic  regulation  of  gene  expression.  Our  study  represents  the  first  
systematic  integrative  genomic  survey  of  sexual  dimorphic  gene  expression  in  COPD,  illustrates  
involvement  of  key  gene  regulation  mechanisms  such  as  hormones,  methylation,  and  genetic  
modification,  and  highlights  the  importance  of  sex-­‐‑specific  approaches  to  the  diagnosis,  
treatment,  and  primary  prevention  of  COPD.  
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Introduction  
Chronic  Obstructive  Pulmonary  Disease  (COPD)  is  the  third  leading  cause  of  death  in  
the  US  [1,2];  for  over  a  decade,  more  women  than  men  have  died  of  COPD  [3,4].  Increases  in  
cigarette  smoking  by  women  in  the  1960s  and  1970s  may  account  for  some  of  the  observed  
increase  in  female  mortality.  However,  even  when  controlling  for  smoking  history,  females  are  
more  susceptible  to  COPD  than  men  [5,6],  develop  more  severe  symptoms  at  an  earlier  age  
[7,8],  and  have  worse  health  outcomes  [9].  In  addition  to  variable  susceptibility  and  severity  of  
COPD,  the  disease  sub-­‐‑phenotypes  differ  between  the  sexes,  with  chronic  bronchitis  more  
prevalent  in  females  and  emphysema  more  prevalent  in  males  [9,10].    
Multiple  mechanisms  may  contribute  to  the  sexually  dimorphic  features  of  COPD,  
including  variable  xenobiotic  metabolism  of  tobacco  smoke,  differential  airway  inflammation  
and  bronchial  hyperresponsiveness  to  noxious  stimuli,  and  differences  in  lung  anatomy  and  
size  [5,6].  In  addition,  sex  hormones  likely  influence  airway  function,  response  to  injury  and  
repair,  as  reflected  in  sex  differences  in  age-­‐‑dependent  risk  of  childhood  asthma  [11],  the  larger  
decrease  in  lung  function  in  adolescent  girls  compared  to  adolescent  boys  who  smoked  
cigarettes  [12],  and  the  increased  risk  for  COPD  among  post-­‐‑menopausal  women  [13].  Estrogen  
has  also  been  associated  with  increased  metabolism  of  nicotine  through  cytochrome  P450  (CYP)  
without  increased  activity  of  the  detoxifying  enzymes  [5],  producing  higher  oxidative  stress  in  
the  lungs  of  female  smokers.  Reduced  endogenous  testosterone  levels  have  been  observed  in  
men  with  COPD  [14,15]  and  testosterone  supplementation  has  been  investigated  to  improve  
muscle  strength  in  men  with  COPD  [16,17].  In  addition,  vitamin  D  receptor  [18,19]  and  
peroxisome  proliferator-­‐‑activated  receptor  gamma  (PPARG)  [20]  have  been  implicated  in  lung  
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disease  and  manifest  sex  specific  functions  [21-­‐‑23]  and  may  contribute  to  sex  differences  in  
COPD.  
While  many  lines  of  evidence  indicate  sex  differences  in  COPD  biology  and  physiology  
[5,24,25],  there  is  little  understanding  of  the  molecular  and  cellular  mechanisms  of  COPD  sexual  
dimorphism.  Gene  expression  studies  have  identified  both  genes  and  pathways  relevant  to  
COPD  [26-­‐‑29],  but  none  of  these  studies  has  systematically  interrogated  sex-­‐‑specific  
associations.  The  Lung  Genomics  Research  Consortium  (LGRC;  www.lung-­‐‑genomics.org)  
provides  genetic,  molecular,  and  quantitative  phenotype  data  for  patient  samples  in  the  
NHLBI’s  Lung  Tissue  Research  Consortium  (LTRC)  biorepository.  The  LGRC  data  include  gene  
expression,  DNA  methylation,  and  genotype  information  on  several  hundred  COPD  and  
control  lung  tissue  samples.  Here  we  describe  an  analysis  of  the  LGRC  data  to  identify  
molecular  processes  and  pathways  that  differ  in  lung  tissue  from  male  and  female  subjects.  We  
identified  959  genes  with  sexually  dimorphic  differential  expression  that  represent  pathways  
including  chemotaxis,  inflammatory  response,  cell  morphogenesis,  and  VEGF  signaling.  These  
959  genes  are  enriched  for  hormone  response  elements,  and  we  have  also  found  evidence  for  
sexually  dimorphic  methylation  and  genetic  regulation,  suggesting  potential  mechanisms  
regulating  sexually  dimorphic  gene  expression.  
Methods  
Reproducible  research  
We  have  provided  the  code  used  in  this  analysis  as  a  Bioconductor  package  
COPDSexualDimorphism  
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(http://www.bioconductor.org/packages/release/bioc/html/COPDSexualDimorphism.html)  and  
a  companion  experiment  data  package  COPDSexualdimorphism.data.  
LGRC  data  processing  
We  retrieved  clinical  metadata,  gene  expression,  and  methylation  data  from  the  LGRC  
Data  Portal  (https://www.lung-­‐‑genomics.org/research);  genotype  data  have  been  deposited  in  
the  dbGaP  repository  (accession  number:  phs000624.v1.p1  in  progress).  The  data  were  
processed,  all  with  Human  Genome  Version  19  (hg19)  annotation,  as  follows.  
LGRC  samples  
There  are  1,359  total  lung  tissue  and  blood  samples  in  the  LGRC,  comprising  576  
samples  from  interstitial  lung  disease  (ILD)  patients,  511  from  COPD  patients,  and  272  from  
controls  (mostly  normal  lung  tissues  from  COPD/ILD-­‐‑free  patients  with  lung  cancer).  We  first  
removed  708  blood  samples,  leaving  651  whole  lung  samples.    Of  the  whole  lung  samples,  283  
clinically  diagnosed  ILD  samples  and  36  samples  with  pathological  features  of  ILD  were  
removed.  To  reduce  genetic  heterogeneity  of  the  data,  16  non-­‐‑Caucasian  samples  were  
removed.  Eight  additional  samples  were  removed  because  they  were  labeled  as  COPD  but  had  
spirometric  measures  in  the  normal  range.  Seven  more  samples  were  removed  because  they  
were  labeled  as  former  smokers  but  had  zero  pack  years  of  cigarette  smoking  in  the  record.  We  
also  removed  15  samples  whose  smoking  statuses  or  pack  years  were  unknown.  Two  samples  
were  excluded  because  they  had  high  pre-­‐‑bronchodilator  FEV1/FVC  ratios  (1.3  and  2.4),  and  an  
additional  15  samples  were  removed  based  on  the  clinical  diagnoses.  Some  subjects  contributed  
more  than  one  sample  (for  example  samples  from  left  and  right  lungs);  we  removed  15  
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duplicate  samples  and  kept  the  samples  with  more  complete  genetic  and  molecular  phenotypes.  
Finally,  we  flagged  26  control  samples  with  low  diffusion  capacity  (DLCO  <  80)  to  perform  
sensitivity  analysis.  In  the  end  179  COPD  samples  (102  male,  77  female)  and  75  control  samples  
(31  male,  44  female)  passed  these  criteria  (254  total)  and  were  used  in  the  subsequent  analyses.  
Gene  expression  data  processing  
GCRMA-­‐‑normalized  gene  expression  data  from  Agilent  Whole  Human  Genome  4  ×  44K  
arrays  (G4112F,  Agilent  Technologies)  were  downloaded  from  LGRC  Data  Portal  (www.lung-­‐‑
genomics.org/research;  accessed  November  2011).  We  mapped  probe  names  to  Ensembl  gene  
ID  using  BiomaRt  R  package.  Only  one  of  the  probes  with  highest  variance  among  the  probes  
mapped  to  the  same  Ensembl  gene  ID  was  kept  (14,497  probes  left).  Surrogate  variable  analysis  
[30]  identified  no  significant  batch  effect.  
SDCD  expression  analysis  
To  identify  genes  with  sexually  dimorphic  differential  expression,  we  performed  two  
complementary  analyses:  stratification  by  sex  and  stratification  by  COPD-­‐‑control  status.  Here  
we  describe  the  analysis  for  case-­‐‑control  stratified  analysis,  and  the  sex-­‐‑stratified  analysis  
proceeds  in  the  same  manner.  For  each  Ensembl  gene  in  the  case  stratum  (N=164),  we  used  the  
limma  R  package  to  fit  a  linear  model  using  the  log  expression  level  as  outcome  and  sex  
indicator  as  predictor,  adjusting  for  age  and  pack  years  of  smoking  (Model  4).  The  same  models  
were  fit  for  the  control  stratum  (N=65,  Model  3).    
Gene  Expression  |  control  =  β  0,control  +  β  1,control  Sex  +  β  2,control  Pkyr  +  β  3,control  Age  +  εcontrol   (3)  
Gene  Expression  |  COPD  =  β  0,COPD  +  β  1,COPD  Sex  +  β  2,COPD  Pkyr  +  β  3,COPD  Age  +  εCOPD   (4)  
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The  standard  errors  of  the  coefficient  associated  with  sex  indicator,  SE(β  1,COPD)  and  
SE(β1,control),  were  combined,  and  the  difference  between  the  coefficients  were  converted  to  
Cohen’s  d  and  evaluated  with  a  two-­‐‑sided  z-­‐‑test:  pCOPD-­‐‑control  =  2(1  –  Φ(|𝛽COPD − 𝛽control|/Spooled))  
[31,32].  Benjamini-­‐‑Hochberg  FDR  correction  was  applied  to  the  p-­‐‑values.  Similar  analysis  was  
performed  for  sex-­‐‑stratified  data,  and  the  genes  with  both  adjusted  p-­‐‑values  less  than  0.25  were  
selected  as  SDCD  genes.  
Validation  of  SDCD  genes  with  independent  datasets  
Gene  expression  profiles  were  downloaded  from  Gene  Expression  Omnibus  (GEO)  
through  the  R  package  GEOquery  (accession  numbers:  GSE8581  for  Bhattacharya  [33]  and  
GSE37147  for  Steiling  [28]).  We  performed  quantile  normalization  using  affyPLM  R  package  
and  batch  effect  correction  using  the  SVA  package.  We  adjusted  for  7  and  24  significant  
surrogate  variables  detected  in  Bhattacharya  and  Steiling  datasets,  respectively.    
The  Bhattacharya  dataset  uses  Affymetrix  Human  Genome  U133  Plus  2.0  arrays  (HG-­‐‑
U133_Plus_2),  which  has  a  total  of  54,675  probes.  1,867  probes  were  mapped  to  SDCD  genes  
through  Ensembl  gene  identifiers,  which  were  used  as  unique  identification  for  SDCD  genes,  
representing  942  of  the  959  SDCD  genes.  The  same  regression  models  as  described  in  “SDCD  
expression  analysis”  section  above  were  fit  to  the  data  except  only  age,  not  pack  years,  was  
adjusted  due  to  the  limited  data  available  publicly.  As  in  the  “SDCD  analysis,”  the  FDR  
threshold  of  0.25  was  used  in  each  stratified  analysis  before  combining  the  results  by  set  
intersection.  The  Steiling’s  dataset  used  the  Affymetrix  GeneChip  Human  Gene  1.0  ST  arrays  
(HuGene10stv1_Hs_ENSG),  which  has  19,793  probes.  Of  those  probes,  948  were  mapped  to  the  
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959  SDCD  genes  through  Entrez  and  Ensembl  gene  identifiers,  representing  944  SDCD  genes.  
SDCD  regression  models  were  fit,  adjusted  for  age  and  pack  year  of  smoking;  FDR  cutoff  of  0.25  
was  applied;  results  from  two  stratified  models  were  combined.  
Functional  enrichment  analysis  
Functional  and  pathway  enrichment  analyses  were  carried  out  by  various  methods,  
namely  a  conditional  hypergeometric  test  by  GOstats  R  package,  a  gene  set  enrichment  analysis  
(GSEA)  by  GAGE  R  package,  and  a  Fisher’s  exact  test  by  Ingenuity  Pathway  Analysis  (IPA,  
Ingenuity  Systems,  www.ingenuity.com).  Genes  presented  in  the  expression  profile  were  
mapped  to  Entrez  ids  via  BiomaRt  R  package.  For  the  GOstats  approach,  all  of  the  mapped  
Entrez  genes  were  used  as  the  background  set,  and  the  Entrez  ids  corresponding  to  SDCD  genes  
were  tested  for  enrichment  in  the  three  classes  of  GO  terms.  For  the  GSEA  approach,  two  
ranking  approaches  were  used.  First  all  available  genes  were  ranked  by  the  absolute  difference  
between  the  coefficients  |Δβ  COPD-­‐‑control|  and  secondly  by  the  adjusted  p-­‐‑value  (pCOPD-­‐‑control  ).  For  
canonical  pathway  analysis,  the  Ensembl  gene  ids  of  the  SDCD  genes  were  imported  into  IPA  
(Ingenuity  Systems,  www.ingenuity.com),  and  we  used  the  IPA  canonical  analysis.  For  all  of  
the  approaches  except  GSEA,  we  selected  functions  with  enrichment  p-­‐‑value  <  0.05  and  at  least  
three  genes  overlap.  
Functional  network  clustering  
For  each  pair  of  functional  annotation  terms  the  number  of  shared  SDCD  genes  and  the  
Jaccard  index  was  calculated.  We  constructed  a  network  with  functional  terms  as  nodes  and  the  
shared  genes  as  edges  and  filtered  for  edges  with  Jaccard  index  greater  than  or  equal  to  0.2.  
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Edges  connecting  nodes  representing  GO  terms  that  are  directly  related  through  parent-­‐‑
progeny  relationship  in  the  GO  hierarchical  structure  were  removed.  The  networks  were  
visualized  using  Cytoscape  [34].  We  used  a  weighted  force-­‐‑directed  layout  method  [35]  to  
visualize  the  networks  and  used  GLay  community  structure  analysis  (fast-­‐‑greedy  algorithm)  
[36]  to  identify  functional  clusters.    
Differential  methylation  analysis  
Methylation  data  processing  
Normalized,  quality-­‐‑controlled,  and  batch  effect-­‐‑corrected  percent  methylation  data  
from  comprehensive  high-­‐‑throughput  arrays  for  relative  methylation  (CHARM)  [37]  for  178  
samples  (134  COPD,  44  controls)  were  downloaded  from  LGRC  Data  Portal  (www.lung-­‐‑
genomics.org/research;  accessed  January  2013).  Pre-­‐‑processing  of  CHARM  methylation  arrays  
used  the  CHARM  Bioconductor  Package  to  perform  standard  CHARM  quality  control,  
normalization,  and  smoothing  to  produce  percent  methylation  at  each  of  the  2,162,405  probes.  
Probes  were  mapped  to  positions  in  Human  Genome  version  19  (hg19).  Surrogate  Variable  
Analysis  (SVA)  [30]  was  used  to  detect  batch  effect  in  the  logit-­‐‑transformed  percent  
methylation.  Two  significant  surrogate  variables,  corresponding  to  the  first  two  principle  
components,  were  removed  using  the  R  Package  SWAMP  (cran.r-­‐‑
project.org/web/packages/swamp/),  and  the  batch-­‐‑corrected  values  were  then  transformed  back  
into  percent  methylation.  Only  data  from  COPD  and  control  samples  were  used  for  the  
differential  methylation  analysis. 
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We  defined  variably  methylated  regions  (VMRs)  as  previously  described  [38,39].  Briefly,  
we  first  calculated  for  all  probes  the  median  absolute  deviation  (MAD)  of  percent  methylation  
across  all  samples  in  our  study.  Adjacent  probes  with  high  MAD  (>80th  percentile)  within  300bp  
were  clustered  into  VMRs.  We  required  at  least  five  probes  in  a  VMR  and  identified  12,094  
VMRs.  
Sexually  dimorphic  and  differential  methylation  
The  SDCD  methylation  analysis  described  above  was  performed  with  logit-­‐‑transformed  
percent  methylation  of  each  VMRs  as  outcome.  Starting  with  12,094  VMRs,  we  used  
GenomicRanges  R  package  to  search  for  SDCD  genes  within  10kb  distance  on  either  side  of  the  
mid  points  of  the  VMRs.  We  found  888  VMRs  with  at  least  one  SDCD  gene  nearby.  These  
accounted  for  395  SDCD  genes.  We  then  ran  SDCD  analysis  on  these  888  VMRs  with  the  linear  
model  adjusting  for  pack  years  and  age,  same  as  SDCD  expression  analysis.  Because  sex-­‐‑
stratified  analysis  yielded  no  significant  VMR  at  FDR  cutoff  0.05,  we  proceeded  with  only  
COPD-­‐‑stratified  analysis,  which  identified  387  SDCD  VMRs  at  FDR  cutoff  of  0.05.  A  VMR  is  
associated  with  a  SDCD  gene  if  the  mid  point  of  the  VMR  is  within  10kb  distance  to  the  gene’s  
transcription  start  site.  
Nuclear  receptor  enrichment  analysis  
Cistrome  database  
Lists  of  targets  of  estrogen  (ESR1/2),  androgen  (AR),  progesterone  (PGR),  vitamin  D  
(VDR),  and  PPAR-­‐‑gamma  (PPARG)  were  downloaded  from  Cistrome  database  (cistrome.org,  
accessed  1/28/2013).  For  each  of  the  nuclear  receptors,  Cistrome  assigns  to  each  gene  a  rank  
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product  score,  which  measures  the  strength  of  regulatory  potential  between  the  nuclear  
receptor  and  the  gene  and  can  be  interpreted  as  a  p-­‐‑value  [40].  Thus,  we  defined  significant  
regulatory  targets  by  selecting  genes  with  rank  product  cutoff  of  0.25  (see  justification  of  the  
cutoff  in  Appendix  4A).  For  each  of  the  regulatory  target  list,  we  used  Fisher’s  exact  test,  with  
genes  in  the  expression  probe  set  as  background,  to  assess  enrichment.    
JASPAR  motif  scan  
To  create  our  motif  prior,  we  downloaded  the  position  weight  matrixes  (PWM)  of  ESR1,  
ESR2,  and  AR  motifs  from  the  JASPAR  database.  To  search  for  motif  target  candidates,  the  
motif  score  of  each  candidate  S  was  defined  as  motif  score  =  log[P(S|M)/P(S|B)],  where  P(S|M)  
is  the  probability  to  observe  sequence  S  given  the  motif  M,  and  P(S|B)  is  the  probability  to  
observe  sequence  S  given  the  genome  background  B.  To  define  motif  targets,  we  modeled  the  
motif  score  distribution  by  randomly  sampling  the  genome  106  times.  Targets  of  motifs  were  
then  defined  as  those  with  a  score  at  a  significance  level  of  p<10-­‐‑5.  We  associated  genes  with  
these  motif  targets  if  that  target  fell  within  its  promoter  region  [750bp,  +250bp].  We  also  used  
Fisher’s  exact  test,  with  genes  in  the  expression  probe  set  as  background,  to  assess  enrichment.  
Other  databases  
A  list  of  estrogen  response  elements  (ERE)  was  downloaded  from  the  mouse  and  human  
ERE  database  (www.mapageweb.umontreal.ca/maders/eredatabase,  accessed  1/17/2013).  2,980  
of  these  genes  were  present  in  our  gene  expression  probe  set,  and  217  SDCD  genes  contained  at  
least  one  ERE.  A  list  of  androgen  responsive  genes  (ARG)  was  downloaded  form  ARGDB  
(argdb.fudan.edu.cn,  accessed  1/22/2013).  1,344  of  the  ARGs  were  in  our  gene  expression  probe  
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set,  and  103  were  SDCD  genes.  Like  Cistrome  and  JASPAR,  we  used  a  Fisher’s  exact  test  to  
assess  enrichment  of  the  genes  with  hormone  response  elements.  
Sex-­‐‑specific  eQTL  analysis  
Genotype  data  processing  for  eQTL  analysis  
Genotyping  of  535  samples  (219  ILD,  224  COPD,  92  controls)  were  from  Illumina  
Infinium  HD  Assay  with  Human  Omni  1  QuAd  and  Human  Omni  2.5  QuAd  arrays.  Genotype  
calling  and  processing  were  performed  at  University  of  Colorado  Boulder  where  the  
genotyping  was  done.  Genome  Studio  (default  settings)  was  used  to  call  genotypes  and  
genotypes  from  Omni  1  arrays  were  imputed  to  the  Omni  2.5  array  design  and  processed  
together  thereafter  (2,443,179  markers).  We  converted  the  genotype  files  into  PLINK  formats  
(.bim  and  .fam)  and  used  PLINK  to  perform  the  following  quality  control  steps.  We  considered  
only  171  COPD  and  control  samples  with  both  genotypes  and  gene  expression.  
For  SNP  quality  controls,  90  male  and  81  female  samples  were  analyzed  separately.  In  
males  and  females,  respectively,  322  and  327  markers  were  excluded  based  on  Hardy-­‐‑Weinberg  
Equilibrium  test  (p  <  0.001);  37,110  and  34,968  markers  were  excluded  because  they  were  
missing  in  more  than  10%  of  the  samples;  and  1,119,893  and  1,141,434  SNPs  were  excluded  
because  the  minor  allele  frequencies  were  less  than  0.05.  In  sum,  1,232,344  SNPs  remained  after  
the  QC  steps  (1,300,303  male  and  1,279,600  female).  No  sample  was  excluded  based  on  the  
genotyping  rate  (call  rates  >  0.95).  
We  removed  7  samples  with  discordance  between  genetic  sex  and  reported  sex.  Inbreeding  
coefficient  F  was  calculated  for  each  subject  after  SNP  pruning  and  Linkage  Disequilibrium  
   93  
(LD)  filtering,  as  an  extreme  (especially  negative)  F  reflects  excess  in  heterozygosity  and  
homozygosity.  All  samples  passed  the  standard  cutoff  of  |F|  >  0.2.  Although  subjects  in  the  
study  are  reported  to  be  unrelated,  we  used  identity  by  descent  (IBD)  to  identify  and  remove  
one  sample  from  a  subject  whose  both  left  and  right  lungs  were  genotyped,  keeping  the  sample  
with  more  complete  molecular  data.  In  the  end,  we  had  126  COPD  and  37  control  samples  for  
the  sex-­‐‑stratified  eQTL  analysis  (86  males,  77  females,  163  total).  
Sex-­‐‑stratified  eQTL  analysis  
We  performed  genome-­‐‑wide  expression  quantitative  trait  loci  (eQTL)  analysis,  which  
fits  mRNA  expression  to  the  following  model:  
Gene  Expression  =  β0  +  β1  ADD  +  β2  Pkyr  +  β3  Age  +  ε  
where  ADD  is  the  allele  dosage  of  a  genotype  (coded  as  0,  1,  and  2  for  the  number  of  minor  
alleles).  Only  cis-­‐‑variants  (SNPs  within  100kb  upstream  and  10kb  downstream  from  TSSs)  of  
SDCD  genes  were  considered.  We  used  PLINK  [41]  to  perform  the  eQTL  analyses.  
Similar  to  the  SDCD  gene  expression  analysis,  models  for  males  and  females  were  fit  
separately  and  the  allelic  effects  (β1)  were  contrasted.  Benjamini-­‐‑Hochberg  multiple  hypothesis  
correction  was  performed.  We  selected  eQTL  with  FDR  <  0.05  and  more  than  five  data  points  
with  homozygous  minor  alleles.  
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Results  
Lung  Genomics  Research  Consortium  (LGRC)  cohort  
We  selected  data  from  254  subjects  from  the  LGRC  (www.lung-­‐‑genomics.org)  (179  
COPD,  75  controls)  (see  Methods).  Clinical  characteristics  are  shown  in  Table  1.  Male  and  
female  subjects  have  different  distributions  of  COPD  severity;  36.4%  of  females  were  classified  
in  GOLD  stage  4  (very  severe  COPD)  compared  to  20.6%  of  the  males,  although  males  smoked  
more  than  females.  Fifteen  percent  of  the  subjects  (N=37)  did  not  self-­‐‑report  cigarette  smoking  
and  these  samples  were  flagged  for  a  sensitivity  analyses  that  focused  only  on  ever-­‐‑smokers.  
Female  COPD  subjects  had  lower  diffusing  capacity  (DLCO)  than  male  COPD  subjects;  control  
samples  with  low  diffusing  capacity  (DLCO  <  80,  N=26)  were  flagged  for  removal  to  address  
potential  misclassification  bias.  
The  LGRC  includes  genotype,  gene  expression,  and  methylation  data.  Of  these  three  
data  types,  gene  expression  was  available  for  229  of  the  254  samples  and  methylation  for  178  
samples.  Moreover  163  had  genome-­‐‑wide  genotypes  in  addition  to  gene  expression  profiles.  
The  exact  breakdown  of  the  number  of  samples  and  data  type  used  in  our  subsequent  analyses  
is  given  in  Table  S1,  and  a  summary  of  data  processing  is  given  in  Figure  S1.  
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Age	  –	  years	   66.55	  ±	  9.14	   64.01	  ±	  9.74	   66.97	  ±	  11.74	   62.18	  ±	  12.31	  
Pack	  years	  of	  smoking	   60.48	  ±	  42.41	   44.53	  ±	  25.02	   37.45	  ±	  45.05	   10.57	  ±	  15.53	  
Smoking	  status	  –	  no.	  (%)	   	   	   	   	  
	  Current	  smoker	   4	  (3.9)	   6	  (7.8)	  	   0	  (0.0)	   1	  (2.3)	  
	  Former	  smoker	   95	  (93.1)	   68	  (88.3)	   22	  (71.0)	   21	  (47.7)	  
	  Never	  smoker*	   3	  (2.9)	   3	  (3.9)	   9	  (29.0)	   22	  (50.0)	  
FEV1/FVC	   0.48	  ±	  0.15	   0.49	  ±	  0.15	   0.77	  ±	  0.06	   0.79	  ±	  0.06	  
DLCO	   59.09	  ±	  22.30	   50.47	  ±	  23.32	   85.50	  ±	  17.56	   88.26	  ±	  13.73	  
GOLD	  stage	  –	  no.	  (%)	   	   	   	   	  
	  0-­‐At	  Risk	   0	  (0.0)	   0	  (0.0)	   31	  (100.0)	   44	  (100.0)	  
	  1-­‐Mild	  COPD	   11	  (10.8)	   6	  (7.8)	   0	  (0.0)	   0	  (0.0)	  
	  2-­‐Moderate	  COPD	   52	  (51.0)	   32	  (41.6)	   0	  (0.0)	   0	  (0.0)	  
	  3-­‐Severe	  COPD	   18	  (17.6)	   11	  (14.3)	   0	  (0.0)	   0	  (0.0)	  
	  4-­‐Very	  Severe	  COPD	   21	  (20.6)	   28	  (36.4)	   0	  (0.0)	   0	  (0.0)	  
*  flagged  for  sensitivity  analysis.  
Table  4.1:  Clinical  characteristics  of  LGRC  cohort  stratified  by  sex  and  COPD  status  
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Figure  4.1:  An  overview  of  sexually  dimorphic  and  COPD  differential  (SDCD)  analysis.  (A)  
Two  parallel  analyses  were  performed:  sex-­‐‑stratified  analysis  and  COPD-­‐‑stratified  analysis.  For  
each  of  the  analyses,  the  differences  between  regression  coefficients  from  the  two  strata  were  
assessed  for  significance  via  Cohen’s  d.  Finally  the  genes  identified  by  both  approaches  were  
selected  and  called  “SDCD  genes.”  (B)  Volcano  plot  from  sex-­‐‑stratified  analysis.  The  purple  
points  represent  SDCD  genes;  shading  represents  density  of  points.  Dashed  vertical  red  lines  
mark  the  top  and  bottom  5%  quantiles  of  Δαmale-­‐‑female  =  αmale  –  αfemale.  Genes  with  the  largest  
absolute  difference  Δαmale-­‐‑female  include  CXCL13,  CTCN2,  TIMP4,  ZDHHC22,  RBFOX1,  EDN3,  
NRAP,  and  HMGCS2.  (C)  Expression  levels  of  TIMP4  stratified  by  sex  and  COPD  status.  TIMP4  
expression  is  lowest  in  female  controls.  Appearing  in  the  top  corner  of  the  volcano  plot,  TIMP4  
expression  is  unchanged  in  males  with  COPD  compared  to  control  but  more  highly  expressed  
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Stratified  analysis  identifies  sexually  dimorphic  and  COPD  differential  (SDCD)  genes  
To  study  sexually  dimorphic  differential  expression  in  COPD,  we  performed  two  
stratified  analyses:  stratified  by  sex  and  by  COPD  status.  We  then  combined  the  results  from  the  
two  complementary  analyses  to  define  a  set  of  “sexually  dimorphic  and  COPD  differential”  
(SDCD)  genes.  Figure  4.1A  shows  an  outline  of  our  approach.  To  avoid  potential  confounding  
effects  from  sex-­‐‑specific  regulation  of  genes  on  the  sex  chromosomes,  we  only  considered  
autosomal  genes  in  all  subsequent  analyses.  
Sex-­‐‑  and  COPD-­‐‑stratified  analysis  
First  we  explored  COPD-­‐‑related  differential  gene  expression  patterns  separately  for  
males  and  females  using  linear  models,  which  are  effective  for  the  study  of  sexually  dimorphic  
gene  expression  [42].  For  each  gene  we  calculated  a  sex-­‐‑specific  regression  coefficient  
representing  differential  expression  in  COPD  compared  to  control  lung  tissues  using  the  
following  models:  
Gene  Expression  |  male  =  α0,male  +  α1,male  COPD  +  α2,male  Pkyr  smoked  +  α3,male  Age  +  εmale    (1)  
Gene  Expression  |  female  =  α0,female  +  α1,female  COPD  +  α2,female  Pkyr  smoked+  α3,female  Age  +  εfemale      (2)  
Here  Pkyr  smoked  is  total  pack-­‐‑years  of  cigarette  smoking  (equal  to  the  number  of  packs  
of  cigarettes  smoked  daily  multiplied  by  the  number  of  total  years  smoked);  the  coefficient  
α1,male  represents  the  degree  of  expression  difference  associated  with  having  COPD  in  males;  and  
α1,female  represents  the  difference  in  females.  We  will  hereafter  refer  to  α1,male  as  αmale  and  α1,female  as  
αfemale.    
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By  stratifying  the  analysis  by  sex,  we  have  separate  coefficients  for  males  and  females,  
representing  sex-­‐‑specific  differential  expression  patterns  in  COPD.  The  difference  between  
these  coefficients,  Δαmale-­‐‑female	  =	  αmale  –  αfemale,  represents  the  difference  of  the  differential  
expression  in  males  from  that  in  females  and  allows  us  to  quantify  sexually  dimorphic  
expression  patterns  in  COPD  relative  to  control  tissue.    
We  can  assess  the  statistical  significance  of  the  difference  (Δα)  using  Cohen’s  d,  defined  
as  the  difference  between  two  means  divided  by  a  pooled  standard  deviation:  d  =  Δα  /Spooled  
[31,32].  As  Cohen’s  d  follows  the  standard  normal  distribution  under  the  null,  the  two-­‐‑tailed  p-­‐‑
value  is  given  as:  pmale-­‐‑female  =  2(1  –  Φ(|d|))  =  2(1  –  Φ(|Δα  /Spooled|))  where  Φ  is  the  cumulative  
distribution  function  of  the  standard  normal  distribution.  Benjamini-­‐‑Hochberg  FDR  was  used  
for  multiple  hypothesis  testing  adjustment.  A  plot  of  these  differences  (Δα)  compared  to  the  
FDR  significance  is  shown  (Figure  4.1B).    
We  used  an  FDR  cutoff  of  0.25  to  identify  1,551  genes  that  are  most  likely  to  be  over-­‐‑
expressed  in  presence  of  COPD  in  one  sex  but  relatively  under-­‐‑expressed  or  unchanged  in  the  
other.  Our  choice  of  the  liberal  FDR  threshold  optimizes  for  sensitivity  [43],  while  the  tradeoff  in  
false  discovery  rate  is  minimized  by  requiring  replication  in  a  complementary  COPD-­‐‑stratified  
analysis  below.  In  addition,  we  performed  a  sensitivity  analysis  on  the  choice  of  the  FDR  
threshold,  as  described  in  Appendix  4A.  
While  stratified  analyses  are  often  used  to  study  sex  differences  [44-­‐‑46],  we  reasoned  
that  by  combining  the  COPD  sex-­‐‑stratified  analysis  above  with  results  from  a  sex-­‐‑differential  
expression  analysis  performed  using  stratification  by  COPD-­‐‑control  status  we  could  increase  
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our  confidence  in  our  findings  (Figure  4.1A).  This  COPD-­‐‑only  and  control-­‐‑only  stratified  
analysis  also  allows  us  to  identify  gene  expression  that  is  not  sexually  dimorphic  in  control  
tissue  but  appears  sexually  dimorphic  in  the  setting  of  COPD.  Therefore,  we  quantified  sex  
differences  in  controls  and  COPD  cases  separately  by  fitting  the  same  basic  model:  
Gene  Expression  |  control  =  β  0,control  +  β  1,control  Sex  +  β  2,control  Pkyr  smoked+  β  3,control  Age  +  εcontrol  (3)  
Gene  Expression  |  COPD  =  β  0,COPD  +  β  1,COPD  Sex  +  β  2,COPD  Pkyr  smoked+  β  3,COPD  Age  +  εCOPD    (4)    
Here,  the  coefficient  β1,control  represents  the  sex-­‐‑specific  differences  in  gene  expression  in  
control  lung  tissue,  accounting  for  age  and  pack  years  of  smoking,  while  the  coefficient  β1,COPD  
represents  sex-­‐‑specific  differences  in  COPD  lung  tissue.  For  simplicity,  we  will  refer  to  β1,control  as  
β  control  and  β1,COPD  as  β  COPD.  A  positive  coefficient  means  higher  gene  expression  in  males  
compared  to  females,  and  a  negative  coefficient  suggests  higher  gene  expression  in  females  
compared  to  males.  As  in  the  sex-­‐‑stratified  analysis,  sex-­‐‑differences  specific  to  either  COPD  or  
controls  can  be  detected  by  contrasting  the  coefficients:  ∆𝛽COPD-­‐control = 𝛽COPD − 𝛽control,  and  the  
significance:  pCOPD-­‐‑control  =  2(1  –  Φ(|Δβ/Spooled|))  (see  volcano  plot  in  Figure  S4.2).  Of  the  autosomal  
Ensembl  genes  analyzed,  1,656  genes  had  significant  sexually  dimorphic  differences  at  
Benjamini-­‐‑Hochberg  false  discovery  rate  of  0.25.    
Identification  of  Sexually  dimorphic  and  COPD  differential  (SDCD)  genes  
We  intersected  the  significant  gene  sets  identified  in  the  sex-­‐‑stratified  and  COPD  
stratified  analyses  to  define  a  set  of  “sexually  dimorphic  and  COPD  differential  genes”  (SDCD  
genes,  listed  in  Supplemental  Table  S2A).  This  overlap  identified  959  SDCD  genes;  some  of  
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these  genes  have  been  previously  associated  with  COPD.  Supplemental  Table  S3  and  Figure  
S4.3  list  a  few  notable  examples  including  TIMP4  (top  left  of  Figure  4.1B),  a  tissue  inhibitor  of  
metalloproteinase,  which  plays  roles  in  mitigating  degradation  of  lung  matrix  [47].  Consistent  
with  a  previous  observation  that TIMP4  is  overexpressed  in  COPD  [48],  we  found  TIMP4  to  be  
highly  expressed  in  female  COPD  subjects  compared  to  female  controls  (αfemale  =  0.249,  
p=1.15×10-­‐‑5);  however,  this  differential  expression  is  absent  for  males  (αmale  =  0.0143,  p=0.710,  
Figure  4.1C).  
Among  of  959  SDCD  genes  we  also  found  genes  with  prior  sex-­‐‑specific  associations  such  
as  AQP7,  which  has  demonstrated  sex-­‐‑specific  association  with  diabetes  [49].  PAQR3  (Figure  
S4.3C),  is  among  the  most  sexually  dimorphic  genes  in  COPD  (based  on  the  magnitude  of  
βCOPD);  this  gene  encodes  a  multiple-­‐‑pass  membrane  which  interacts  with  progesterone  and  has  
been  identified  in  bronchoalveolar  lavage  fluid  from  ex-­‐‑smokers  [50]. At  the  individual  gene  
level,  this  set  of  959  SDCD  genes  represents  a  promising  collection  of  genes  relevant  to  both  
sexual  dimorphism  and  COPD  biology  and  forms  the  basis  for  our  further  analyses.  
Validation  of  SDCD  genes  using  independent  datasets  
To  validate  the  SDCD  gene  set,  we  repeated  our  stratified  gene  expression  analysis  
using  independent  gene  expression  datasets  from  two  COPD  case-­‐‑control  studies.  From  the  
Gene  Expression  Omnibus  (GEO)  database  we  selected  datasets  from  Bhattacharya  et  al.  (GEO#:  
GSE8581)  [33]  and  Steiling  et  al.  (GEO#:  GSE37147)  [28]  based  on  the  completeness  of  the  
clinical  metadata  and  the  sample  sizes.  In  total,  411  SDCD  genes  were  identified  as  differentially  
expressed  in  at  least  one  independent  dataset,  and  78  were  observed  in  both.  A  detailed  
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discussion  of  the  datasets  is  provided  in  Appendix  4A,  and  the  lists  of  SDCD  genes  are  
provided  in  the  Supplemental  Table  S4.    
Functional  enrichment  analysis  of  SDCD  genes  shows  sex-­‐‑specific  expression  of  pathways  
We  performed  functional  enrichment  analysis  on  the  SDCD  genes.  We  were  motivated  
by  the  fact  that  significant  enrichment  for  biological  processes  known  to  be  important  for  COPD  
would  add  support  for  SDCD  genes  while  additional  processes  may  be  relevant  for  sexually  
dimorphic  features  of  the  disease.  To  determine  the  enrichment  of  SDCD  genes  in  Gene  
Ontology  (GO)  terms,  we  used  the  conditional  hypergeometric  test  (Bioconductor  Package  
GOstats  [51]  which  accounts  for  the  hierarchical  structure  of  GO),  and  identified  181  terms  with  
a  significant  over-­‐‑representation  of  annotations  from  SDCD  genes  (defined  as  a  p-­‐‑value  
significance  less  than  0.05  and  limited  to  terms  containing  three  or  more  genes).  Among  the  top  
GO  terms  is  “anatomical  structure  morphogenesis”  (GO:0009653),  which  may  support  the  
suggestion  that  sex  differences  in  COPD  are  influenced  by  lung  size  and  anatomy.  Also  key  
COPD  processes  such  as  “response  to  wounding”  (GO:0009611)  and  “acute  inflammatory  
response”  (GO:0002526)  are  represented.  A  full  list  of  these  enriched  GO  terms  is  provided  in  
Supplemental  Tables  S5A.  We  note  that  alternative  approaches:  pre-­‐‑ranked  Gene  Set  
Enrichment  Analysis  (GSEA)  [52]  and  DAVID  [53,54],  gave  similar  results  and  are  included  in  
Supplemental  Tables  S5B-­‐‑D.    
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Figure  4.2:  Network  representation  of  Gene  Ontology  enrichment  of  SDCD  genes.  Nodes  
represent  functions  or  pathways,  colored  by  median  sex-­‐‑specific  differential  expression  
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(continued)    
Edges  represent  the  number  of  shared  SDCD  genes  between  pairs  of  functions  or  pathways,  
colored  by  the  associated  Jaccard  index,  which  measures  similarity  between  gene  sets.  The  size  
of  the  edges  represents  the  number  of  shared  genes.  The  genes  listed  on  each  cluster  are  SDCD  
genes  annotated  in  the  majority  of  the  terms  in  the  cluster.  (A)  Through  GLay  “fast-­‐‑greedy”  
network  clustering  [36],  enriched  biological  processes  are  organized  in  groups  with  coherent  
themes  such  as  cell  morphogenesis,  negative  and  positive  regulation  of  locomotion,  and  GTPase  
activity.  Some  of  these  functions  appear  to  be  sex  specific  in  their  expression  patterns.  For  
example  amine/norepinephrine  transport  is  down-­‐‑regulated  primarily  in  male  (blue  nodes  on  
the  right)  while  positive  regulation  of  locomotion  is  up-­‐‑regulated  primarily  in  female  (pink  
nodes  on  the  left).  (B)  Canonical  pathways  are  also  organized  in  modules.  Each  module  has  a  
coherent  theme  for  example:  VEGF  signaling,  actin  cytoskeleton  signaling,  FAK  signaling,  and  
integrin  signaling  pathways  are  all  involved  in  cell  migration,  while  FGF  signaling,  IL6  
signaling,  oncostatin  M  signaling,  and  interferon  signaling  pathways  are  involved  in  immune  
responses.  Two  pathways,  Histamine  Degradation  and  Phenylalanine  Degradation  IV,  do  not  
share  genes  with  other  pathways  and  are  not  shown  here.  
Functional  network  organization  
To  visualize  the  functional  enrichment  results,  we  constructed  a  network  representation  
of  the  significantly  enriched  GO  terms,  with  edges  defined  based  on  shared  SDCD  genes  
between  two  functions  (Figure  4.2A).  We  removed  edges  connecting  functions  to  their  
subcategories  to  avoid  simply  recapitulating  the  GO  hierarchy.  We  used  the  Jaccard  index  [55],  
which  measures  similarity  between  two  gene  sets  as  a  proportion  of  the  total  shared  genes,  to  
define  connectivity  and  only  considered  edges  with  a  Jaccard  index  greater  than  or  equal  to  0.2  
[56],  suggesting  the  gene  sets  share  a  substantial  number  of  genes.    
To  highlight  trends  of  sex-­‐‑specific  differential  expression  of  each  function,  we  colored  
nodes  in  the  network  based  on  the  median  differential  expression  coefficients  (median(αmale)  and  
median(αfemale))  from  male-­‐‑only  and  female-­‐‑only  analyses.  We  used  a  fast-­‐‑greedy  clustering  
algorithm  [36]  to  organize  the  network  into  several  distinct  groups  of  related  biological  
processes,  as  shown  in  Figure  S4.4  and  highlighted  in  Figure  4.2A.  For  example,  three  terms  
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related  to  inflammatory  response,  a  major  contributing  factor  to  COPD  [57],  form  a  small  cluster  
in  the  middle  of  the  network  (Figure  4.2A).  Chemotaxis  and  cell  localization,  other  key  
processes  in  COPD,  appear  in  two  distinct  clusters  based  on  whether  they  are  either  positively  
or  negatively  regulated.  Terms  related  to  ATP  biosynthesis  process  and  GTPase  activity  are  also  
represented  in  the  network.  An  increase  in  extracellular  ATP  has  been  suggested  to  play  a  role  
in  emphysema  and  COPD  [58],  potentially  through  altering  chemotaxis  and  activation  of  
inflammatory  cells.    
The  SDCD  genes  associated  with  the  same  function  are  often  differentially  regulated  in  a  
sex-­‐‑specific  manner  (node  colors  in  Figure  4.2).  For  example,  we  find  that  genes  involved  in  
amine  and  norepinephrine  transport  are  strongly  down-­‐‑regulated  in  COPD  compared  to  
control  in  males  but  are  not  significantly  differentially  expressed  in  females  (lower  center  of  
Figure  4.2A).  Genes  involved  in  inflammatory  response  are  strongly  differentially  expressed  in  
females  but  not  in  males  (upper  center  of  Figure  4.2A).  Genes  involved  in  positive  regulation  of  
locomotion  are  over-­‐‑expressed  in  males,  while  genes  involved  in  negative  regulation  of  
locomotion  are  over-­‐‑expressed  in  females  (top  of  Figure  4.2A).  As  can  be  seen  by  the  absence  of  
edge  connections  between  the  two  clusters,  positive  and  negative  regulations  of  locomotion  
involve  distinct  set  of  genes,  and  thus  the  agreement  in  the  direction  of  differential  expression  
between  the  two  groups  (positive  regulation  in  male  and  negative  regulation  in  female)  
suggests  robustness  of  the  sexually  dimorphic  signal.  
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Canonical  Pathways  
We  performed  a  similar  enrichment  analysis  on  canonical  pathways  defined  in  the  
Ingenuity  Pathway  Knowledge  Base  and,  using  IPA  (Ingenuity  Systems,  www.ingenuity.com)  
identified  twenty-­‐‑two  pathways  with  significant  associations  with  SDCD  genes  (p<0.05  with  at  
least  three  SDCD  genes,  see  Supplemental  Table  S5E),  including  the  NRF2,  VEGF,  and  IL6  
pathways,  all  of  which  have  been  implicated  in  various  aspects  of  COPD.  After  representing  the  
pathways  as  a  network  (Figure  4.2B)  in  the  same  manner  as  the  GO  network,  we  found  VEGF  
signaling,  integrin  signaling,  actin  cytoskeleton  signaling,  and  FAK  signaling  pathways  to  be  
highly  connected,  sharing  actin  (ACTA2,  ACTG2,  ACTN1),  paxillin  (PXN),  vinculin  (VCL),  
SOS1,  and  RAF1.  These  pathways  also  have  many  connections  to  NRF2-­‐‑mediated  oxidative  
stress  response  through  RAF1,  ACTA2,  and  ACTG2.  VEGF  signaling  is  a  crucial  response  to  
lung  injury  and  VEGF  deficiency  has  been  associated  with  emphysema  [59].  Murine  models  
have  implicated  NRF2  in  lung  detoxification  pathways  for  cigarette  smoke  and  altered  NRF2  
activity  has  been  associated  with  emphysema  [60].  Another  module  comprises  several  immune  
response  pathways  including  interferon  signaling  (JAK-­‐‑STAT),  IL-­‐‑6  signaling,  FGF  signaling,  
and  oncostatin  M  signaling  pathways.  Of  note,  both  VEGF  and  IL-­‐‑6  have  demonstrated  sexual  
dimorphism  as  plasma  biomarkers  in  men  and  women  with  COPD  and  represent  highly  
plausible  sexually  dimorphic  COPD  pathways  [61].  
Molecular  mechanisms  of  sexual  dimorphism  
Sexually  dimorphic  gene  expression  may  arise  as  a  result  of  sex  specific  gene  regulation.  
While  regulation  by  sex  hormones  is  a  major  mechanism  of  sex  differences,  genetic  and  
epigenetic  factors  may  also  contribute.  We  used  public  databases  of  hormone  responsive  
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elements,  as  well  as  genotypes  and  DNA  methylation  data  from  the  LGRC  to  assess  possible  
mechanisms  of  sex-­‐‑specific  regulation  of  the  959  SDCD  genes.  As  described  in  more  detail  
below,  we  found  that  hormones  and  DNA  methylation  likely  play  roles  in  sex-­‐‑specific  
regulation  of  SDCD  gene  expression  while  genetic  variation  provides  limited  evidence.    
The  SDCD  genes  are  enriched  for  hormone  response  elements  
Hormones,  especially  sex  hormones,  contribute  to  sex  differences  in  lung  development  
and  physiology  [5,11,24,25].  Hormones  regulate  gene  expression  in  part  by  activating  their  
respective  receptors,  which  then  act  as  transcription  factors,  binding  to  specific  hormone  
response  elements  (HREs)  to  alter  gene  transcription.  Thus,  if  hormones  are  involved  in  gene  
regulation  of  SDCD  genes,  SDCD  genes  may  harbor  significantly  higher  number  of  hormone  
response  elements  than  expected  by  chance.    




Cistrome  [62,63],    
ERE  DB  [64],  
JASPAR  [65]  





174   0.0165  
Progesterone  (PGR)	   Cistrome  [69]   47   0.0076  
PPAR-­‐‑gamma	   Cistrome  [70]   70   0.0136  
Vitamin  D  (VDR)   Cistrome  [71]   42   0.0391  
Table  4.2:  SDCD  genes  are  enriched  for  regulation  by  hormone  receptors.  *  The  number  of  
SDCD  genes  targeted  by  the  nuclear  receptor  in  at  least  one  database.  See  Appendix  4A  for  
details.  
A  number  of  studies  have  cataloged  hormone  response  elements  (see  Appendix  4A  for  
description).  We  used  Fisher’s  exact  test  to  assess  significance  of  the  number  of  SDCD  genes  
harboring  HREs  curated  in  these  databases  and  found  there  were  more  SDCD  genes  with  HREs  
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than  would  be  expected  by  chance  (see  Table  2).  Because  there  are  some  content  differences  
between  HRE  databases,  we  combined  regulatory  target  gene  lists  from  a  number  of  databases.  
Here,  we  used  the  Cistrome  database  [62,63,72],  ERE  DB  [64],  and  the  JASPAR  motif  scan  [65],  
and    found  an  enrichment  of  SDCD  genes  regulated  by  estrogen  receptor  (ESR1/2,  284  genes,  
p=0.0290).  Enrichment  was  also  observed  for  the  progesterone  receptor  with  an  elevated  
number  of  SDCD  genes  regulated  by  progesterone  receptor  in  the  Cistrome  database  [69]  (47  
genes,  p  =  0.0076).  
Both  progesterone  and  estrogen  may  influence  COPD  susceptibility  through  up-­‐‑
regulation  of  cytochrome  P450  (CYP)  enzymes  [73,74].  Binding  of  estradiol  to  sex-­‐‑hormone  
binding  globulin  (SHBG)  triggers  cAMP-­‐‑dependent  signaling,  up-­‐‑regulating  adenyl  cyclase  
(ADCY)  and  other  downstream  signaling  molecules  [75].  We  observed  that  not  only  are  cAMP-­‐‑
mediated  signaling  pathways  enriched  for  SDCD  genes  (Supplemental  Table  S5E),  but  we  also  
found  adenyl  cyclase  3  (ADCY3)  and  adenyl  cyclase  5  (ADCY5)  to  be  sexually  dimorphic  and  
differentially  expressed  in  COPD.  
We  also  observed  significant  results  for  androgen.  Androgen  receptor  binding  sites  are  
overrepresented  in  SDCD  genes  (174  genes,  p=0.0165)  using  three  databases:  Cistrome  [66,67],  
ARGDB  [68]  and  JASPAR  motif  scan  targets  [65].  One  specific  example  is  for  SOD3  
(extracellular  superoxide  dismutase  3);  evidence  for  androgen  regulation  is  observed  for  SOD3  
in  all  three  databases—importantly,  SOD3  has  been  implicated  in  COPD  and  emphysema  [76].    
Finally,  two  nuclear  receptors  known  to  be  important  in  COPD  PPAR-­‐‑gamma  [21]  and  
vitamin  D  receptor  (VDR)  [22,23]  are  also  known  to  target  SDCD  genes.  In  the  Cistrome  
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database  [70,71],  42  and  70  SDCD  genes  are  targeted  by  PPAR-­‐‑gamma  and  VDR,  respectively  (p  
=  0.0391  and  0.0136,  respectively).  PPAR-­‐‑gamma  may  function  in  a  sex-­‐‑specific  manner  [21]  and  
has  been  proposed  as  a  therapeutic  target  for  COPD  [20],  as  activation  of  PPAR-­‐‑gamma  
attenuates  inflammation  [77].  Recent  studies  have  found  association  between  vitamin  D  
deficiency  and  lung  function  [18],  association  between  genetic  variability  in  vitamin  D  binding  
protein  and  COPD  severity  [19]  and  emphysema  [78];  reports  of  sex-­‐‑specific  effects  of  vitamin  D  
in  COPD  have  been  limited.    
Sexually  dimorphic  methylation    
Variable  DNA  methylation  has  been  associated  with  cigarette  smoke  exposure  [79-­‐‑82],  
and  COPD  [83],  and  is  sex-­‐‑specific  in  many  tissues  and  cell  types  [84-­‐‑88].  Since  methylation  of  
the  regulatory  sequences  can  alter  gene  transcription,  sex-­‐‑specific  methylation  may  contribute  
to  sexually  dimorphic  expression  of  SDCD  genes.    
We  assessed  sexual  dimorphism  of  methylated  sites  within  promoter  regions  of  SDCD  
genes.  Methylation  data  was  available  on  178  LGRC  samples  (134  COPD,  44  controls;  92  male,  
86  female)  on  the  Comprehensive  High-­‐‑throughput  Arrays  for  Relative  Methylation  (CHARM)  
platform  [37].  We  normalized  the  data  using  R  package  CHARM,  corrected  for  potential  batch  
effects  using  surrogate  variable  analysis  (SVA),  and  summarized  as  “variably  methylated  
regions”  (VMRs),  as  previously  described  [38,39]  (see  Methods).  Of  the  959  SDCD  genes,  395  
have  VMRs  within  the  promoter  regions  (defined  as  10kb  window  around  transcription  start  
sites).  
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We  detected  sexually  dimorphic  and  COPD-­‐‑differential  methylation  patterns  by  
stratified  regression  analysis,  similar  to  the  approach  for  the  gene  expression.  We  stratified  the  
methylation  profiles  by  COPD  status,  fitted  COPD-­‐‑only  and  control-­‐‑only  regression  models,  
contrasted  the  regression  coefficients  through  Cohen’s  d,  and  corrected  the  p-­‐‑values  using  
Benjamini-­‐‑Hochberg  FDR.  At  the  0.05  FDR  cutoff,  387  VMRs,  within  promoter  regions  of  235  
SDCD  genes,  showed  significant  sexually  dimorphic  and  COPD-­‐‑differential  methylation  
(termed  “SDCD  VMRs”;  Supplemental  Table  S6A).    
One  of  the  most  significant  SDCD  VMRs  is  6.5kb  from  calpain  12  (CAPN12,  adjusted  p-­‐‑
value  =  0.002).    Although  there  is  little  published  data  regarding  a  role  for  calpain  12  in  the  lung,  
calpain  12  has  been  implicated  in  apoptosis  pathways  and  is  a  member  of  the  general  calpain  
superfamily.  Calpains  have  also  been  described  as  mediating  cigarette  smoke  induced  
angiogenic  response  [89].  In  our  data  the  CAPN12  VMR  is  hypermethylated  in  male  controls  
compared  to  the  other  groups  (Figure  4.3A).  Moreover,  the  high  level  of  methylation  of  the  
CAPN12  region  in  male  controls  corresponds  with  their  low  expression  of  CAPN12  mRNA  
(Figure  4.3B).    
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Figure  4.3:  Regulatory  mechanisms  of  SDCD  gene  expression.  (A)  Calpain  12  harbors  a  
variably  methylated  region  (VMR)  that  demonstrates  sexually  dimorphic  methylation  in  
controls.  In  particular,  male  control  samples  tend  to  be  more  highly  methylated  and  male  COPD  
cases  relatively  hypomethylated  compared  to  male  controls;  females  are  equally  methylated  at  a  
lower  level.  (B)  Stratified  boxplot  of  CAPN12  mRNA  expression  shows  lowest  expression  in  
male  controls,  which  is  in  agreement  with  their  higher  methylation  level.  (C)  An  example  of  a  
sexually  dimorphic  genetic  regulation  of  gene  expression  (eQTL).  Points  represent  gene  
expression  of  NCOR2  in  male  (blue)  and  female  (red)  in  subjects  with  homozygous  dominant  
(CC),  heterozygous  (CT),  and  homozygous  recessive  (TT).  Lines  connect  median  expression  in  
each  subgroup  to  demonstrate  the  trend.  In  males,  expression  of  NCOR2  decreases  as  the  
number  of  minor  allele  increases,  but  there  is  no  trend  in  females.  (D)  Combining  all  three  lines  
of  evidence  for  molecular  mechanisms  SDCD  gene  regulation,  we  provided  hypotheses  for  594  
SDCD  genes.  Almost  half  of  the  SDCD  genes  (458)  are  targeted  by  sex  hormone  receptors,  
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The  SDCD  genes  with  sexually  dimorphic  methylation  are  also  functionally  distinct.  We  
performed  functional  enrichment  analysis  [53,54]  of  the  235  SDCD  VMR  genes  relative  to  the  
background  of  all  SDCD  genes  and  found  overrepresentation  of  genes  associated  with  
nucleotide  binding  (GO:0000166,  38  genes,  adjusted  p  =  0.018),  especially  ATP  binding  
(GO:0005524,  32  genes,  adjusted  p  =  0.016).  These  include  several  ATPases,  kinases,  and  ABCF2.  
ABDF2  is  particularly  interesting  as  it  is  a  member  of  ATP-­‐‑binding  cassette  family  which  
includes  genes  for  surfactant  production  and  the  cystic  fibrosis  transmembrane  conductance  
regulator  (CFTR)  [90].  The  full  list  of  functional  enrichment  results  is  provided  (Supplemental  
Table  S6B).  
Genetic  markers  show  evidence  for  sexually  dimorphic  regulation  of  gene  expression  
Genetic  variants  can  also  affect  gene  expression  by  modifying  transcription  factor  
binding  sites  and  so  can  alter  response  to  co-­‐‑factors,  including  sex-­‐‑specific  factors  such  as  
androgen  and  estrogen.  Expression  quantitative  trait  loci  (eQTL)  analysis  can  be  used  to  
identify  potential  regulatory  variants.  We  performed  sex-­‐‑stratified  cis-­‐‑eQTL  analysis,  in  which  
gene  expression  is  modeled  as  a  linear  function  of  the  additive  effect  of  a  SNP,  adjusting  for  age  
and  pack  years  of  smoking  (see  Methods).  As  in  the  SDCD  gene  expression  analysis,  we  
contrasted  the  coefficients  of  male-­‐‑only  and  female-­‐‑only  eQTL  models.    
A  screen  of  28,301  SNPs  within  100kb  upstream  and  10kb  downstream  of  the  
transcription  start  sites  (TSS)  of  SDCD  genes  identified  302  variant  positions  associated  with  94  
genes  that  were  statistically  significant,  sexually  dimorphic  eQTLs  (Supplemental  Table  S6C).  
Here  we  used  an  FDR  cutoff  of  0.05  and  required  that  the  SNPs  had  more  than  five  samples  
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with  homozygous  recessive  alleles  in  each  sex,  to  mitigate  the  influence  of  outliers.  Among  the  
top  sexually  dimorphic  eQTL  are  MMP15  (adjusted  p=0.002),  an  important  matrix  protease  
whose  genetic  variation  is  associated  with  lung  function  [91,92];  NCOR2  (adjusted  p=0.002),  
which  interacts  with  HDAC3,  implicated  in  inflammatory  response  to  cigarette  smoke  [93],  
PXN  (adjusted  p=0.003),  a  key  signaling  protein  in  VEGF  pathway  [94];  and  TIMP4  (adjusted  
p=0.011),  an  inhibitor  of  MMP  proteins  found  to  be  overexpressed  in  COPD  [48].    
Figure  4.3C  shows  the  relationship  between  the  number  of  minor  alleles  of  SNP  
kgp7219237  and  gene  expression  of  NCOR2,  a  gene  that  has  been  implicated  as  required  for  
terminal  lung  development  [95],  potentially  a  point  when  sexual  dimorphism  in  the  lung  may  
begin.    NCOR2,  nuclear  receptor  corepressor  2  or  silencing  mediator  of  retinoic  acid  and  thyroid  
hormone  receptor  (SMRT),  also  functions  by  recruiting  histone  deacetylases  (HDACs),  which  
may  suppress  inflammation  in  COPD  [96,97].  Here,  the  expression  of  NCOR2  mRNA  decreases  
in  males  as  a  function  of  the  number  of  minor  allele,  but  the  NCOR2  expression  in  females  does  
not  appear  to  change  significantly  (Figure  4.3C). 
Sensitivity  Analyses  
Although  we  made  an  effort  to  adjudicate  the  clinical  classification  of  the  LGRC  study  
cohort  based  on  available  data,  some  samples  may  be  incorrectly  classified.  In  particular,  a  
subset  of  control  samples  have  atypically  low  diffusion  capacity  (DLCO;  N=24),  and  about  14%  
(N=32)  of  the  LGRC  samples  self-­‐‑reported  never  having  smoked  cigarettes.  Therefore  we  
repeated  our  sexually  dimorphic  differential  expression  analysis  to  assess  the  sensitivity  of  our  
results  to  the  presence  of  these  samples.  We  found  that  the  SDCD  genes  and  their  functional  
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enrichments  are  robust  to  the  inclusion  or  exclusion  of  these  samples,  with  majority  of  the  
SDCD  genes  replicated  in  both  sensitivity  analyses  (see  Appendix  4A  and  Supplemental  Tables  
S7A-­‐‑D).  
We  also  tested  the  sensitivity  of  our  results  to  FDR  threshold  and  effect  size.  To  assess  
our  choice  of  FDR  threshold,  we  reran  the  stratified  differential  expression  analyses  varying  the  
FDR  threshold  between  0.01  and  1  and  found  the  significance  of  the  overlap  between  sex-­‐‑
stratified  and  COPD-­‐‑stratified  analyses  is  optimal  at  the  FDR  threshold  between  0.1  and  0.25,  
thus  supporting  our  choice  of  0.25  (see  Appendix  4A).  To  evaluate  the  relevance  of  effect  size  in  
the  definition  of  SDCD  genes,  we  selected  the  top  5%  based  on  the  magnitude  of  differential  
expression  |Δαmale-­‐‑female|  and  |ΔβCOPD-­‐‑control|  and  found  their  functional  enrichments  to  be  
consistent  with  that  of  the  full  SDCD  gene  set  (see  Appendix  4A  and  Supplemental  Tables  S7E-­‐‑
F).  This  consistency  suggests  that  the  full  set  of  SDCD  genes  is  at  least  as  functionally  relevant  
as  the  set  with  large  effect  size.  Appendix  4A  contains  a  detailed  discussion  of  the  sensitivity  
analyses,  and  the  lists  of  genes  and  their  functional  enrichments  can  be  found  in  Supplemental  
Table  S7.  Taken  together  sensitivity  analyses  affirm  that  SDCD  genes  and  their  functional  
enrichments  are  robust  against  clinical  misclassification  and  model  parameter  choices.  
Discussion  
Sex  and  gender  disparities  in  COPD  have  been  recognized  for  several  decades,  
highlighting  the  importance  of  sex-­‐‑  and  gender-­‐‑based  research  that  may  yield  insights  into  sex-­‐‑
specific  treatments  for  COPD.  Evidence  suggests  that  females  may  be  more  susceptible  to  
COPD,  yet  little  is  known  about  the  molecular  mechanisms  underlying  the  sexual  
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dimorphism—information  with  potential  translational  relevance  for  sex-­‐‑specific  therapeutics.  
Our  analysis  represents  the  first  systematic  genome-­‐‑wide  integrative  genomics  analysis  of  
sexual  dimorphism  in  COPD.  Using  gene  expression  profiles  from  COPD  and  control  samples  
from  the  Lung  Genomics  Research  Consortium  (LGRC),  we  identified  959  autosomal  genes  with  
evidence  for  sexually  dimorphic  and  COPD  differential  expression  (SDCD  genes);  150  of  these  
genes  are  not  dimorphic  at  baseline  between  men  and  women  and  demonstrate  dimorphism  in  
the  presence  of  COPD,  perhaps  highlighting  the  most  relevant  sex-­‐‑specific  disease  targets.    
The  959  genes  are  involved  in  key  functions  including  cell  morphogenesis,  inflammatory  
response,  and  regulation  of  chemotaxis,  as  well  as  functions  not  typically  associated  with  COPD  
such  as  GTPase  activity,  amine  transport,  and  endocrine  processes.  By  using  publicly  available  
hormone  response  element  databases  and  methylation  and  genotyping  data  from  the  LGRC,  we  
found  potential  regulatory  mechanisms  involving  hormonal  regulation  and  DNA  methylation  
that  that  may  be  associated  with  the  sexually  dimorphic  gene  expression  patterns  we  observed.  
Of  the  959  SDCD  genes,  a  few  are  particularly  interesting.  Lung  tissue  remodeling  and  
faulty  repair  in  response  to  cigarette  smoke  are  important  in  COPD  pathogenesis  [89]  as  
impaired  tissue  repair  process  may  lead  to  permanent  structural  remodeling  of  the  lung,  a  key  
characteristic  of  COPD.  Calpains,  a  family  of  calcium-­‐‑dependent  intracellular  proteases,  have  
been  implicated  in  angiogenic  response  to  cigarette  smoke  [89].  Here  we  found  CAPN12  to  
exhibit  strong  sexual  dimorphism  in  both  gene  expression  and  methylation.  The  pattern  of  
differential  expression  of  CAPN12  inversely  associated  with  methylation  (Figure  4.3A-­‐‑B).  Since  
cigarette  smoke-­‐‑induced  inhibition  of  calpain  could  lead  to  an  impaired  tissue  remodeling,  
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down-­‐‑regulation  of  CAPN12  in  females  may  suggest  an  inadequate  response  to  cigarette  smoke  
among  females,  in  line  with  the  epidemiologic  observations.    Since  there  is  not  much  literature  
for  a  role  for  this  calpain  in  the  lung  more  research  is  needs  to  define  mechanistic  relevance  of  
our  observation.  
Additional  interesting  candidates  include  the  matrix  metalloproteinases  (MMP3,  
MMP15,  MMP28)  and  their  inhibitor  TIMP4  (Figure  S4.3).  MMPs,  extracellular  matrix  enzymes,  
and  their  inhibitor  TIMPs  play  roles  in  COPD  disease  progression  via  degradation  of  elastin  and  
aberrant  lung  tissue  remodeling  [47].  MMP3  (stromolysin;  Figure  S4.3B)  and  TIMP4  (Figure  
4.1C)  are  among  the  most  statistically  significant  SDCD  genes  in  our  expression  analysis  and  
have  been  investigated  in  association  with  airway  inflammation  and  remodeling  [47]  as  well  as  
COPD  development  and  progression  [98,99].  While  a  previous  report  found  overexpression  of  
MMP3  and  TIMP4  in  COPD  [48],  our  analysis  suggests  that  this  might  be  driven  by  the  
direction  and  magnitude  of  effect  in  females  (Figures  1C  and  S3B).  Variants  in  the  MMP15  gene  
have  been  associated  with  lung  function  in  two  genome-­‐‑wide  association  studies  [91,92],  and  
MMP15  was  highlighted  in  our  eQTL  analysis  (Figure  4.3C).  MMP28  (epilysin)  is  overexpressed  
in  response  to  injury  [100]  and  has  been  implicated  in  airway  epithelial  cell  survival  [101].  In  
our  analysis,  MMP28  is  one  of  the  genes  whose  expressions  are  sexually  dimorphic  only  in  
COPD,  not  among  controls  (Figure  S4.3F).  The  fact  that  three  members  of  MMP  family  and  their  
inhibitor  TIMP4  exhibit  sexually  dimorphic  differential  expression  presents  a  strong  case  for  
sex-­‐‑specificity  of  the  roles  of  MMP  and  TIMP  in  COPD.  Inhibition  of  MMPs  has  been  proposed  
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as  a  potential  therapeutic  for  COPD  [102];  thus  the  finding  of  sexual  dimorphism  in  MMPs  
supports  the  relevance  of  our  results  toward  considerations  of  sex-­‐‑specific  therapeutics.  
A  total  of  150  of  the  959  SDCD  were  sexually  dimorphic  in  the  presence  of  COPD  only  
(Supplemental  Table  S2B).  Genes  meeting  these  criteria  include  AQP7,  which  has  demonstrated  
sex-­‐‑specific  association  with  diabetes  [49],  and  TRIM40,  a  Class  I  MHC  gene  that  has  been  
associated  with  multiple  sclerosis  [103].  PAQR3  (Figure  S4.3C),  is  also  among  the  most  sexually  
dimorphic  genes  in  COPD  (based  on  the  magnitude  of  βCOPD);  this  gene  encodes  a  multiple-­‐‑pass  
membrane  protein  that  interacts  with  progesterone  and  has  been  identified  in  bronchoalveolar  
lavage  fluid  from  ex-­‐‑smokers  [50]. One caveat about this set of genes is that their expression 
may not appear significantly sexually dimorphic in control tissues because of the smaller sample 
size of controls compared to COPD (75 vs 179).  
The  pathways  enriched  in  SDCD  genes  include  NRF2,  IL6  and  VEGF  signaling.    
Vascular  endothelial  growth  factor  (VEGF)  signaling  is  of  particular  interest  as  VEGF  is  a  key  
mediator  of  angiogenesis,  with  associated  effects  on  lung  development  and  pulmonary  
physiology  [104,105]  and  has  been  observed  to  demonstrate  sex  differences  as  a  plasma  
biomarker  in  men  and  women  with  COPD  [61].  In  particular,  VEGF-­‐‑activated  cell  migration  
pathway  (left  most  path  in  Figure  4.4A-­‐‑B)  appears  to  be  highly  sexually  dimorphic,  with  four  of  
the  five  components  (actin,  alpha  actin,  paxillin,  vinculin)  of  the  signaling  protein  complex  
classified  as  SDCD  genes.    
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VEGF  signaling,  integrin  signaling,  and  actin  signaling  pathways  share  a  number  of  
genes  (Figure  4.2B).  A  closer  look  reveals  that  the  actin-­‐‑alpha  actin-­‐‑paxillin-­‐‑vinculin  complex  is  
a  common  feature  among  the  three  pathways.  In  the  VEGF  signaling  pathway  (Figure  4.4)  and  
actin  cytoskeleton  signaling  pathway  (Figure  S4.6A-­‐‑B),  the  complex  triggers  downstream  focal  
adhesion  assembly  and  cell  migration,  while  in  the  integrin  signaling  pathway  (Figure  S4.6C-­‐‑D),  
the  complex  is  an  important  component  of  integrin  receptor  aggregation,  which  stimulates  
signal  transduction  cascades.  It  is  possible  that  the  VEGF  signaling  and  integrin  signaling  
pathways  may  function  together,  and  further  in  vitro  research  is  needed  to  investigate  this  
potential  dimorphic  signaling  cascade.    
Integrating  the  mechanistic  and  functional  information  gives  a  more  complete  view  of  
the  regulation  of  VEGF  signaling  pathway.  Of  the  eleven  SDCD  genes  involved  in  VEGF  
signaling  pathway,  as  defined  in  Ingenuity  Pathway  Knowledge  Base,  two  contained  estrogen  
response  elements  (BCL2L1  and  ACTN1).  The  connection  between  estrogen  and  VEGF  
signaling  pathway  has  been  observed  during  lung  development  [106],  in  thyroid  tumors  [107],  
and  breast  cancer  [108],  in  which  an  estrogen-­‐‑mediated  angiogenesis  functions  through  the  
VEGF  pathway  [108];  to  date,  there  is  minimal  research  specifically  on  estrogen-­‐‑VEFG  
interactions  and  COPD.  
   A  few  limitations  exist  in  our  study.  First  many,  but  not  all,  of  the  subjects  had  lung  
cancer.  Although  the  lung  tissues  were  taken  from  areas  distal  to  the  tumors,  the  potential  field  
effect  associated  with  lung  cancer  could  impact  our  findings.  Second,  since  the  tissue  samples  
are  whole  lung  homogenates,  it  is  not  possible  to  resolve  the  impact  of  cell  type  composition  on  
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the  results.  Due  to  potential  variation  in  cell  type  composition  across  control,  COPD,  male,  and  
female  lungs,  the  differential  expression  signatures  may  be  driven  by  cellular  heterogeneity  and  
is  the  focus  of  ongoing  research.    
Although  we  are  able  to  validate  sexually  dimorphic  expression  of  78  genes  in  two  
independent  datasets,  a  number  of  SDCD  genes  are  not  replicated.  This  is  possibly  due  to  a  few  
key  characteristic  differences  among  the  datasets.  For  instance,  Steiling  and  colleagues  collected  
samples  from  airway  epithelial  brushings,  a  different  tissue  type  than  the  LGRC.  If  cell  types  
other  than  the  airway  epithelium  are  major  drivers  of  COPD  sexual  dimorphism,  one  may  not  
expect  the  results  to  replicate  well  in  Steiling’s  dataset.  Since  about  a  quarter  of  SDCD  genes  
were  replicable  in  the  Steiling’s  dataset,  we  believe  airway  epithelial  cells  partly  contribute  to  
the  sexually  dimorphic  signal,  but  other  cell  types  are  likely  important  as  well.    
Our  study  begins  to  address  the  complexity  of  molecular  contributions  to  sex  differences  
in  COPD  by  systematically  investigating  sexually  dimorphic  differential  expression  signatures  
and  integrating  these  findings  with  regulatory  information.  This  analysis  leverages  the  Lung  
Genomics  Research  Consortium  rich  data,  and  the  list  of  959  SDCD  genes  can  provide  as  an  
entry  point  for  future  functional  studies  in  COPD  to  further  elucidate  sex-­‐‑specific  biology  
underlying  this  devastating  lung  disease.  Our  study  highlights  sexually  dimorphic  features  of  
some  pathways  already  implicated  in  COPD,  including  VEGF,  IL6  and  NRF2  signaling  
pathways,  and  uncovers  other  pathways  not  traditionally  associated  with  COPD  such  as  
GTPase  activity,  amine  transport,  and  endocrine  processes.    While  mechanisms  such  as  
methylation  and  hormone  regulation  shed  light  on  the  complex  nature  of  COPD  susceptibility  
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and  severity,  integrative  genomics  approaches  may  offer  hope  for  elucidation  of  sex-­‐‑specific  
therapeutic  targets.  Our  results  stress  the  importance  of  considering  sex  as  a  key  factor  in  the  
development  of  diagnostic,  therapeutic,  and  preventative  strategies.    
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Chapter  5:  Bicluster-­‐‑based  error  rate  control  for  eQTL  analysis—BBER    
Abstract  
Background:  Expression  quantitative  trait  loci  (eQTL)  analysis  combines  genotype  and  
mRNA  expression  data  to  identify  genetic  variants  that  have  a  gene-­‐‑regulatory  association.  
Because  millions  of  genetic  variants  and  tens  of  thousands  of  measured  gene  expression  profiles  
are  compared,  adjusting  for  multiple  testing  is  essential  to  assure  reliable  results.  Widely-­‐‑used  
approaches  such  as  the  Benjamini-­‐‑Hochberg  procedure  largely  assume  independence  between  
tests  and  ignore  intrinsic  and  strong  correlations  among  genetic  and  expression  markers,  
resulting  in  suboptimal  sensitivity.  
Results:  BBER  extends  Benjamini-­‐‑Hochberg  procedure  by  grouping  correlated  tests  
based  on  genetic  linkage  disequilibrium  and  co-­‐‑expression  pattern,  thus  reducing  the  apparent  
number  of  independent  tests  and  mitigating  the  need  for  multiple  testing  correction.  
Simulations  show  that  BBER  can  substantially  improve  sensitivity  while  maintaining  high  
specificity.  We  also  explore  operating  characteristics  of  the  algorithm  with  respect  to  the  
structure  of  the  data  and  discuss  its  strengths  and  weaknesses.  Finally,  we  apply  BBER  to  eQTL  
analysis  using  data  from  the  Lung  Genomic  Research  Consortium  and  find  significant  eQTL  to  
be  enriched  for  SNPs  previously  identified  in  genome-­‐‑wide  association  studies  of  COPD.  
Conclusions:  BBER  improves  sensitivity  and  is  suitable  for  discovery  of  genetic  variants  
that  may  play  roles  in  gene  regulation.  BBER  can  be  applied  to  genome-­‐‑wide  eQTL  analysis,  
and  an  implementation  of  BBER  is  available  through  Bioconductor  Package  BBER.  
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Introduction  
Expression  quantitative  trait  locus.  (eQTL)  analysis  offers  functional  interpretation  of  
disease-­‐‑associated  single  nucleotide  polymorphisms  (SNPs)  from  genome-­‐‑wide  association  
studies  (GWAS)  [1-­‐‑3].  In  practice,  eQTL  analysis  involves  several  million  association  tests  
between  tens  of  thousands  of  quantitative  gene  expression  measurements  and  millions  of  
genetic  markers,  making  multiple-­‐‑testing  correction  both  essential  and  challenging.  
Genetic  markers  often  possess  a  correlative  structures  due  to  linkage  disequilibrium  
(LD),  a  process  in  which  alleles  at  multiple,  adjacent  loci  are  inherited  together  as  “LD  blocks”  
and  therefore  correlate  with  one  another.  Gene  expression  profiles  can  also  be  correlated  as  
genes  in  the  same  pathways  may  be  co-­‐‑regulated  and  therefore  co-­‐‑expressed.  Direct  application  
of  the  standard  multiple-­‐‑testing  correction  methods  such  as  Benjamin-­‐‑Hochberg  false  discovery  
rate  (FDR)  and  Bonferroni  procedure  ignore  this  correlation  structure  and  therefore  are  not  
appropriate  for  eQTL  analysis  as  they  can  overestimate  false  discovery  rates  and  over-­‐‑correct  p-­‐‑
values,  both  of  which  substantially  reduce  power  to  detect  SNP-­‐‑gene  associations  [4].    
Several  methods  have  been  proposed  to  address  the  problem.  Permutation  testing  is  
widely  used  in  eQTL  analysis  [5,  6]  because  it  preserves  the  correlation  structure  between  
genetic  markers;  heuristic  or  asymptotic  approximation  methods  were  developed  to  speed  up  
the  computationally  intensive  permutation  test  [7,  8].  However,  because  of  its  high  
computational  cost,  permutation  testing  is  generally  done  only  on  SNPs;  thus  it  does  not  correct  
for  the  correlation  between  gene  expression  measurements  [4].    
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Chen  et  al.  [9]  and  Kendziorski  et  al.  [10]  proposed  mathematical  frameworks  to  address  
both  genotyping  and  gene  expression  correlation  simultaneously.  Chen  et  al.  [9]  developed  a  
variance  estimator  for  false  discoveries  and  used  weighted  upper  bound  of  false  discovery  
proportion  (wuFDP),  with  correlation  between  markers  as  weights,  for  false  discovery  control.  
Kendziorski  et  al.  [10]  proposed  an  empirical  Bayes  hierarchical  mixture  model  that  shares  
information  across  transcripts  to  determine  a  posterior  probability  that  each  transcript  maps  to  
each  marker.  While  mathematically  elegant,  both  of  these  approaches  were  developed  for  a  
small  number  of  markers  (a  few  hundred),  making  them  less  useful  for  a  genome-­‐‑wide  eQTL  
analysis.  Furthermore,  Kendziorski’s  mathematical  constructions  also  restrict  the  eQTL  model  
to  the  hierarchical  mixture  model,  disallowing  adjustment  of  potential  confounders.    
Here  we  present  BBER  (bicluster-­‐‑based  error  rate  control),  an  algorithm  that  defines  
biclusters  of  correlated  eQTL  tests  by  hierarchical  clustering  and  then  applies  a  Benjamini-­‐‑
Hochberg  FDR  correction  to  the  biclusters.  BBER  recognizes  that  association  tests  of  SNPs  in  the  
same  LD  block  yield  highly  correlated  test  statistics  as  they  are  effectively  the  same  test;  and  the  
grouping  reduces  the  effective  number  of  independent  tests    
We  developed  and  tested  BBER  using  simulated  data  and  then  applied  it  to  real  data  
from  163  patients  with  and  without  chronic  obstructive  pulmonary  disease  (COPD)  from  the  
Lung  Genomics  Research  Consortium  (LGRC;  http://lung-­‐‑genomics.org/research).  
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Methods  
Development  of  BBER  procedure  
The  principle  underlying  BBER  is  that  correlations  due  to  the  genome’s  haplotype  
structure  and  co-­‐‑expression  among  genes  in  the  same  pathways  effectively  reduce  the  number  
of  independent  tests  that  should  be  performed.  BBER  takes  advantage  of  this  structure  in  the  
data  and  uses  a  modified  Benjamini-­‐‑Hochberg  FDR  adjustment  (BH)  based  on  the  number  of  
biclusters  as  opposed  to  the  number  of  tests.  
Simulation  study  
Following  the  approach  described  by  Kendziorski  et  al.  [4]  and  Chen  et  al.  [11],  we  used  
a  series  of  simulations  to  assess  the  performance  of  multiple  testing  correction  procedures.  The  
code  for  the  simulation  as  well  as  the  BBER  procedure  is  available  in  the  Bioconductor  package  
BBER  (URL).  Genotypes  of  specified  minor  allele  frequencies  (MAF)  were  simulated  as  
described  by  Emrich  and  Piedmonte  [12]  in  which  correlated  binary  data  are  simulated  through  
dichotomizing  multivariate  normal  vectors  (Figure  S5.1,  top  left  panel).  SNP-­‐‑gene  expression  
pairs  were  chosen  at  random  to  be  the  “ground  truth”  eQTLs  (Figure  S5.1,  top  middle  panel)  
such  that  about  half  of  the  genes  are  regulated  by  one  eQTL.  The  means  of  the  gene  expression  
profiles  were  calculated  according  to  a  genetic  model  (additive,  recessive,  or  dominant),  and  the  
standard  deviation  is  scaled  linearly  with  the  square  root  of  the  mean  [13].  Given  the  mean  and  
standard  deviation,  gene  expression  log  intensities  were  drawn  from  the  multivariate  normal  
distribution  (Figure  S5.1,  top  right  panel).    
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More  formally,  let  a  block  correlation  matrix  𝐁!,! 𝜌 = 𝐈!⨂  𝐂!(𝜌)  where  Im  is  a  m×m  
identity  matrix  and  Cn(ρ)  is  a  n×n  correlation  matrix  with  off-­‐‑diagonal  correlation  ρ.  Let  Gip  
denote  the  minor  allele  count  of  SNP  p  of  Subject  i,  Gip  ε  [14],  such  that  the  matrix  G  =  [G..]  has  
correlation  Corr(G)  =  BP,P(r),  and  β  denote  the  eQTL  effect  size.  The  indicator  function  1(p,q)  is  1  
if  SNP-­‐‑gene  expression  pair  (SNPp,  Geneq)  is  selected  as  an  eQTL.    
The  mean  and  standard  deviation  of  the  gene  expression  q  of  Subject  i  are:  
𝜇!" = 𝛽𝟏(𝑝, 𝑞)𝐺!" for  additive  model,𝛽𝟏(𝑝, 𝑞)𝟏(𝐺!" > 0) for  dominant  model,𝛽𝟏 𝑝, 𝑞 𝟏(𝐺!" = 2) for  recessie  model.   
and   𝜎!" = 1 + 𝜇!".  
With  the  mean,  standard  deviation,  and  correlation  matrix,  we  simulated  gene  expression  
profile  for  each  subject  by  drawing  from  multivariate  normal  distribution.  Thus,  the  log  
expression  profile  of  Subject  i  is:  
log  (𝑌!)  ~  𝒩(𝜇! , 𝚺!)  
where  𝚺! = diag 𝜎!   𝚸(𝜌)  diag 𝜎!   and  P(ρ)  =  BQ,Q(ρ)  is  the  expression  correlation  matrix.  
The  correlation  matrices  of  genotype  and  gene  expression  data  are  of  particular  
importance.  They  were  specified  to  represent  clusters  of  correlated  markers  with  intra-­‐‑cluster  
correlation  r  and  ρ  for  genotype  and  gene  expression  data  respectively;  inter-­‐‑cluster  correlation  
is  set  to  zero  to  represent  independence  between  clusters.  Evidence  suggests  the  LD  correlation  
r  ranges  between  0.5  and  1,  while  the  co-­‐‑expression  correlation  ρ  is  somewhat  weaker.  
Therefore  we  used  r  =  0.1,  0.5,  or  0.9  and  ρ  =  0.5  for  our  simulations.    
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Because  each  LD  block  and  co-­‐‑expression  cluster  is  independent  and  identically  
distributed  in  our  simulation,  the  numbers  of  LD  blocks  and  gene  clusters  do  not  affect  the  
results  and  were  chosen  so  that  the  simulation  can  be  completed  in  about  three  days  on  a  250-­‐‑
node  cluster.  Thus,  we  chose  to  simulate  10  LD  blocks  of  10  correlated  SNPs  and  5  gene  
expression  clusters  of  5  co-­‐‑expressed  genes,  for  number  of  subjects  N  =  200.  All  simulations  
were  repeated  100  times.  Also  based  on  prior  observations,  the  eQTL  effect  size  β  is  around  2,  so  
we  simulated  the  eQTL  data  with  β  from  0.1  to  4  to  capture  the  range  of  possible  values.    
Because  each  simulation  was  generated  with  a  ground  truth  eQTL,  we  were  able  to  
calculate  sensitivity  and  specificity  and  compare  them  across  multiple  testing  correction  
methods.  In  the  sensitivity  analyses,  we  varied  the  key  data  generation  parameters  including  
LD  correlation  r,  co-­‐‑expression  correlation  ρ,  and  the  eQTL  regulation  effect  size  β.  
A  linear  model  for  eQTL  analysis  
We  consider  a  model  of  eQTL  analysis  in  the  context  of  correlated  data.  For  each  
individual  (i  =  1,  …,  N),  let  Yi  =  (Yi1  Yi2  …  YiP)T  be  a  vector  of  gene  expression  values  from  P  
different  genes,  and  Gi  =  (Gi1  Gi2  …  GiQ)T  be  a  genotype  vector  containing  minor  allele  counts  (0,  
1,  or  2)  of  Q  SNPs.  Let  Xi  be  a  covariate  vector  that  contains  1  as  the  first  element  and  may  
include  environmental  and  demographic  variables  such  as  age,  sex,  and  smoking  status.    
An  association  between  gene  expression  Y.p  and  SNP  G.q  can  be  assessed  through  a  
generalized  linear  model:  
𝐸 𝑌!" 𝐗! ,𝐆!" = 𝑔(𝐗!!𝛼!" + 𝐆!"! 𝛽!")  
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where  𝛼!"  is  a  vector  of  covariate  effects,  𝛽!"   is  a  Q-­‐‑dimensional  vector  of  additive  genetic  
effects,  and  g  is  a  link  function.    
The  corresponding  PQ-­‐‑dimensional  vector  of  score  statistics  is:  
𝐔! = 𝐘! − 𝐘!!!!! ⨂𝐆!  
where  𝐘! = 𝑔(𝐗!!𝛼!")  is  the  vector  of  predicted  gene  expression  trait  values  given  covariates,  
under  the  assumption  of  no  genetic  association.  And  as  shown  by  Conneely  and  Boehnke  [7],  
𝐔!~𝑁(0,𝐕!)  
where  𝐕!  is  estimable  by  𝛀⨂ 𝐆𝐆! − 𝐆𝐗!(𝐗𝐗!)!!𝐗𝐆! ,  the  Kronecker  product  of  the  sample  
covariance  matrices  of  traits  and  genotypes  G  =  (G1  G2  …  GN),  conditioned  on  covariates  X  =  (X1  
X2  …  XN).    
Following  the  definition  above,  the  trait  covariance  matrix  conditioned  on  X  is  𝛀 = (𝐘! − 𝐘!)(𝐘! − 𝐘!)!!!!! .  
Thus  the  normalized  test  statistics:  
𝑇! = 𝐔!,!𝐕!,!! .  
And  𝐓~𝑁(0,𝐑)  where  the  correlation  matrix  R  can  be  estimated  as  a  Kronecker  product  
of  the  sample  correlation  matrices  of  gene  expression  traits  and  genotypes.  Therefore,  the  
correlation  between  two  score  statistics  Cor(Tp,q,  Tp’,q’)  is  a  product  of  the  correlation  between  the  
genotypes  Cor(Gq,  Gq’)  and  the  correlation  between  the  gene  expression  profiles  Cor(Yp,  Yp’).  
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Biclusters  of  SNPs  and  gene  expression  profiles  
The  analysis  above  suggests  that  the  correlation  between  eQTL  test  statistics  can  be  
factorized  into  two  independent  components:  correlation  between  SNPs  and  correlation  
between  gene  expression  profiles.  Thus,  biclusters  of  eQTL  tests  can  be  defined  as  combinations  
of  clusters  of  correlated  SNPs  (LD  blocks)  and  clusters  of  correlated  gene  expression.  More  
precisely,  if    
GEk  =  {p  |  Cor(Yp,  Yp’)  >  ρ,  for  all  p’  in  GEk},  
for  some  ρ,  and  for  k  =  1,  …,  K,  
LDl  =  {q  |  Cor(Gq,  Gq’)  >  r,  for  all  q’  in  LDl},  
for  some  r,  and  for  l  =  1,  …,  L,  the  corresponding  bicluster  is  the  Cartesian  product:    
(GEk,  LDl)  =  GEk×LDl.  
Practically,  clustering  of  both  SNPs  and  gene  expression  can  be  achieved  through  
hierarchical  clustering  with  absolute  Pearson’s  correlation  distance  (1  -­‐‑  |corr|)  and  complete  
linkage  agglomeration  method.    
By  cutting  the  clustering  dendrogram  at  the  height  x,  we  can  define  clusters  of  with  
absolute  intra-­‐‑cluster  correlation  of  1  –  x.  To  maximize  the  inter-­‐‑cluster  distance  (Figure  S5.2),  
we  chose  to  cut  the  dendrogram  at  x  =  0.4.  In  the  case  of  SNP  clustering,  there  exist  a  number  of  
haplotype  block  detection  methods  [5,  15],  which  take  advantage  of  the  biological  fact  that  SNPs  
in  LD  tend  to  be  in  close  proximity,  typically  within  a  few  hundred  thousand  base  pairs  [16].  
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(continued)  
Figure  5.1:  Overview  of  BBER  procedure.  (A)  eQTL  analysis  is  performed  by  a  standard  
method  such  as  linear  regression.  LD  blocks  and  gene  expression  clusters  are  identified  
independently  from  data,  using  hierarchical  clustering  with  complete  linkage  and  absolute  
Pearson’s  correlation  distance.  (B)  A  grid  defined  by  the  LD  blocks  and  gene  expression  clusters  
constitutes  biclusters.  We  select  the  90th  percentile  p-­‐‑value  from  each  bicluster  as  the  
representative  statistic  to  be  ranked  across  all  biclusters  in  the  Benjamini-­‐‑Hochberg  procedure.  
We  use  the  number  and  rank  of  the  biclusters  instead  of  the  individual  tests  to  obtain  adjusted  
p-­‐‑values.  (C-­‐‑D)  90th  percentile  of  the  p-­‐‑values  is  the  best  bicluster  representative  statistics  in  
terms  of  specificity,  while  all  representative  statistics  achieve  comparable  sensitivity.  
Multiple  hypothesis  testing  adjustment  
The  Benjamini-­‐‑Hochberg  (BH)  procedure  [4]  uses  a  false  discovery  rate  (FDR)  
adjustment  to  correct  for  multiple  hypothesis  testing.  The  BH  adjustment  assumes  that  all  p-­‐‑
values  are  independent.  Suppose  that  V  is  the  number  of  false  discoveries,  R  is  the  number  of  
rejected  null  hypotheses  (“discoveries”),  and  S  is  the  number  of  true  positives.  The  FDR  is  given  
by:  
FDR  =  E[V/R]  =  E[V/(V+S)]  
Under  the  null  hypothesis,  the  p-­‐‑values  are  uniformly  distributed,  U(0,1),  and  V  can  be  
estimated  by  the  rank  of  the  p-­‐‑value.  Thus,  FDR  <  α  when  H(1),  H(2),  …,  H(k)  are  rejected  for  the  
largest  integer  k  such  that  q(k)  =  p(k)  m/k  <  α,  where  m  is  the  total  number  of  tests.  
BBER-­‐‑adjusted  P-­‐‑value  
After  clustering  eQTL  tests  into  biclusters,  we  treat  each  bicluster  as  an  independent  test  
to  be  corrected  for  in  the  Benjamini-­‐‑Hochberg  FDR  procedure.  For  each  bicluster,  defined  by  a  
pair  of  gene  expression  cluster  𝐺𝐸!  and  LD  block  𝐿𝐷!  (Figure  5.1A-­‐‑B),  we  use  the  90th  percentile  
of  the  p-­‐‑values  from  all  individual  eQTL  tests  𝑇 ∈ {𝑇!"|𝑝 ∈ 𝐺𝐸! , 𝑞 ∈ 𝐿𝐷!}  to  represent  the  
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bicluster.  That  is,  for  a  bicluster  (GEk,  LDl),  the  representative  statistic  is  𝑝!"rep = 𝑃!"(𝑝!"|𝑝 ∈𝐺𝐸! , 𝑞 ∈ 𝐿𝐷!).  And  𝑝!"rep  are  then  raked:  𝑝(!)rep ≤ 𝑝(!)rep ≤ ⋯ ≤ 𝑝 !"rep .  
and  if  t  is  the  rank  of  𝑝!"rep,  i.e.  𝑝!"rep = 𝑝(!)rep,  then  the  BBER-­‐‑adjusted  FDR  is:  
𝑝!"adj = 𝐾𝐿𝑡 𝑝!"  
for  all  p  in  GEk  and  q  in  LDl.    
Choice  of  the  bicluster  representative  statistic  
In  BBER,  a  representative  statistic  is  selected  for  each  bicluster  of  correlated  tests,  and  
that  choice  is  crucial  to  the  performance  of  the  method  (Figure  5.1B).  As  true  associations  likely  
exhibit  strong  signal  compared  to  other  associations  in  the  same  bicluster,  extreme  statistics  
such  as  minimum  p-­‐‑values  likely  correspond  to  the  true  eQTL.  However,  minimum  p-­‐‑value  
could  bias  towards  larger  clusters,  as  they  have  a  higher  chance  of  containing  extreme  p-­‐‑values.  
A  robust  statistic  such  as  median  could  be  more  appropriate.  Though  robust  to  biases,  median  
p-­‐‑values  might  represent  the  true  signal  poorly  while  a  higher  percentile,  such  as  the  90th  
percentile,  might  present  a  better  compromise.    
We  used  simulations  to  compare  sensitivity  and  specificity  of  BBER  under  three  
different  statistics:  minimum  p-­‐‑value,  median  p-­‐‑value,  and  90th  percentile  of  the  p-­‐‑values.  As  
show  in  Figure  5.1C-­‐‑D,  simulations  suggest  90th  percentile  p-­‐‑value  outperforms  minimum  and  
median  p-­‐‑values  on  specificity  while  maintaining  comparable  sensitivity.  Based  on  these  
results,  we  decided  to  implement  BBER  using  the  90th  percentile  p-­‐‑value  as  the  representative  
statistic.  
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Application  to  the  Lung  Genomics  Research  Consortium  Data  
We  then  applied  BBER  to  data  from  a  case-­‐‑control  study  of  chronic  obstructive  
pulmonary  disease  (COPD).  We  retrieved  clinical  metadata  and  gene  expression  profiles  from  
the  Lung  Genomics  Research  Consortium  (LGRC)  Data  Portal  (https://www.lung-­‐‑
genomics.org/research)  and  genotyping  data  from  the  same  study  (dbGaP  accession  number:  
phs000624.v1.p1).  We  selected  samples  having  both  gene  expression  and  genotyping  data.  Gene  
expression  data  (collected  using  the  Agilent  Technologies  G4112F  array)  contains  information  
on  14,557  Ensembl  genes.  Following  GCRMA  normalization  [17],  we  used  surrogate  variable  
analysis  (SVA)  [18]  and  found  no  batch  effects.    
Genotype  data  (collected  using  the  Illumina  Infinium  HD  Assay  with  Human  Omni  
QuAd  arrays)  contains  2,443,179  markers.  To  control  for  genotyping  errors,  we  removed  any  
markers  that  failed  Hardy-­‐‑Weinberg  equilibrium  test  (p  <  0.001,  1,166  markers  removed),  were  
missing  in  more  than  10%  of  samples  (35,577  markers  removed),  or  had  minor  allele  frequency  
lower  than  5%  (1,131,328  markers  removed).  There  were  1,288,792  SNPs  remaining.  Related  
subjects  based  on  identity  by  descent  were  also  removed.  This  quality  control  yields  126  COPD  
and  37  control  samples  for  the  eQTL  analysis  (86  males,  77  females,  163  total).  
eQTL  analysis  
Using  the  LGRC  data,  we  performed  genome-­‐‑wide  expression  quantitative  trait  loci  
(eQTL)  analysis,  which  fits  mRNA  expression  to  the  following  model:  
Gene  Expression  =  β0  +  β1  ADD  +  β2  Pkyr  +  β3  Age  +  β4  Sex  +  ε  
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where  ADD  is  the  allele  dosage  of  a  genotype  (coded  as  0,  1,  and  2  for  the  number  of  minor  
alleles)  and  Pkyr  is  the  number  of  pack  years  of  smoking.  We  used  PLINK  v.1.07  to  carry  out  the  
analysis  with  the  command:  
plink --bfile <input.genotype> --pheno <input.expression> --all-pheno --
linear --pfilter 0.05 --adjust --covar <pkyrs.age.sex>  
The  p-­‐‑value  filter  (pfilter  flag)  discarded  all  SNP-­‐‑gene  expression  pairs  with  
(unadjusted)  p-­‐‑values  less  than  0.05  as  those  would  become  insignificant  after  multiple  testing  
adjustment  and  would  not  affect  the  outcome  of  the  BBER  procedure.  
LD  block  identification  
LD  blocks  were  identified  by  the  command  “blocks”  in  PLINK  v.1.07  [6]:  
plink --bfile <input.genotype> --blocks --hap-freq  
The  algorithm  follows  the  default  procedure  in  Haploview  [5].  
Gene  expression  clustering  
To  obtain  gene  expression  clusters,  we  used  R  to  perform  complete  linkage  hierarchical  
clustering  with  absolute  Pearson’s  correlation  distance,  1-­‐‑|Corr|,  on  the  expression  profiles  of  
the  14,557  genes  represented  on  the  Agilent  array.  We  used  absolute  Pearson’s  correlation  as  
gene  pairs  that  are  either  negatively  or  positively  correlated  can  often  be  shown  to  be  co-­‐‑
regulated.  We  defined  clusters  by  cutting  the  hierarchical  clustering  dendrogram  at  the  height  
0.4,  which  optimizes  for  the  intra-­‐‑cluster  distance  (Figure  S5.2).  This  produced  8,288  clusters  
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with  an  average  cluster  size  of  1.75  genes  (max  cluster  size  81  genes).  The  small  average  cluster  
size  reflects  independence  of  the  expression  probes  and  is  expected.    
Enrichment  of  GWAS  SNPs  
We  assessed  enrichment  of  published  COPD-­‐‑related  genome-­‐‑wide  associations  in  our  
eQTL  SNPs  using  the  database  of  publicly  available  GWAS  (GWASdb;  
http://jjwanglab.org/gwasdb/,  version  3,  released  6/20/2013,  accessed  10/28/2013).  Filtering  from  
a  total  of  170,385  SNPs  in  GWASdb  using  keywords  “chronic  obstructive  pulmonary  disease”  
and  “emphysema,”  we  have  178  unique  SNPs  from  in  7  studies  (see  Supplemental  Table  S5.1);  
of  these  COPD-­‐‑associated  SNPs,  93  are  present  in  the  LGRC  SNP  set.  Using  LD  structure  in  the  
LGRC  samples,  we  inferred  an  additional  718  SNPs  previously  associated  with  COPD.  We  used  
Fisher’s  exact  test  to  assess  overrepresentation  of  the  overlap  between  the  GWAS  SNPs  and  
eQTL  SNPs  and  used  Wilcoxon  rank  sum  test  to  show  that  BBER-­‐‑adjusted  p-­‐‑values  of  GWAS  
SNPs  are  lower  than  those  of  non-­‐‑GWAS  SNPs.  The  enrichment  shows  that  our  eQTL  results  
identify  genetic  variants  relevant  to  COPD.    
Results  and  Discussion  
BBER  improves  specificity  with  little  compromise  on  sensitivity  
Compared  to  multiple-­‐‑testing  adjustment  approaches  like  Benjamini-­‐‑Hochberg  (BH)  
and  Bonferroni  corrections,  BBER  limits  over-­‐‑correction  by  grouping  dependent  tests  into  
blocks  and  only  corrects  for  the  number  of  the  de  facto  independent  blocks.  Thus  we  expected  
BBER  would  improve  on  sensitivity  while  maintaining  high  specificity.    
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We  demonstrated  this  using  a  series  of  simulations,  following  the  approach  described  by  
Kendziorski  et  al.  [4]  and  Chen  et  al.  [11].  Although  the  simulation  may  not  capture  the  
complexities  of  a  real  dataset,  it  allows  for  an  unbiased  assessment  the  performance  of  BBER  
relative  to  other  methods  and  helps  explicate  its  operating  characteristics.    
The  simulation  parameters  were  chosen  to  represent  a  typical  eQTL  dataset  (based  on  an  
empirical  observation  of  the  LGRC  data;  see  Methods  for  dataset  description):  the  average  SNP  
MAF  of  0.3,  effect  size  β  =  2,  and  the  average  intra-­‐‑cluster  expression  correlation  of  0.5.  All  three  
genetic  models  (additive,  recessive,  and  dominant)  and  three  levels  of  LD  correlation  (r  =  0.1,  
0.5,  and  0.9)  were  considered.  The  eQTL  analysis  used  a  linear  regression  under  the  additive  
model  assumption.  
Results  in  Table  5.1  show  reduced  power  of  BH  and  Bonferroni  approaches  and  
highlight  advantages  of  BBER  in  improving  power.  If  we  regard  sensitivity  achieved  by  the  
unadjusted  cases  as  the  maximal  achievable  sensitivity,  using  BH  and  Bonferroni  procedures  
reduces  sensitivity  to  detect  additive  effects  by  as  much  as  58.6%  (from  0.76  to  0.31)  and  66.4%  
(from  0.76  to  0.26),  respectively  (first  row  of  Table  5.1).  The  reduction  is  more  severe  in  the  cases  
of  the  dominant  and  recessive  models,  possibly  due  to  the  lower  baseline  sensitivity.  The  sub-­‐‑
optimal  sensitivity  demonstrates  how  BH  and  Bonferroni  procedures  over-­‐‑adjust  the  p-­‐‑values  
due  to  the  independence  assumption.  A  major  tradeoff  of  BBER  is  a  slightly  lower  specificity  
compared  to  BH  and  Bonferroni.  Depending  on  the  application,  this  tradeoff  can  be  worthwhile  
as  BBER  can  improve  sensitivity  of  the  analysis  while  maintaining  a  reasonable  specificity  (>  
0.95).  
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(continued)  
Figure  5.2:  Sensitivity  analyses.  All  simulations  were  produced  with  parameters:  N  =  200,  MAF  
of  0.3,  effect  size  β  =  2,  LD  correlation  r  =  0.9,  and  co-­‐‑expression  correlation  ρ  =  0.5,  unless  
otherwise  noted.  Each  simulation  is  repeated  100  times  (n  =  100)  (A-­‐‑B)  Sensitivity  and  specificity  
of  BBER  at  various  eQTL  effect  size  β.  Sensitivity  increases  as  the  effect  size  increases.  For  
correlated  markers  (r  =  0.9,  ρ  =  0.5),  the  increase  in  sensitivity  is  accompanied  by  decrease  in  
specificity.  (C-­‐‑D)  This  decrease  in  specificity  is  a  result  of  strong  correlation  between  genetic  
markers.  When  markers  are  weakly  correlated  (r  =  0.1),  the  specificity  does  not  decrease  as  a  
function  of  the  effect  size	  β.  (E)  Sensitivity  of  BBER  is  similar  to  BH  at  low  ρ  correlations  and  to  
the  unadjusted  case  at  high  ρ  correlations.  (F)  The  bimodality  behavior  of  BBER  can  be  
explained  by  convergence  of  the  number  of  clusters  to  the  “true”  number  (k  =  5),  which  
coincides  with  the  convergence  of  BBER  sensitivity  toward  the  unadjusted  case.  
  
	   	   BBER	   Unadjusted	   BH	   Bonferroni	  
Model	   r	   Sens.	   Spec.	   Sens.	   Spec.	   Sens.	   Spec.	   Sens.	   Spec.	  
Additive	  









































































































































Table  5.1:  Sensitivity  and  specificity  of  BBER  and  other  multiple  testing  adjustments.  The  
values  shown  are  mean  with  standard  deviation  in  parenthesis.  
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Sensitivity  Analysis  
To  understand  the  operating  characteristics  of  BBER,  we  observed  how  specificity  and  
sensitivity  change  in  response  to  varying  key  data  simulation  parameters.  Of  the  parameters,  
two  are  particularly  important:  eQTL  effect  size  and  correlation  between  genetic/gene  
expression  markers.  The  eQTL  effect  size  is  important  as  it  directly  affects  the  eQTL  linear  
model  and  influences  the  specificity-­‐‑sensitivity  tradeoff.  As  BBER  relies  on  the  ability  to  group  
together  correlated  markers,  the  correlation  between  markers  has  a  profound  impact  of  the  
quality  and  accuracy  of  clustering,  thus  influencing  BBER.  
eQTL  Effect  Size  
In  a  typical  statistical  test,  the  power  (sensitivity)  of  the  test  increases  as  the  effect  size  
increases  while  specificity,  which  is  a  function  of  the  false  positive  rate,  remains  constant  and  
independent  of  the  sensitivity.  However,  when  tests  are  correlated,  as  is  the  case  for  genetic  
data,  a  greater  effect  size  could  bias  the  p-­‐‑value  distribution,  leading  to  an  elevated  false  
positive  rate.  We  demonstrated  this  by  varying  the  eQTL  effect  size  β  from  0.1  to  2  (values  
chosen  based  on  empirical  observations  of  the  LGRC  data).  When  the  markers  are  correlated  (r  
=  0.9,  ρ  =  0.5),  power  increases  as  a  function  of  the  effect  size  (Figure  5.2A)  as  expected,  but  we  
observed  a  slight  decrease  in  specificity  as  a  tradeoff  (Figure  5.2B).  This  reduction  in  specificity  
is  a  result  of  the  high  correlation  between  genetic  markers  (r  =  0.9)  as  this  decrease  in  specificity  
is  much  more  subtle  when  the  genetic  markers  are  only  weakly  correlated  (r  =  0.1,  Figure  5.2D).    
Clustering  and  BBER  
The  strength  of  the  correlation  between  genetic  and  gene  expression  markers  influences  
the  performance  of  BBER  as  it  determines  the  number  of  biclusters  to  correct  for.  At  one  
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extreme,  if  markers  are  highly  correlated,  and  the  clustering  algorithm  groups  all  tests  into  one  
single  cluster,  there  will  be  no  adjustment,  and  BBER  is  equivalent  to  the  unadjusted  case.  On  
the  other  hand,  if  markers  are  all  independent,  and  each  test  is  its  own  cluster,  BBER  is  
equivalent  to  BH.  In  an  ideal  case,  BBER  should  strike  the  balance  by  appropriately  grouping  
together  correlated  tests.  Thus  intuitively  weakly  correlated  markers  should  result  in  BH-­‐‑like  
results,  and  conversely,  highly  correlated  markers  should  result  in  unadjusted  case-­‐‑like  
behaviors.    
To  test  this,  we  simulated  gene  expression  to  have  different  levels  of  correlation  (0-­‐‑0.9)  
while  keeping  the  correlation  between  genotypes  low,  at  r  =  0.1.  As  expected,  at  low  expression  
correlation  (ρ	  <	  0.4),  sensitivity  of  BBER  resembles  that  of  BH  and  at  high  correlation  (ρ	  >	  0.4),  it  
resembles  the  unadjusted  case  (Figure  5.2E).  We  further  validated  the  intuition  that  hierarchical  
clustering,  which  forms  a  basis  for  BBER  algorithm,  is  adaptive  to  the  strength  of  intra-­‐‑cluster  
correlation  and  identifies  the  correct  number  of  clusters.  As  show  in  Figure  5.2F,  when  gene  
expression  correlations	  are	  low	  (ρ	  <	  0.4),	  the	  number  of  clusters  identified  is  high,  reflecting  the  
weak  clustering.	  But	  as	  expression	  correlation	  ρ	  increases,	  the	  identified	  number	  of	  clusters  
converges  to  the  “true”  number  of  clusters  (k  =  5),  and  the  sensitivity  of  BBER  starts  to  resemble  
that  of  the  unadjusted  case.  
It  is  not  coincidental  that  0.4  is  the  point  at  which  BBER  “switches”  from  BH-­‐‑like  
sensitivity  to  unadjusted  case-­‐‑like  sensitivity.  In  the  BBER  procedure,  0.4  was  used  to  define  
clusters  in  hierarchical  clustering  and  we  selected  0.4  to  maximize  inter-­‐‑cluster  distance  (Figure  
S5.2).  This  cutoff  can  and  should  be  changed  based  on  the  specific  characteristics  of  a  dataset.  
   149  
Validating  BBER  specificity  with  biological  data  
To  corroborate  the  results  of  the  simulation  study,  we  used  real  data  to  construct  a  
negative  control  dataset  by  permuting  the  links  between  genotype  and  gene  expression  data  
from  Lung  Genomics  Research  Consortium  (LGRC).  We  accomplished  this  by  label-­‐‑swapping  
gene  expression  data,  as  described  previously  [19].  Because  the  permutation  procedure  breaks  
genotype-­‐‑gene  expression  association,  any  positive  calls  can  be  regarded  as  false  positives.  We  
used  this  permuted  dataset  to  assess  specificity  of  BBER  as  well  as  other  multiple  testing  
adjustment  methods.  As  shown  in  Table  5.2,  specificity  from  various  methods  agreed  with  our  
previous  simulation  results  and  confirmed  that  BBER  was  able  to  improve  specificity  of  the  
eQTL  analysis.  
Method	   Specificity	  
mean	  (sd)	  
BBER	   0.9753	  (0.0086)	  
Unadjusted	   0.9508	  (0.0047)	  
Permutation	   0.9522	  (0.0052)	  
Bonferroni	   1.0000	  (0.0008)	  
BH	   1.0000	  (0.0011)	  
Table  5.2:  Specificity  of  BBER  and  other  methods,  estimated  from  permuted  LGRC  data.  
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Figure  5.3:  Examples  of  eQTL  identified  by  BBER.  Each  point  represents  genotype  and  gene  
expression  of  one  sample,  and  the  line  connects  median  expression  of  the  genotype  groups.  (A)  
The  eQTL  associating  the  SNP  rs16940665  with  the  expression  of  MAPK8IP1  gene  is  among  the  
strongest  eQTL.  (B)  The  SNP  rs12906951  is  a  cis-­‐‑eQTL  SNP  of  CHRNA5,  an  important  COPD-­‐‑
associated  gene  [20].  
BBER  identified  COPD-­‐‑associated  variants  found  in  a  large  GWAS  
We  used  BBER  to  analyze  data  from  Lung  Genomics  Research  Consortium  (LGRC;  lung-­‐‑
genomics.org).  There  are  163  LGRC  subjects  with  both  gene  expression  and  genotype  data:  126  
COPD  patients  and  37  controls;  the  subjects  are  all  Caucasians.  After  normalization  and  data  
processing  (see  Methods),  we  performed  eQTL  analysis  using  a  linear  model  adjusted  for  three  
standard  potential  confounders  for  lung  function  modeling:  pack  years  of  smoking,  age,  and  
sex,  and  corrected  for  multiple-­‐‑hypothesis  testing  using  BBER.  LD  blocks  were  defined  by  
PLINK  [6],  and  gene  expression  was  clustered  using  complete-­‐‑linkage  hierarchical  clustering  
with  absolute  Pearson’s  correlation  distance.  We  used  a  cutoff  of  0.4  to  define  clusters  in  the  
dendrogram,  which  optimizes  for  the  inter-­‐‑cluster  distance  (see  Figure  S5.2).  The  size  
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373,708  LD  blocks  (average  size  3.4  SNPs/block)  and  8,288  gene  clusters  (average  size  1.75  
genes/cluster).  
There  are  62,739  significant  eQTL  at  the  level  0.001,  a  conservative  cutoff  which  gives  
high-­‐‑confident  eQTL  calls.  Of  those,  5,991  eQTL  are  cis-­‐‑acting,  (SNPs  within  1Mb  from  genes’  
transcription  start  sites).  Consistent  with  conventional  wisdom  [3],  the  cis-­‐‑eQTL  are  more  
statistically  significant,  as  the  BBER-­‐‑adjusted  FDRs  are  lower  compared  to  the  trans-­‐‑eQTL  
(Wilcoxon  p-­‐‑value  <  2.2×10-­‐‑16).  In  total,  there  are  36,364  SNPs  and  9,614  genes  with  significant  
eQTL.  These  comprise  about  2.82%  of  all  SNPs  and  a  substantial  portion  (63.37%)  of  the  genes  
in  the  dataset.  eQTL  with  strongest  BBER-­‐‑adjusted  FDRs  include  trans-­‐‑eQTL  of  MAPK8IP1  on  
Chromosome  17q21.31  (Figure  5.3A,  BBER  FDR=3.5×10-­‐‑41),  cis-­‐‑eQTL  of  OR7D2  (BBER    
FDR=1.1×10-­‐‑80),  LDHC  (BBER  FDR=3.0×10-­‐‑44),  PSPH  (BBER  FDR=3.0×10-­‐‑41),  LRRC14  (BBER  
FDR=5.2×10-­‐‑41),  AMFR  (BBER  FDR=2.4×10-­‐‑37),  and  SLC5A11  (BBER  FDR=1.1×10-­‐‑36).  The  list  of  top  
eQTL  is  given  in  Table  S5.1.  
Because  disease-­‐‑associated  variants  have  been  found  to  often  be  regulatory  [21],  the  
COPD-­‐‑associated  SNPs  are  likely  to  be  in  eQTL,  and  so  one  would  expect  enrichment  of  
variants  associated  with  COPD.  From  GWASdb,  a  database  of  published  genome  wide  
association  studies  [22],  we  identified  178  COPD-­‐‑associated  SNPS  from  7  COPD  association  
studies.  Of  those,  93  SNPs  are  present  in  the  LGRC  genotyping  arrays  (Supplemental  Table  
S5.1).    
Since  SNPs  in  GWASdb  are  mostly  tag  SNPs,  a  representative  subset  for  other  SNPs  in  
the  haplotype  blocks,  the  overlap  between  GWASdb  and  the  LGRC  SNP  set  under-­‐‑estimates  the  
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number  of  COPD-­‐‑associated  SNPs  in  the  LGRC  dataset.  Hence,  we  inferred  association  of  
additional  718  SNPs  that  are  in  LD  with  the  93  COPD-­‐‑associated  SNPs.  Of  these  SNPs,  42  are  in  
our  significant  eQTL  list,  representing  a  1.6-­‐‑fold  enrichment  over  the  genome-­‐‑wide  background  
(Fisher’s  exact  p-­‐‑value  =  0.002)  (Supplemental  Table  S5.3).  Moreover,  these  COPD-­‐‑associated  
eQTL  SNPs  tend  to  have  strong  BBER  FDR  compared  to  the  non-­‐‑COPD-­‐‑associated  eQTL  
(Wilcoxon  p-­‐‑value  <  1.27×10-­‐‑8).    
In  addition  to  the  overall  enrichment  of  COPD  GWAS  hits,  a  number  of  well-­‐‑replicated  
COPD  SNPs  are  present.  For  example,  SNPs  in  an  important  COPD-­‐‑associated  region  on  
Chromosome  15q25.1  spanning  CHRNA3,  CHRNA5,  and  IREB2  [20]  are  present  in  our  results  
as  cis-­‐‑eQTL  of  CHRNA5  gene  expression  (Figure  5.3B).  A  set  of  COPD-­‐‑associated  SNPs  on  
Chromosome  6q21.3  includes  cis-­‐‑eQTL  of  PSORS1C1  and  POU5F1.  The  eQTL  SNP  of  POU5F1  
(rs2074488)  has  been  associated  with  circulating  level  of  surfactant  protein  D  (SP-­‐‑D),  which  is  
linked  exacerbations  of  COPD  [23].    
SNPs  in  this  6q21.3  region  are  also  associated  with  COPD  susceptibility  in  a  previous  
eQTL  analysis  of  sputum  gene  expression  [24].  Another  important  COPD  gene  is  hedgehog  
interacting  protein  (HHIP),  for  which  multiple  SNPs  have  been  strongly  associated  with  lung  
function  and  COPD  [20,  25-­‐‑29].  Ten  significant  trans-­‐‑eQTL  of  HHIP  gene  are  found  in  our  
analysis  (Supplemental  Table  S5.4).  The  enrichment  of  COPD-­‐‑associated  SNPs  in  our  eQTL  
results  and  the  ability  of  BEBR  to  identify  eQTL  for  important  COPD  genes  CHRNA5  and  HHIP  
suggest  that  BBER  can  detect  regulatory  signals  relevant  to  COPD.  
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Conclusions  
Standard  multiple  testing  adjustment  approaches  for  eQTL  analysis  make  assumptions  
about  independence  of  genotypes  and  gene  expression  probes  that  do  not  reflect  the  structure  
of  relationships  in  real  data,  potentially  resulting  in  overestimation  of  the  number  of  
independent  tests  and  therefore  greatly  reducing  the  power.  We  developed  BBER  (bicluster-­‐‑
based  error  rate  control)  as  an  extension  of  the  standard  Benjamini-­‐‑Hochberg  (BH)  by  reducing  
the  effective  number  of  tests  from  the  number  of  individual  tests  to  the  number  of  biclusters  of  
correlated  tests.  Based  on  a  series  of  simulation  studies,  BBER  is  able  to  improve  sensitivity  over  
Benjamini-­‐‑Hochberg  and  Bonferroni  procedures  while  maintaining  the  improved  specificity.  
The  method  is  scalable  and  can  be  applied  to  a  genome-­‐‑scale  eQTL  analysis.  BBER  has  been  
implemented  in  R  and  is  available  as  a  Bioconductor  package,  BBER.  	  
Sensitivity  analysis  demonstrated  that  BBER  can  be  characterized  as  an  adaptive  
compromise  between  two  approaches:  BH  and  no  adjustment.  BBER  is  more  similar  to  BH  
when  markers  are  weakly  correlated  and  is  more  similar  to  no  adjustment  when  markers  are  
highly  correlated.  In  reality,  the  strength  of  marker  correlation  is  highly  variable.  The  main  
advantage  of  BBER  is  that  it  is  a  data-­‐‑driven  way  to  strike  the  balance  between  these  two  
commonly  used  approaches.  
Based  on  simulation  studies,  BBER  was  able  to  improve  sensitivity  substantially  over  BH  
and  Bonferroni  procedures  but  with  some  tradeoff  on  the  specificity.  Thus,  BBER  is  most  
appropriate  for  hypothesis  generation  rather  than  a  confirmatory  study.  In  an  exploratory  
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study,  the  eQTL  results  can  corroborate  other  lines  of  evidence  such  as  GWAS  and  differential  
expression  studies  and  help  prioritize  disease-­‐‑associated  variants.    
In  our  application  of  BBER  to  LGRC  data,  we  found  our  eQTL  SNPs  to  be  enriched  for  
COPD-­‐‑associated  SNPs  from  several  GWAS.  Intersection  of  the  two  lines  of  evidence  also  sheds  
light  on  important  COPD-­‐‑associated  regions  such  as  Chromosome  15q25.1  (CHRNA5)  [20]  and  
Chromosome  4q31  (HHIP)  [20,  25-­‐‑29]  and  highlights  a  promising  region  on  Chromosome  
6q21.3,  which  has  recently  been  associated  with  COPD  [24].  
Although  BBER  derives  motivation  from  eQTL  analysis,  the  method  is  generalizable  to  
any  type  of  multidimensional  association  studies.  For  example,  correlation  between  DNA  
methylation  and  gene  expression,  sometimes  called  mQTL  analysis,  suffers  the  same  problem  of  
high  dimensionality  and  highly  correlated  markers.  As  genomic  technologies  continue  to  
advance,  we  will  see  increasing  diversity  and  volume  of  high-­‐‑dimensional  data.  There  will  be  a  
need  to  integrate  multiple  data  types  at  higher  dimensionality  and  with  possibly  stronger  
correlation  among  markers.  A  method  such  as  BEBR  that  accounts  for  such  correlation  may  
prove  increasingly  useful.  
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Chapter  6:  Conclusion  
The  clinic  of  the  future  
In  2011,  two  leading  scientists  and  technologists  Stephen  Friend  and  Trey  Ideker  wrote  a  
commentary  in  Nature  Biotechnology  [1]  envisioning  “the  clinic  of  the  future.”    In  their  vision,  
future  routine  doctor  visit  will  involve  collecting  not  only  the  standard  seven  biometrics  (sex,  
age,  height,  weight,  temperature,  pulse  rate,  and  blood  pressure)  but  also  bio-­‐‑specimens  used  to  
monitor  patient’s  molecular  phenotypes  such  as  buccal  swab  for  full  genome  sequence,  stool  
samples  for  microbiome  composition  in  the  gastrointestinal  track,  and  blood  or  urine  samples  
for  mRNA,  miRNA,  proteome,  and  metabolome  profiles.    All  of  the  information  will  be  
integrated  with  the  patient’s  electronic  health  record,  and  the  new  information  augments  the  
history  gathered  in  previous  visits,  constructing  a  holistic  portrayal  of  the  patient’s  health  over  
his/her  lifetime.  
Like  many  technological  visions  of  the  past,  “the  clinic  of  the  future”  may  not  manifest  
itself  as  imagined  by  Friend  and  Ideker.    Think  back  to  the  vision  for  Artificial  Intelligence  in  
the  1980s.    Early  success  of  chess-­‐‑playing  computers  such  as  IBM  Deep  Blue  inspired  
imagination  of  humanoid  robots  living  among  human,  like  those  portrayed  in  the  movie  
Terminator.    Instead,  the  last  few  decades  have  seen  artificial  intelligence  manifesting  itself  as  
“smart”  augmentation  to  the  existing  technologies,  for  example  book,  movie,  and  song  
recommendation  systems  (e.g.  Amazon,  Netflix,  and  Pandora)  and  context-­‐‑aware  search  engine  
(e.g.  Google).    How  genomic  technology  will  eventually  integrate  itself  into  the  medical  practice  
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might  be  analogous.    Instead  of  requiring  an  all-­‐‑new  way  of  seeing  and  treating  patients,  
genomics  will  build  upon  the  current  time-­‐‑tested  clinical  practice.    We  may  not  be  collecting  
blood  or  stool  samples  for  all  patients  at  every  visit,  but  will  for  patients  with  related  
conditions,  such  as  inflammatory  bowel  disease  and  diabetes.    Family  history  is  already  
routinely  used  as  a  line  of  diagnostic  evidence  for  certain  conditions.    Genome  sequencing  
would  simply  be  the  logical  next  step.      
A  road  toward  personalized  medicine  
Regardless  of  how  “personalized  medicine”  will  manifest,  the  future  points  toward  an  
increasing  use  of  genomic  technologies.    Major  research  hospitals  are  now  starting  to  collect  bio-­‐‑
specimens  for  routine  genomic  screens.    For  example,  in  2011  Brigham  and  Women’s  Hospital  
and  Dana-­‐‑Farber  Cancer  Institute  launched  Profile  project1,  which  aims  to  genotype  a  large  
number  of  patients  and  make  the  data  available  to  researchers  in  the  system.    Similar  efforts  are  
also  being  made  across  the  county  and  the  world,  for  instance  VA  Healthcare’s  Million  Veteran  
Program  and  UK10K  Program  in  the  United  Kingdom.    With  the  potential  influx  of  information,  
regardless  of  how  the  clinic  of  the  future  would  shape  up  to  be,  three  areas  of  advancement  are  
required  to  advance  our  genomic  future:  technology  development,  links  between  disease  and  
markers,  and  integrative  analysis  approaches.      
  
  
                                                                                                              
1  http://www.dana-­‐‑farber.org/Research/Featured-­‐‑Research/Profile-­‐‑Somatic-­‐‑Genotyping-­‐‑Study.aspx  
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Technology  Development  
In  order  for  a  genomic  technology  to  be  useful  in  the  clinical  setting,  it  requires  “clinical-­‐‑
grade”  sensitivity  and  specificity  and  a  reasonable  turn-­‐‑around  time.  A  number  of  technologies  
routinely  used  in  research  do  not  match  one  or  more  of  those  requirements.    The  limiting  factors  
are  partly  the  biochemical  assays  themselves  but  perhaps  to  a  greater  extent  the  lack  of  
bioinformatics  tools  to  process  and  make  sense  of  the  data.    While  the  sequencing  technology  
has  advanced  at  a  rapid  pace  over  the  last  decade,  its  full  power  can  only  be  realized  when  
coupled  with  well-­‐‑reasoned  and  appropriately  contextualized  computational  tools.      
Exome  sequencing  is  one  of  the  applications  of  next  generation  sequencing  that  has  been  
used  in  the  clinical  setting.    Following  the  sensational  success  at  the  Medical  College  of  
Wisconsin  [2],  a  number  of  commercial  and  academic  labs  —  including  Ambry  Genetics;  
University  of  California,  Los  Angeles;  Washington  University'ʹs  School  of  Medicine;  and  
Cincinnati  Children’s  Hospital  —  have  recently  begun  offering  clinical  sequencing  services.    
Because  of  its  cost-­‐‑effectiveness,  exome  sequencing  has  become  the  technology  of  choice. 
ExomeCNV,  described  in  Chapter  2,  is  an  example  of  a  tool  used  in  clinical  exome  
sequencing.    Since  its  publication  in  2011,  ExomeCNV  has  been  used  in  several  studies  and  cited  
more  than  60  times  (Google  Scholar,  accessed  September,  2013).    More  importantly,  it  has  been  
used  to  supplement  clinical  exome  sequencing  (personal  communication,  Dr.  Hane  Lee)  at  
UCLA  Clinical  Genomics  Center.    Although  the  tool  was  developed  for  research  purposes,  
oversight  by  Genomics  Data  Board,  which  includes  Board  Certified  Pathologists,  Molecular  
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Geneticists,  Molecular  Cytogeneticists,  Clinical  Geneticists,  Genetic  Counselors,  and  Informatics  
Specialists,  helps  improve  its  utility  and  reliability.  
Associating  markers  and  disease  
Genomics  technologies  help  aid  discovery  of  variants  and  measure  molecular  activities  
in  a  system,  but  they  are  only  useful  when  put  in  a  context  of  traits  and  disease.    Most  of  the  
variants  in  the  human  genome  are  benign  polymorphisms,  and  most  of  the  expressed  genes  are  
housekeeping  genes.    Genome-­‐‑wide  association  study  and  differential  expression  analysis  are  
ways  to  connect  the  genomic  information  to  clinical  phenotypes.  
Because  of  the  high  dimensionality  and  possibly  small  effect  size,  statistical  techniques  
that  optimize  for  the  technology  and  biological  signal  are  crucial.    Several  major  findings  in  
genomics  are  made  possible  by  the  unique  combination  of  data,  statistics,  and  clinical  
understanding.    For  example,  in  2000,  Perou  et  al.  presented  a  seminal  paper  in  breast  cancer  [3]  
that  combines  a  groundbreaking  microarray  technology,  a  hierarchical  clustering  technique,  
and  a  deep  understanding  of  cancer  biology.    The  paper  created  a  deep  impact  not  only  by  
clarifying  four  major  subtypes  of  breast  cancers  but  also  by  popularizing  the  use  of  microarray  
and  hierarchical  clustering.  
In  a  similar  manner,  our  work  in  Chapter  4  has  combined  data,  statistics,  and  clinical  
insights  to  elucidate  sexual  dimorphism  in  COPD.    Leveraging  mRNA  expression  from  Lung  
Genomics  Research  Consortium,  Chapter  4  describes  a  technique  to  link  differential  gene  
expression  to  COPD  in  a  sex-­‐‑specific  manner.    A  careful  consideration  of  samples’  disease  
classification  based  on  a  deep  clinical  insight  has  proven  crucial,  as  without  the  clinical  
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adjudication  the  sample  heterogeneity  in  our  data  would  obscure  what’s  already  very  subtle  
signals.    Thus  the  success  of  a  marker-­‐‑disease  association  study  depends  on  a  close  
collaboration  between  technologists,  bioinformaticians,  and  clinicians.    
Integrative  approach  to  personalized  medicine  
The  power  of  genomics  is  derived  from  the  versatility  of  genomics  technologies.  With  a  
few  common  tools,  we  can  interrogate  multiple  aspects  of  a  biological  system.  For  example  
next-­‐‑generation  sequencing  can  be  applied  to  study  gene  function  and  regulation,  discovering  
new  variants,  and  sequencing  genomes  of  new  organisms  de  novo  (Figure  1).    Because  complex  
diseases  likely  involve  more  than  one  type  of  variants,  several  studies  collect  multiple  types  of  
genomic  information  on  the  same  set  of  patients.    The  Cancer  Genome  Atlas  
(cancergenome.nih.gov),  one  of  the  largest  collaborative  research  project  supported  by  National  
Cancer  Institute,  assays  and  makes  available  several  types  of  genomic  data  on  thousands  of  
cancer  samples,  including  mRNA  expression,  miRNA  expression,  protein  expression,  single  
nucleotide  variations,  copy  number  variations,  RNA-­‐‑seq,  and  DNA  methylation.    Lung  
Genomics  Research  Consortium  (www.lung-­‐‑genomics.org)  is  the  largest  and  most  
comprehensive  genomic  survey  for  Chronic  Obstructive  Pulmonary  Disease  (COPD),  profiles  
genotypes,  mRNA  expression,  miRNA  expression,  RNA-­‐‑seq,  and  DNA  methylation  of  several  
hundreds  of  patients.    
Each  type  of  genomic  data  comes  with  a  unique  set  of  challenge.    For  example,  in  
Chapter  3,  we  discuss  challenges  of  studying  co-­‐‑occurrence  and  co-­‐‑exclusion  relationships  
among  commensal  microbes  in  the  healthy  human  microbiome.    There,  we  employ  an  ensemble  
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strategy  to  study  various  correlational  patterns  and  develop  a  novel  method  called  ReBoot  to  
mitigate  spurious  correlation  arising  from  compositionality  of  microbial  abundance  data.  
Inasmuch  as  processing  one  type  of  data  is  challenging,  much  more  so  is  integrating  
across  data  types.    In  Chapter  4  we  corroborate  our  sexually  dimorphic  and  COPD  differential  
genes  with  DNA  methylation,  ChIP-­‐‑seq  binding  sites  of  sex  hormones,  and  genetic  regulation  of  
expression  (eQTL).    The  eQTL  analysis  is  our  first  step  to  integrate  genotyping  and  gene  
expression  data.    We  found  that  after  adjusting  for  multiple  hypothesis  testing,  the  eQTL  
analysis  was  grossly  underpowered.    This  served  as  a  motivation  for  Chapter  5,  which  
introduces  BBER,  a  bicluster-­‐‑based  multiple  hypothesis  correction  procedure.    BBER  extends  the  
current  standard  Benjamini-­‐‑Hochberg  procedure  by  taking  into  account  the  profound  
correlation  structure  between  co-­‐‑expressed  genes  and  within  LD  blocks.    By  taking  advantage  
of  the  basic  characteristics  of  gene  expression  and  genotypes,  we  were  able  to  improve  
sensitivity  of  eQTL  analysis  considerably.  
Though  challenging,  integrating  multiple  types  of  data  will  be  an  important  step  
forward  in  genomics.    Already  many  studies  have  reported  success  in  integrating  information  
across  platforms.    The  Cancer  Genome  Atlas  Network  has  recently  published  comprehensive  
molecular  portraits  of  human  breast  tumors,  which  combine  copy  number  variation,  DNA  
methylation,  exome  sequences,  mRNA  expression,  miRNA  expression,  and  protein  expression  
to  describe  detailed  molecular  features  of  breast  cancer  subtypes  [4].    More  sophisticated  
integrative  approaches  such  as  the  network  model  start  to  surface  and  show  great  promise  [5].    
There  is  a  newfound  appreciation  for  a  more  holistic  view  of  a  biological  system,  with  an  
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emergence  of  Systems  Biology  [6]  and  Network  Medicine  [7],  and  integrative  genomics  is  going  
to  play  an  increasingly  important  role  in  pushing  this  frontier.  
  
  
Figure  6.1:  Applications  of  sequencing  technology.  Next-­‐‑generation  sequencing  serves  as  a  
common  platform  to  interrogate  genetic  map  and  molecular  activities  of  a  biological  system.    
Epilogue  
The  advancement  in  genomics  insinuates  not  only  the  data  integration  but  also  the  
integration  of  disciplines.    Because  of  its  far-­‐‑reaching  field  of  applications,  genomics  touches  
and  draws  expertise  from  virtually  all  areas  of  biology,  computer  science,  and  statistics.    A  close  


















Reproduce from: http://finchtalk.geospiza.com/2010/09/genomics-genealogy.html 
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hypothesis  generation  and  experimental  validation.    Unbiased  and  high-­‐‑throughput  nature  of  
genomic  surveys  can  accelerate  discovery  of  new  biomarkers  that  can  be  developed  into  
diagnostics  and  treatments.    But  without  collaborators  with  the  capability  to  validate  the  
biomarkers  and  translate  them  to  clinical  uses,  computational  predictions  would  remain  mere  
hypotheses.  
To  create  a  productive  trans-­‐‑disciplinary  collaboration,  scientists  from  both  sides  have  to  
learn  to  appreciate  and  speak  each  other’s  language.    For  computational  scientists,  the  ability  to  
put  a  statistical  method  in  a  biological  and  experimental  context  can  help  improve  the  accuracy  
and  more  importantly  the  sensibility  of  the  results.    For  experimental  scientists,  the  ability  to  
appreciate  and  intuitively  evaluate  different  statistical  models  is  key  to  choosing  the  most  
promising  hypotheses  to  pursue.  
With  the  whole  world  moving  toward  more  open  sharing  of  information,  a  phenomenon  
initiated  by  social  media  and  accelerated  by  Meaningful  Use  and  improvement  on  electronic  
health  records,  clinical  information  is  going  to  become  more  connected  and  available.    Making  
sense  of  all  the  information  available  on  a  patient’s  record  is  going  to  require  a  well-­‐‑designed  
informatics  engine  that  represents  and  summarizes  the  information  effectively.    More  
importantly,  the  clinic  of  the  future  will  require  a  collaborative  network  of  experts  who  help  put  
context  to  data—to  translate  from  data  to  information,  and  from  information  to  understanding.  
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Appendix  2A:  Supplemental  Materials  for  Chapter  2  
Biases  in  Exon  Capture  Process  
We  start  with  an  observation  that  if  the  exome  capture  has  no  bias  and  the  distribution  
of  reads  is  uniform  across  the  exome,  the  distribution  of  depth  of  coverage  (average  number  of  
reads  per  basepair)  will  appear  to  follow  a  Poisson  distribution,  with  mean  equal  to  variance.    
However,  if  exon  capture  biases  are  present,  the  variance  to  mean  ratio  will  inflate  above  1,  a  
situation  called  overdispersion.    Thus,  we  use  the  variance  to  mean  ratio,  called  overdispersion  
factor  ϕ,  as  a  measure  of  the  exon  capture  bias.    The  effect  of  known  sources  of  bias,  i.e.  GC-­‐‑
content  and  sequence  mapability,  is  considered  and  a  final  justification  for  using  paried-­‐‑sample  
comparison  approach  is  given.    All  of  the  data  presented  here  are  based  on  the  melanoma  
samples  described  in  the  paper  and  the  methods.  
Within  one  sample,  there  is  a  substantial  amount  of  biases,  and  this  is  reflected  through  
the  Poisson  Q-­‐‑Q  plot  (Figure  S2.1)  and  the  overdispersion  factor  of  9.5.    Part  of  this  variability  
comes  from  the  exons  with  zero  coverage.    We  have  examined  theses  exons  with  no  coverage  
(available  at  
http://genome.ucla.edu/~fah/ExomeCNV/supplement/SureSelect_No_Coverage_Exons_G3362.b
ed)  and  found  that  they  correspond  to  homologs  or  repetitive  sequences  and  have  low  
mapability  scores  (based  on  ENCODE  CRG  mapability  score).    The  aligner  program  discarded  
reads  mapped  to  these  regions  because  of  the  ambiguity.    Even  when  removing  these  zero  
coverage  exons,  the  amount  of  bias  observed  remains  substantial  (overdispersion  factor  of  8.9).  
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Figure  S2.1:  Poisson  Q-­‐‑Q  plot  and  histogram  shows  poor  fit  to  Poisson  distribution  and  a  
high  level  of  overdispersion.  
Effect  of  Overdispersion  on  Specificity  and  Sensitivity  of  ExomeCNV  
The  effect  of  overdispersion  to  Poisson  distribution  can  be  modeled  through  the  quasi-­‐‑
likelihood  approach  in  which  the  variance  is  allowed  to  inflate:  σ2  =  ϕ  µμ.    Thus  the  transformed  
depth-­‐‑of-­‐‑coverage  ratio  statistic  (see  Methods  for  definition  and  derivation)  becomes:  
𝑡 𝜌,𝜙 = 𝜇!𝑅 − 𝜇!𝜎!!𝑅! + 𝜎!! = 𝜆𝑅 − 𝜌𝜆𝜙𝜆𝑅! + 𝜌𝜙𝜆 = 𝑅 − 𝜌𝑅! + 𝜌 𝜆𝜙.  
That  is,  the  overdispersion  factor  ϕ  affects  the  statistic  t  by  directly  scaling  down  the  
average  depth-­‐‑of-­‐‑coverage  λ  by  a  factor  of  ϕ.    In  other  words,  overdispersion  will  reduce  the  
power  and  accuracy  of  prediction  as  though  the  depth-­‐‑of-­‐‑coverage  is  reduced  by  the  factor  ϕ.    
For  example,  an  exon  with  35x  depth-­‐‑of-­‐‑coverage  and  an  overdispersion  factor  of  5  will  have  
the  same  power  of  prediction  as  an  exon  with  7x  coverage  but  no  overdispersion.    Figure  S2.2  
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illustrates  the  effect  on  the  ROC  curves  for  prediction  of  a  duplication  event  on  an  exon  size  
500bp  with  35x  depth-­‐‑of-­‐‑coverage.  
However,  it  is  noteworthy  that  this  calculation  is  only  true  under  an  assumption  that  
taking  the  ratio  of  depth-­‐‑of-­‐‑coverage  does  not  get  rid  of  the  overdispersion  (the  biases).    We  will  
soon  see  that  this  is  fortunately  not  the  case,  and  taking  the  ratio  of  depth-­‐‑of-­‐‑coverage  of  the  
same  exon  does  significantly  reduce  the  overdispersion  effect.  
  
Figure  S2.2:  Effect  of  overdispersion  on  specificity  and  sensitivity  of  detecting  a  duplication  
event  on  an  exon  of  size  500bp  with  35x  depth-­‐‑of-­‐‑coverage.    The  solid  red  curve  is  the  ROC  
curve  for  the  case  where  there  is  no  overdispersion,  and  the  subsequent  curves  are  for  the  cases  
with  increasing  overdispersion  factors.  
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Figure  S2.3:  Effect  of  GC-­‐‑content  and  mapability  on  depth-­‐‑of-­‐‑coverage  of  exons.  
Effect  of  GC-­‐‑Content  
Figure  S2.3A  shows  that  sequences  with  extreme  GC  contents  (especially  high  GC-­‐‑
content)  tend  to  have  lower  depth-­‐‑of-­‐‑coverage.    This  is  in  agreement  with  previous  sequencing  
projects  1,2.    By  linear  regression,  GC-­‐‑content  accounts  for  38.52%  of  the  variability  in  the  depth-­‐‑
of-­‐‑coverage.    Correcting  for  GC-­‐‑content,  we  managed  to  reduce  the  overdispersion  factor  to  6.  
Effect  of  Mapability  
Mapability,  or  uniqueness  of  DNA  sequence,  can  affect  the  efficiency  of  sequence  
alignment.    Repetitive  sequences  have  low  mapability  score  and  tend  to  be  harder  to  align,  
resulting  in  generally  lower  depth-­‐‑of-­‐‑coverage.    On  the  other  hand,  high  mapability  scores  
indicate  unique  sequences,  and  higher  depth-­‐‑of-­‐‑coverage  is  observed.    Mapability  scores  (CRG  
GEM-­‐‑Alignability  of  36mers  with  no  more  than  2  mismatches)  were  retrieved  from  UCSC  
Genome  Browser,  and  an  average  score  is  calculated  for  each  exon.    Figure  S2.3B  shows  the  
A	   	   	   	   	   	   	  	  	  	  	  B	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effect  of  mapability  score  on  depth-­‐‑of-­‐‑coverage,  with  higher  scores  associated  with  higher  
coverage.    Ordinary  linear  regression  suggests  that  mapability  accounts  for  2.43%  of  the  
variance  in  depth-­‐‑of-­‐‑coverage  distribution.    Correcting  for  both  GC-­‐‑content  and  mapability  
reduces  the  overdispersion  factor  to  4.  
Taking  the  Ratio  of  Depth-­‐‑of-­‐‑Coverage  Reduces  Probe-­‐‑specific  Biases  
Although  GC-­‐‑content  and  mapability  can  help  explain  some  of  the  extra  variability  in  
depth-­‐‑of-­‐‑coverage,  more  biases  remain  unexplained.    Since  our  exon  capture  was  done  using  
microarray  probes,  probe-­‐‑specific  biases  such  as  capture  efficiency  can  have  strong  effect  on  the  
number  of  mapped  reads.    Because  of  the  lack  of  mean  to  measure  and  correct  for  these  biases  
directly,  we  considered  the  usefulness  of  the  indirect  approach  of  taking  the  ratio  of  depth-­‐‑of-­‐‑
coverage.    Our  assumption  is  that  if  the  effect  of  biases  on  depth-­‐‑of-­‐‑coverage  of  an  exon  is  
consistent  across  samples,  taking  the  ratio  of  depth-­‐‑of-­‐‑coverage  of  the  exon  from  two  
independent  samples  will  reduce  the  biases.    We  looked  at  the  distribution  of  depth-­‐‑of-­‐‑coverage  
of  an  exon  across  10  exomes  available  internally  and  measured  the  overdispersion  factor  of  the  
exon.    Each  overdispersion  factor  measures  how  well  the  depth-­‐‑of-­‐‑coverage  of  the  exon  follows  
Poisson  distribution,  and  it  turned  out  that  most  of  the  exons  have  overdispersion  factors  of  less  
than  1  (mean  0.91,  median  0.74,  and  3rd  quartile  1.17).    This  implies  that  it  is  reasonable  to  model  
depth-­‐‑of-­‐‑coverage  by  Poisson  distribution  and  that  taking  the  depth-­‐‑of-­‐‑coverage  ratio  from  two  
samples  will  reduce  the  biases.  
Justification  for  the  depth-­‐‑of-­‐‑coverage  ratio  threshold  used  for  calling  CNV  
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In  calling  CNV,  we  need  to  identify  a  cutoff  r(ρ)  which  yields  desired  minimum  
specificity  and/or  sensitivity  for  testing  a  particular  copy-­‐‑number  ratio  ρ  at  a  particular  exon  
with  some  depth-­‐‑of-­‐‑coverage  and  length.    Solving  the  equations  in  the  main  paper  Section  2.1  
for  R,  we  derive  the  cutoff  value  for  an  α-­‐‑level  test:  
𝑟! 1 = 𝜆 + 𝑡! 2𝜆 − 𝑡!!𝜆 − 𝑡!! ,  
where    
𝑡! = Φ!! 𝛼Φ!! 1 − 𝛼 if  𝜌 < 1,if  𝜌 ≥ 1   
And  the  cutoff  value  for  a  test  of  power  at  least  1  –  β  is:  
𝑟! 𝜌 = 𝜌𝜆 + 𝑡! 𝜌(𝜆 − 𝑡!! + 𝜌𝜆)𝜆 − 𝑡!! ,  
where    
𝑡! = Φ!! 1 − 𝛽Φ!! 𝛽 if  𝜌 < 1,if  𝜌 ≥ 1   
If  ρ  >  1,  that  is  we  are  considering  a  duplication  event,  a  test  rejects  when  the  observed  
coverage  ratio  R  >  rcutoff.    Conversely  if  ρ  <  1,  that  is  we  are  considering  a  deletion  event,  a  test  
rejects  when  R  <  rcutoff.  
Figure  S2.5  shows  a  graphical  representation  of  the  relationship  among  α,  β,  rα(1),  and  
rβ(ρ).    From  Figure  S2.5,  we  note  that  the  exon  represented  by  the  red  curve  does  not  have  
sufficient  coverage  to  achieve  the  desired  specificity  (1  –  α)  and  sensitivity  (1  –  β)  
simultaneously,  whereas  the  exon  represented  by  the  green  curve  does  have  sufficient  coverage.    
If  ρ  >  1,  R  increases  in  the  direction  of  the  arrows,  and  the  inequality  rα(1)  >  rβ(ρ)  indicates  
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sufficiency  of  the  coverage  (as  is  the  case  for  the  green  line),  and  the  reverse  indicates  
insufficiency  of  the  coverage  (as  is  the  case  for  the  red  line).    If  an  exon  does  not  have  sufficient  
coverage,  we  refrain  from  declaring  CNV  for  that  exon.  
In  the  case  when  an  exon  has  enough  coverage  to  call  CNV,  there  are  multiple  possible  
cutoff  values  r  ε  [rβ(ρ),  rα(1)],  and  one  can  choose  to  optimize  r  for  sensitivity,  specificity,  or  a  
function  of  the  two,  e.g.  area  under  curve  (AUC)  =  (sensitivity  +  specificity)/2.    We  allow  the  
user  to  choose  which  option  to  optimize  when  performing  the  test  as  each  option  is  suitable  for  
different  applications.  
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ROC  of  detecting  deletion  and  duplication  
A B   
C D   
Figure  S2.4:  ROC  curves  for  detecting  (A,C)  deletion  and  (B,D)  one  copy  duplication.  The  
depth-­‐‑of-­‐‑coverage  is  fixed  at  35x  and  read  length  at  70bp.  The  dotted  gray  lines  correspond  to  
95%  specificity  and  sensitivity.  Generally,  it  is  more  difficult  to  detect  amplification  than  it  is  
deletion.  And  at  35x  coverage,  deletion  event  (A)  can  be  detected  at  95%  sensitivity  and  
specificity  for  exons  of  size  100  or  less  while  duplication  (B)  can  be  detected  for  exons  of  size  250  
or  less.    In  the  presence  of  admixture  of  normal  genomes,  the  copy-­‐‑number  ratio  ρ  tends  to  one.    
For  example,  at  the  admixture  rate  of  50%,  ρ  =  0.75  for  deletion  and  ρ  =  1.25  for  duplication.  The  
power  and  sensitivity  decreases  as  a  result  of  the  admixture,  and  the  ROC  curves  show  that  (C)  
deletion  can  be  detected  at  95%  sensitivity  and  specificity  for  exons  of  size  500bp  or  less  and  (D)  
duplication  can  be  detected  for  exons  of  size  less  than  500bp.  
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Figure  S2.5:  A  schematic  sketch  showing  relationship  among  α,  β,  rα(1),  and  rβ(ρ).  The  red  
curve  is  an  ROC  curve  of  an  exon  with  insufficient  coverage  to  achieve  desired  specificity  and  
sensitivity  1  –  α  and  1  –  β,  while  the  green  curve  is  one  with  sufficient  coverage.  The  arrows  
indicate  the  direction  in  which  the  copy-­‐‑number  ratio  R  increases.  Thus,  an  exon  has  sufficient  
coverage  to  call  CNV  when  rα(1)  >  rβ(ρ),  and  not  otherwise.  
  
Figure  S2.6:  Sequential  Merging  Procedure.  
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Sequential  Merging  Procedure  
This  illustrates  three  levels  of  granularity  of  segmentation.  (A)  At  the  finest  level  of  
granularity,  copy-­‐‑number  variation  is  assessed  at  each  exon  individually.  Exons  1  and  2  are  
called  as  duplicated  (copy  number=3)  while  Exon  3  is  called  as  amplified  (copy  number  >  3).  
Exons  5  and  7  are  called  as  deleted  while  Exons  4  and  6  are  called  as  copy-­‐‑neutral,  either  
because  they  are  truly  copy-­‐‑neutral  or  because  of  the  lack  of  power.  (B)  Circular  Binary  
Segmentation  (CBS)  subdivides  the  genome  into  segments  at  fine  granularity.  Exons  1  and  2  
merge  into  one  duplicated  segment  while  Exon  4  and  5  merge  into  a  deleted  segment.  With  the  
merged  segment  at  this  level,  there  is  enough  power  to  call  deletion  on  Exon  4.  (C)  Final  
segmentation  at  the  coarsest  level.  Exons  4-­‐‑7  merge  together  into  a  large  deleted  segment,  
giving  power  to  call  deletion.  The  final  CNV  calls  consist  of  three  segments  as  shown.  
Other  Statistics  for  Detecting  Segmental  LOH  
Here  we  discuss  the  choice  of  statistics  used  to  detect  LOH  in  a  segment  produced  by  
the  circular  binary  segmentation  (CBS)  algorithm.    An  F-­‐‑test  for  equality  of  variance  described  
in  the  Methods  Section  appears  to  be  very  sensitive  and  can  detect  slight  changes  in  copy-­‐‑
number,  which  are  sometimes  caused  by  non-­‐‑LOH  events  such  as  amplification.    Since  the  
increase  in  variance  due  to  LOH  is  generally  greater  than  those  due  to  non-­‐‑LOH  events,  we  can  
compensate  for  this  over-­‐‑sensitivity  with  a  conservative  p-­‐‑value  threshold.    However,  since  the  
choice  of  p-­‐‑value  threshold  is  quite  arbitrary,  we  considered  other  statistics:  non-­‐‑parametric  
Wilcoxon  rank-­‐‑sum  test  and  folded-­‐‑normal  test.  
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One  major  challenge  in  detecting  LOH  is  the  fact  that  non-­‐‑reference  or  B-­‐‑alleles  are  not  
always  on  the  same  chromosome  strand.    Thus,  the  direction  of  the  deviation  of  B-­‐‑allele  
frequencies  (BAFs)  from  0.5  cannot  be  used,  and  the  BAFs  cannot  be  combined  directly  in  any  
meaningful  way.    The  only  information  we  can  gain  from  BAFs  is  the  magnitude  of  the  
deviation:  |BAF  –  0.5|  or  |BAFcase  –  BAFcontrol|  (Figure  S2.8).    For  a  non-­‐‑LOH  region,  we  may  
assume  that  BAF  is  normally  distributed  with  mean  0.5  and  certain  variance  σ2  (Figure  S2.7A),  
and  so  |BAF  –  0.5|  and  |BAFcase  –  BAFcontrol|  follows  the  corresponding  folded-­‐‑normal  
distribution  (Figure  S2.7C,D).    For  an  LOH  region,  BAF  will  have  a  bimodal  distribution  
centering  around  0.5,  with  each  half  approximable  by  a  normal  distribution  (Figure  S2.7B).    
These  observations  serve  as  basis  on  which  Wilcoxon  test  and  folded-­‐‑normal  test  are  developed.  
The  motivation  for  using  Wilcoxon  test  arises  from  an  observation  that  the  deviations  of  
BAF  |BAF  –  0.5|  in  LOH  and  non-­‐‑LOH  regions  follow  two  distributions  with  different  means  
(Figure  S2.8B).    Thus  we  can  use  Wilcoxon  rank-­‐‑sum  test,  which  is  non-­‐‑parametric  and  
insensitive  to  model  assumption,  to  detect  the  difference  in  the  means  of  the  BAF  deviation  
between  case  and  control.    The  Wilcoxon  test  appears  to  be  very  sensitive,  achieving  as  high  as  
96.89%  sensitivity  in  detecting  LOH  in  the  melanoma  sample.    However,  because  of  its  
sensitivity,  it  also  detects  changes  in  the  deviation  of  BAF  due  to  other  non-­‐‑LOH  copy-­‐‑number  
changes,  resulting  in  low  specificity  (50-­‐‑61%).    In  general,  the  Wilcoxon  test  performs  very  
similarly  to  the  F-­‐‑test.  
We  attempt  to  address  over-­‐‑sensitivity  problem  encountered  by  the  Wilcoxon  test  and  F-­‐‑
test  by  developing  a  test  that  is  less  sensitive  and  is  able  to  distinguish  between  LOH  and  non-­‐‑
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LOH  BAF  shifts.    Because  the  absolute  difference  in  BAF  |BAFcase  –  BAFcontrol|  can  be  assumed  to  
follow  a  folded-­‐‑normal  distribution,  we  can  use  the  folded-­‐‑normal  distribution  to  test  for  a  
significant  deviation  from  the  null  case  where  BAFcase  and  BAFcontrol  are  identically  distributed.    
The  mathematical  details  of  the  test  are  outlined  here:  
Assuming  BAFcase  and  BAFcontrol  follow  the  normal  distributions  N(µμcase,  σ2)  and  N(µμcontrol,  
σ2),  respectively,  the  difference  BAFcase  –  BAFcontrol  follows  N(µμcase  –  µμcontrol,  2σ2),  and  the  absolute  
difference  |BAFcase  –  BAFcontrol|  follows  a  folded-­‐‑normal  distribution  with  mean:  
𝐸 𝐵𝐴𝐹case − 𝐵𝐴𝐹control = 𝜎 2/𝜋 exp − 𝜇!2𝜎! + 𝜇 1 − 2Φ 𝜇𝜎   
and  variance:  
Var 𝐵𝐴𝐹case − 𝐵𝐴𝐹control = 𝜇! + 𝜎! + 𝜎 2/𝜋 exp − 𝜇!2𝜎! + 𝜇 1 − 2Φ 𝜇𝜎 !  
where  µμ  =  µμcase  –  µμcontrol,  and  Φ  is  the  standard  normal  cumulative  distribution  function  (CDF).  
When  BAFcase  and  BAFcontrol  are  identically  distributed,  µμ  =  µμcase  –  µμcontrol  =  0,  i.e.  a  half-­‐‑
normal  distribution.    Thus,  the  CDF  of  the  folded-­‐‑normal  becomes:  
𝑃 𝑋 ≤ 𝑥 = 1 − 𝑃 𝑋 > 𝑥 = 1 − 2𝑃 𝑍 > 𝑥 = 2 1 − 𝑃 𝑍 > 𝑥 − 1 = 2Φ 𝑥 − 1  
and  the  p-­‐‑value  for  the  folded-­‐‑normal  test  is  given:  
𝑃 𝑋 > 𝑥 = 1 − 𝑃 𝑋 ≤ 𝑥 = 2 1 − Φ 𝑥   
where  x  is  a  realization  of  the  standardized  X  =  |BAFcase  –  BAFcontrol|/σ.    In  practice,  we  use  𝑥 = average( 𝐵𝐴𝐹!"#$ − 𝐵𝐴𝐹!"#$%"& ) s. e. ( 𝐵𝐴𝐹case − 𝐵𝐴𝐹control ).  
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As  expected  the  folded-­‐‑normal  test  gives  more  conservative  results,  achieving  97.52%  
specificity  with  54.27%  sensitivity.    When  combined  with  the  position-­‐‑wise  binomial  test  
(described  in  the  main  text),  we  can  improve  the  sensitivity  to  67.55%  while  lowering  specificity  
to  88.01%.  
The  choice  of  test  for  LOH  depends  on  the  application  and  users’  tolerance  to  false  
positive  and  false  negative.    Finally,  we  believe  that  there  exists  a  more  efficient  test  that  makes  
use  of  other  information,  such  as  predicted  CNV  status  and  haplotype,  and  more  sophisticated  
computational  techniques,  such  as  Hidden-­‐‑Markov  Model  (HMM),  but  we  consider  this  to  be  
beyond  the  scope  of  our  present  study.  
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Figure  S2.7:  Distribution  of  B-­‐‑allele  Frequencies  (BAF)  in  non-­‐‑LOH  and  LOH  regions.  (A)  
The  distribution  of  BAF  in  a  non-­‐‑LOH  region  follows  a  normal  distribution  with  mean  0.5,  
while  (B)  the  distribution  of  BAF  in  an  LOH  region  follows  a  bimodal  mixture  of  normal.    (C),  
(D)  The  deviation  of  BAF  from  0.5  |BAF  –  0.5|  and  the  absolute  difference  in  BAF  (|BAFcase  –  
BAFcontrol|)  follow  folded-­‐‑normal  distributions.  
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Size  Distribution  of  CNV  Segments  
  
Figure  S2.9:  Size  distribution  of  CNV  calls  in  the  melanoma  samples.  The  sizes  of  the  CNV  
segments  from  ExomeCNV  range  from  single  exon  (120bp)  to  whole  chromosome  (chr  10  and  
18).    The  distribution  of  amplified  segments  are  biased  toward  smaller  segments  because  
ExomeCNV  distinguishes  segments  with  evidence  for  higher  copy  numbers  (e.g.  3,  4,  5)  apart  
while  considering  all  deleted  segments  the  same.    Thus  all  the  deleted  segments  were  merged  
together  forming  larger  segments  while  amplified  segments  remain  fragmented.    We  cannot  
verify  the  biological  validity  of  this  behavior  at  this  point.  
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In  the  analysis  of  melanoma  samples,  ExomeCNV  was  allowed  to  call  higher  copy  
numbers  (3,  4,  5,  etc.).    These  higher  number  amplifications  were  observed  in  small  segments,  
often  single  exon,  and  were  not  merged  together  during  the  CBS-­‐‑sequential  merging  step.    
Thus,  the  amplified  segments  have  higher  number  of  small  segments  (<  500bp).    In  our  
validation,  we  treated  these  higher  copy  number  amplifications  as  one  group.  
We  processed  sequencing  data  from  two  lanes  of  the  same  matched  skin  sample  run,  call  
these  Lane1  and  Lane2.    The  average  depth-­‐‑of-­‐‑coverage  of  Lane1  and  Lane2  are  comparable  
(21.3x  and  20.4x,  respectively).    Since  Lane1  and  Lane2  were  from  the  same  library  and  
processed  exactly  the  same  way,  Lane1  should  have  no  copy-­‐‑number  change  with  respect  to  
Lane2,  and  any  CNV  calls  are  false  positives.    We  ran  ExomeCNV,  treating  Lane1  as  case  and  
Lane2  as  control,  and  counted  the  number  of  exons  falsely  classified  as  deleted  or  amplified.    
Here  we  set  estimated  admixture  rate  to  30%.    Adjusting  minimum  specificity  from  0.9  to  0.999,  
we  observe  empirical  specificities  as  reported  in  the  main  text  (Figure  S2.10).    When  the  
minimum  specificity  was  set  to  0.999,  ExomeCNV  made  2865  calls;  all  of  which  were  copy  
neutral.    At  minimum  specificity  of  0.99,  ExomeCNV  made  5738  calls:  25  deletions,  5711  copy-­‐‑
neutral,  and  two  duplications.    And  at  minimum  specificity  of  0.9,  27366  calls  were  made:  1903  
deletions,  25073  copy-­‐‑neutral,  and  390  duplications.  
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Lane1-­‐‑Lane2  Test  for  False  Positive  
  
  
Figure  S2.10:  Lane1-­‐‑Lane2  Test  for  False  Positive.    The  plots  show  log  depth-­‐‑of-­‐‑coverage  ratio  
and  CNV  calls  (yellow  =  copy-­‐‑neutral,  red  =  amplification,  green  =  deletion)  by  chromosome.    
Gray  dots  are  the  exons  with  insufficient  coverage  to  be  called  on  their  own.    (A)  is  the  results  
from  setting  minimum  specificity  to  0.99  and  (B)  from  setting  minimum  specificity  to  0.9.    Note  
that  (A)  yields  higher  sensitivity  but  also  lowers  the  sensitivity  by  calling  CNV  for  a  less  
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Sex-­‐‑Chromosome  Test  for  False  Negative  
  
Figure  S2.11:  Sex-­‐‑Chromosome  Test  for  False  Negative.    Exons  on  Chromosome  X  are  called  as  
amplified  by  ExomeCNV  with  most  (>99.9%)  of  the  log  depth-­‐‑of-­‐‑coverage  ratio  greater  than  0.    
Only  Chromosome  X  is  shown  here  because  almost  all  of  the  exons  in  Chromosome  Y  have  
depth-­‐‑of-­‐‑coverage  of  zero  in  male  exome  and  cannot  be  meaningfully  represented  (the  few  
exons  with  non-­‐‑zero  depth-­‐‑of-­‐‑coverage  have  very  low  depth-­‐‑of-­‐‑coverage,  are  called  as  deleted  
by  ExomeCNV,  and  are  sequencing  errors).    Different  shades  of  red  represent  strength  of  the  
signal.  
Since  we  knew  the  exact  copy-­‐‑number  of  sex-­‐‑chromosomes  in  normal  males  and  
females,  we  used  two  internally  available  exomes,  one  male  and  one  female,  to  test  if  
ExomeCNV  can  detect  this  copy-­‐‑number  difference.    The  two  individual  exomes  are  from  
individuals  with  no  evidence  of  sex-­‐‑liked  copy-­‐‑number  aberration.    Treating  the  male  exome  as  
case  and  female  as  control,  ExomeCNV  correctly  identified  Chromosome  X  as  being  
“amplified”  and  Chromosome  Y  as  being  “deleted”  with  no  false  negative  (Figure  S2.11).    Here  
we  set  minimum  specificity  to  0.9999  in  exon-­‐‑wise  calling  and  0.9  in  segment-­‐‑wise  calling  
(which  is  the  default  settings)  and  set  admixture  rate  to  0.  
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Comparison  between  ExomeCNV  and  ERDS  
  
Figure  S2.12:  Analysis  of  Melanoma  and  Paired  Normal  Samples.  Comparison  of  CNV  calls  
from  exome  sequencing  data  using  ExomeCNV  and  ERDS,  compared  to  calls  from  genotyping  
array.  The  most  outer  ring  (D)  shows  the  chromosome  ideograms  in  a  pter-­‐‑qter  orientation,  
clockwise  with  the  centromeres  in  red.  From  inside  to  outside,  each  data  track  represents  (A)  
Log  R  Ratio  (LRR)  from  genotyping  array  with  the  region  of  gain  highlighted  in  red  and  the  
region  of  loss  highlighted  in  green;  (B)  CNV  calls  from  ERDS,  the  region  of  gain  highlighted  in  
red  and  the  region  of  loss  highlighted  in  green  (C)  log  ratio  of  tumor  and  normal  depth-­‐‑of-­‐‑
coverage  with  the  segment  mean  in  red  line,  the  region  of  gain  highlighted  in  red  and  the  region  
of  loss  highlighted  in  green.  The  CNV  for  the  chromosome  Y  were  not  called  for  the  genotyping  
data  as  genoCN  (the  algorithm  used  to  call  CNV  from  Omni-­‐‑1)  is  not  designed  to  analyze  
chromosome  Y.  The  table  in  the  middle  summarizes  best  achievable  specificity  and  sensitivity  
of  ExomeCNV  and  ERDS  in  detecting  CNV  relative  to  CNV  calls  from  Omni-­‐‑1  array  
assessment.  
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Using  Pooled  Sample  as  Control  
In  many  applications,  for  example  in  identifying  germline  CNVs,  we  do  not  have  
matched  normal  sample  to  compare  the  exome  of  interest  with.    We  propose  using  a  pooled  
sample  as  control  sample.    Samples  to  be  pooled  have  to  be  from  libraries  of  the  same  type  (e.g.  
paired-­‐‑end,  single-­‐‑end)  and  processed  by  the  same  exon  capture  and  sequencing  protocols.    
This  usually  means  all  of  the  samples  should  be  processed  at  a  particular  site.    Pooling  can  be  
done  by  averaging  depth-­‐‑of-­‐‑coverage  of  each  exon  across  all  exomes  weighting  each  exome  
equally  or  by  their  total  depth-­‐‑of-­‐‑coverage.      
We  have  pooled  eight  available  exomes  which  were  processed  and  sequenced  in  the  
same  manner  as  the  melanoma  samples  used  in  our  study.    The  depth  of  coverage  on  each  exon  
was  averaged  and  used  as  a  “normal”  control  to  compare  against  normal  and  tumor  exomes  
from  a  melanoma  patient.    The  variance  of  the  pooled  depth-­‐‑of-­‐‑coverage  decreased,  as  expected  
by  the  central  limit  theorem  (Figure  S2.13).    The  ExomeCNV  results  are  shown  in  Figure  S2.14.  
As  cautioned  in  the  main  text,  there  is  a  problem  in  validating  such  analysis.    First,  we  
cannot  ascertain  that  the  pooled  exome  actually  represents  an  exome  with  normal  copy  number  
of  two.    These  exomes  we  used  were  from  patients  with  various  genetic  abnormalities  which  
may  have  abnormal  copy  number  variants.    Moreover,  4  of  the  8  exomes  came  from  the  related  
individuals  and  may  share  substantial  amount  of  germline  CNVs  which  would  skew  the  
distribution  of  the  pooled  copy  number.    And  even  if  all  samples  are  from  unrelated  
individuals,  there  might  be  common  CNVs  in  the  population  that  distorts  the  “normality”  of  
the  pooled  sample.  
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Moreover,  a  CNV  call  from  this  analysis  could  arise  because  of  many  factors,  and  there  
is  no  direct  way  to  validate  the  results.    A  CNV,  say  deletion,  found  by  comparing  the  tumor  
exome  against  pooled  exome  may  arise  from  1)  somatic  deletion  in  tumor  exome  2)  germline  
deletion  3)  duplication  in  pooled  exome  or  4)  false  positive.    Since  we  do  not  have  a  germline  
CNV  profiling  of  the  subjects,  there  is  no  simple  way  to  assess  validity  of  this  approach.    Thus,  
we  left  this  as  a  speculation  in  our  discussion.    
  
Figure  S2.13:  Pooling  depth-­‐‑of-­‐‑coverage  of  as  few  as  8  exomes  reduces  the  variance  
significantly.  
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A  (tumor  vs.  pooled  control)  
  
B  (normal  vs.  pooled  control)  
  
Figure  S2.14:  ExomeCNV  results  from  comparing  melanoma  tumor  (A)  and  matched  normal  
(B)  with  the  pooled  sample.    The  amplification  observed  in  chromosome  Y  is  likely  due  to  the  
imbalance  composition  of  male/female  in  the  pooled  sample.  
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Figure  S2.15:  ROC  and  Power  curves  showing  effect  of  varying  admixture  rates.  (A)  ROC  
curves  showing  sensitivity  and  specificity  of  detecting  deletion  and  duplication  of  segments  size  
500bp.  (B)  Power  curves  for  detecting  CNV  segments  of  size  500bp.  Power  is  plotted  relative  to  
mean  depth-­‐‑of-­‐‑coverage  in  the  genomic  segment,  setting  false  positive  to  1  per  genome  based  
on  an  analytical  model  of  genome-­‐‑wide  power  of  detection.    (C)  Same  as  (B)  but  for  detecting  
CNV  segments  of  size  1000bp.  
Estimation  of  Admixture  Rate  from  LOH  Regions  
Because  LOH  detection  method  does  not  require  prior  knowledge  of  admixture  rate,  we  can  
use  LOH  detection  to  estimate  admixture  rate.    In  particular,  because  we  know  that  B-­‐‑allele  
frequency  (BAF)  in  a  LOH  region  is  either  0.5(1  –  c)  or  0.5(1  +  c)  where  c  is  the  admixture  rate,  
the  value  |BAF  –  0.5|  =  0.5  c.    Thus,  c  can  be  estimated  by    
𝑐 = 2  Average( 𝐵𝐴𝐹LOH − 0.5 )  
where  BAFLOH  is  the  B-­‐‑allele  frequency  of  a  LOH  region.    In  our  melanoma  sample,  the  
admixture  rate  is  estimated  to  be  about  30%  by  this  method,  which  is  in  agreement  with  an  
estimate  from  the  SNP  genotyping  arrays.  
   192  
Appendix  2A  Bibliography  
1.   Campbell,  P.J.,  et  al.  Identification  of  somatically  acquired  rearrangements  in  cancer  
using  genome-­‐‑wide  massively  parallel  paired-­‐‑end  sequencing.  Nat  Genet  40,  722-­‐‑729  
(2008).  
2.   Chiang,  D.Y.,  et  al.  High-­‐‑resolution  mapping  of  copy-­‐‑number  alterations  with  massively  
parallel  sequencing.  Nat  Methods  6,  99-­‐‑103  (2009).  
  
  
   193  
Appendix  2B:  Supplemental  Analysis  for  Chapter  2  
To  demonstrate  the  shortcomings  of  array-­‐‑based  CNV  calling  algorithms,  we  used  a  
state-­‐‑of-­‐‑the-­‐‑art  array-­‐‑based  algorithm,  genoCN  [1],  to  call  CNV  from  the  exome  sequencing  
data.    In  particular,  we  are  examining  the  impact  of  exome  sequencing  data  violating  two  
assumptions  made  by  genoCN:  the  high  density  of  genotype  markers  and  the  distribution  of  log  
ratio  of  the  signal  intensity.    We  started  by  converting  exome  sequencing  data  to  an  appropriate  
format  and  applying  genoCN.  
Method  
The  objective  of  this  experiment  is  to  use  an  appropriate  array-­‐‑based  CNV  calling  
method  to  call  CNV  on  the  exome  sequencing  data.    Since  our  “gold  standard”  CNV  calls  are  
from  using  the  state-­‐‑of-­‐‑the-­‐‑art  method  genoCN  on  the  Illumina  Omni-­‐‑1  Quad  BeadChip  SNP  
array  data,  we  converted  the  exome  sequencing  data  into  59,857  SNPs  based  on  the  Omni-­‐‑1  
Quad  array  annotation.    For  each  SNP,  the  B-­‐‑allele  frequency  (BAF)  is  the  fraction  of  the  total  
sequencing  reads  with  B  allele  (minor  allele),  and  the  log  ratio  (LRR)  is  the  log2  of  the  
normalized  read  counts  between  tumor  and  normal  samples.    Default  values  were  used  for  
other  genoCN  parameters.  
Comparison  between  the  genoCN  calls  based  on  the  exome  sequencing  data  and  the  
gold  standard  calls  proceeded  the  same  way  as  other  comparisons  in  the  ExomeCNV  paper.    
Namely,  the  CNV  regions  were  first  map  to  exons  with  at  least  three  genotype  markers  (total  
   194  
3,516  exons),  then  the  true/false  positive/negative  were  calculated  in  terms  of  the  number  of  
exons  correctly/incorrectly  identified  as  copy-­‐‑number  gain  (>2)/loss  (<2)/neutral  (2).  
Results  
In  our  melanoma  sample,  used  in  the  ExomeCNV  paper  (Sathirapongsasuti  et  al.  2011),  
genoCN  called  3,103  as  loss  and  237  exons  as  gain  CNVs  based  on  exome  sequencing,  while  the  
gold  standard  (based  on  the  appropriate  application  of  genoCN  to  the  dense  SNP  array  data  of  
the  same  sample)  called  377  exons  as  gain  and  426  as  loss  CNVs.    The  total  number  of  exons  in  
consideration  is  3,516.    These  correspond  to  specificity  of  0.955  and  sensitivity  of  0.252  for  
amplification  and  specificity  of  0.132  and  sensitivity  of  0.988  for  deletion  (Table  SA2.1).  








Specificity   Sensitivity    
Deletion   421   2682   408   5   0.132   0.988  
Amplification   95   142   2997   282   0.955   0.252  
Table  SA2.1:  An  array-­‐‑based  approach  genoCN  as  applied  to  exome  sequencing  data  
GenoCN  appears  to  call  much  fewer  amplifications  than  deletions.    This  is  not  
surprising  as  the  power  analysis  of  CNV  detection  suggests  lower  statistical  power  to  detect  
amplification  than  deletion.    Because  of  the  lower  number  of  positive  calls,  the  sensitivity  is  low  
(0.252)  but  the  specificity  is  considerably  higher  (0.955).    On  the  other  hand,  a  much  higher  
number  of  exons  (1,589)  are  called  as  deleted,  yielding  markedly  low  specificity  (0.132)  but  
achieving  a  considerable  sensitivity  (0.988).  
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Figure  SA2.1:  Circos  plot  comparing  CNV  calls  from  three  methods:  (from  outside  in)  1)  
ExomeCNV  2)  exome  sequencing-­‐‑based  genoCN  and  3)  SNP  array-­‐‑based  genoCN.    Using  the  
appropriate  application  of  SNP  array  to  genoCN  as  the  gold  standard,  ExomeCNV  achieves  
high  sensitivity  (0.86  deletion,  0.88  amplification)  and  specificity  (0.97  deletion,  0.92  
amplification),  while  the  application  of  exome  sequencing  data  to  genoCN  achieves  low  
sensitivity  (0.25  amplification)  or  low  specificity  (0.132  deletion).  
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Discussion  
GenoCN  makes  two  primary  assumptions  about  the  input  log  ratio  intensity  (LRR)  
values:  the  LRR  follow  a  mixture  of  uniform  and  normal  distributions,  and  there  is  at  most  one  
state  transition  between  two  adjacent  SNP  probes.    The  first  assumption  is  not  appropriate  in  
the  setting  of  exome  sequencing  as  we  and  others  [2]  have  shown  that  the  read  counts  from  
exome  sequencing  follows  a  Poisson  distribution.  Consequently  the  log  ratio  of  the  read  count  is  
not  normally  distributed,  as  shown  by  the  QQ  plot  of  the  LRR  from  exome  sequencing  data  
from  the  melanoma  samples  used  in  the  main  analysis  (Figure  SA2.2).  
The  second  assumption  is  that  there  is  at  most  one  state  transition  between  two  adjacent  
SNP  probes.    This  assumption  is  appropriate  to  make  in  the  setting  of  the  SNP  array  because  of  
the  high-­‐‑density  of  genotype  probes  [1].    In  exome  sequencing,  this  assumption  is  not  
appropriate  to  make  because  there  are  regions  in  the  genome  with  few  exons  (gene  deserts).    
Moreover,  exons  tend  to  be  more  highly  conserved  and  have  lower  density  of  SNPs.    In  our  
particular  dataset,  out  of  1,140,419  SNPs  in  the  Omni-­‐‑1  Quad  annotation  set,  only  59,857  SNPs  
are  in  the  exome  (19-­‐‑fold  reduction  of  information).    And  some  of  the  regions  that  were  falsely  
called  by  genoCN  are  indeed  SNP-­‐‑poor  regions.    For  example,  the  regions  false  called  as  copy-­‐‑
gain  CNVs  have  on  average  4  genotype  probes  per  region,  compared  to  the  genome-­‐‑wide  
average  of  7  probes  per  region.  
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Figure  SA2.2:  QQ  plot  of  LRR  values  from  exome  sequencing.    The  distribution  of  exome  
sequencing  read  counts  has  been  show  to  follow  a  Poisson  distribution,  and  at  >  30x,  the  ratio  of  
the  read  counts  can  be  approximated  by  a  Cauchy  distribution.    Thus  the  log  ratio  of  read  
counts  is  not  normally  distributed,  as  illustrated  by  this  QQ  plot.  
The  difference  between  SNP  array  and  exome  sequencing  can  also  be  seen  at  the  
individual  probe  level.    Because  of  the  19-­‐‑fold  reduction  in  the  number  of  genotype  probes,  
genoCN  is  much  less  reliable.    As  with  any  data  set,  a  single  measurement  by  a  genotype  probe  
can  be  unreliable.    A  comparison  of  LRR  values  between  the  two  data  types  (Figure  SA2.3)  
shows  that  although  there  is  a  strong  correlation  between  the  two  LRR  (Spearman’s  0.294),  there  
are  clear  differences  at  individual  probe  LRR.    In  particular,  there  appear  to  be  a  number  of  
probes  with  near  zero  LRR  in  one  but  high  LRR  in  the  other.    This  could  be  because  of  the  
normalization  of  the  read  counts  and  probe  intensity  that  regress  the  values  toward  the  means,  
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benefit  from  borrowing  information  across  probes,  with  19-­‐‑time  less  number  of  probes,  exome  
sequencing-­‐‑based  approach  can  be  misleading.  
Two  illustrative  examples  highlight  the  need  for  a  new  method  that  properly  model  the  
data  are  the  deleted  q-­‐‑arm  of  Chromosome  6  and  the  duplicated  p-­‐‑arm  of  Chromosome  7.    
Figure  SA2.4  shows  the  B-­‐‑allele  frequency  (BAF)  and  log  ratio  intensity  (LRR)  that  were  used  by  
genoCN.    Clearly  the  shift  of  LRR  below  zero  in  Chromosome  6  and  above  zero  in  Chromosome  
7  were  evident,  suggesting  that  with  a  proper  modeling  of  the  BAF  and  LRR,  CNVs  can  be  
called  from  the  exome  sequencing  data.    As  discussed  above,  the  assumptions  made  by  genoCN  
do  not  hold  in  this  data,  justifying  the  need  for  a  new  method.  
  
Figure  SA2.3:  Comparison  of  log  ratio  between  exome  sequencing  read  counts  and  SNP  array  
intensity.  Despite  the  overall  correlation  (Spearman’s  0.294),  there  are  a  number  of  probes  with  
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Figure  SA2.4:  LRR  and  BAF  as  input  for  genoCN.    The  deletion  of  the  q-­‐‑arm  of  Chromosome  6  
and  duplication  of  the  p-­‐‑arm  of  Chromosome  7  are  evident  in  the  LRR  plot  by  the  shift  of  LRR  
below  and  over  the  zero  line.    GenoCN  failed  to  detect  both  of  these  events  (see  also  Figure  
SA2.1).    This  illustrates  that  the  information  about  CNV  existed  in  the  exome  sequencing  data  
but  a  proper  modeling  was  needed.  
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Appendix  3A:  Supplemental  Methods  for  Chapter  3  
Accounting  for  Compositional  Structure  in  Relative  Abundance  Data  
Data  summarized  as  relative,  rather  than  absolute,  abundances  such  as  16S  profiling  is  
known  to  be  challenging  to  analyze  due  to  compositional  measurements.    Specifically,  since  
relative  abundances  are  normalized  to  sum  to  one  (or  equivalently  rarefied  to  an  arbitrary  
constant  total),  an  increase  in  one  relative  abundance  must  be  accompanied  by  a  compositional  
decrease  in  another.    This  is  true  even  for  raw  sequence  read  counts  due  to  the  fixed  depth  of  
sequencing,  which  samples  proportionally  from  a  total  underlying  population.    Assessing  
correlation  between  compositional  data  by  traditional  measures  such  as  Pearson’s  correlation  
can  lead  to  spurious  correlations  [1].    Thus,  we  developed  a  novel  methodology  that  mitigates  
the  compositional  effect  in  data  while  assessing  significance  of  an  association.    In  particular,  we  
compare  the  distribution  of  correlations  from  bootstrap  sampled  data,  which  represents  the  
confidence  interval  of  the  observed  correlation,  with  the  null  distribution  of  correlations  from  
renormalized  permuted  data,  which  represents  the  correlation  structure  arising  purely  from  the  
compositionality.    
In  general,  assessing  significance  of  an  association  (e.g.  correlation  between  two  vectors)  
involves  comparing  an  observed  value  to  an  appropriate  null  distribution.    Permutation,  which  
breaks  any  true  association  in  the  data,  is  a  common  approach  for  constructing  the  null  
distribution.    Here,  we  show  that  simple  permutation  does  not  give  an  appropriate  null  
distribution  for  compositional  data,  as  it  breaks  compositionality  and  provides  anti-­‐‑
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conservative  estimates.    However,  appropriate  compositional  structure  can  be  re-­‐‑introduced  to  
permuted  data  by  renormalization,  and  a  null  distribution  can  be  obtained  from  the  resulting  
permutation-­‐‑renormalization  scheme.    This  approach  can  be  further  improved  by  using  
bootstrapped  confidence  intervals  for  the  observed  value  as  opposed  to  the  point  observation  
itself,  since  the  bootstrap  process  scales  the  variance  of  the  test  according  to  the  severity  of  
compositional  effect  as  manifested  through  the  signal-­‐‑to-­‐‑noise  ratio.  
Compositionality  leads  to  spurious  correlation  and  loss  of  information  
As  discussed  previously  [1],  relative  abundance  data  which  sum  to  a  constant  (e.g.  one)  
can  exhibit  spurious  correlation.    For  example,  in  Figure  SM3.1,  the  absolute  (A  and  B)  and  
relative  (C)  abundances  of  four  microbes  (b1-­‐‑4)  are  shown.    Microbes  b1  and  b2  are  uncorrelated  
in  Figure  SM3.1A,  but  the  relative  abundance  (Figure  SM3.1C)  shows  negative  correlation  
between  them  because  of  the  compositional  effect  introduced  through  normalization.    It  is  then  
important  to  account  for  the  compositional  effect  in  assessing  correlation  between  abundance  
data.  
Unfortunately,  some  true  correlation  may  not  be  possible  to  recover.    In  the  example  
shown  in  Figure  SM3.1,  although  the  relationship  between  b1  and  b2  is  different  in  A  and  B,  the  
two  different  absolute  abundance  datasets  produce  exactly  the  same  relative  abundance  
profiles,  masking  the  difference  in  the  true  correlation  structure.    Thus,  in  some  cases,  it  may  be  
impossible  to  uncover  the  true  underlying  correlation  given  the  relative  abundance  data  alone.    
Hence,  it  is  important  to  stress  that  because  only  the  relative  abundances  were  observed  in  our  
HMP  16S  dataset,  some  true  correlation  between  microbes  may  not  be  possible  to  elicit.    And  in  
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evaluating  the  performance  of  our  method,  we  need  to  bear  in  mind  that  our  aim  is  to  mitigate  
the  effect  of  compositionality  and  lessen  the  confidence  in  correlations  that  are  likely  results  of  
the  compositional  structure  rather  than  to  completely  recover  all  true  correlations.  
Standard  permutation  tests  result  in  false  positive  correlations  
One  standard  procedure  to  evaluate  the  significance  of  a  correlation  is  a  permutation  
test.    Unfortunately,  the  permutation  test  cannot  distinguish  spurious  compositional  
correlations,  as  the  permutation  process  removes  all  compositional  effects  and  generates  a  
highly  anti-­‐‑conservative  null  distribution.  As  demonstrated  in  an  example  in  Figure  SM3.2,  the  
permutation  test  declares  all  pairwise  correlation  in  a  synthetic  dataset  to  be  highly  significant.    
This  is  because  the  location  and  scale  of  the  permutation  null  distribution  does  not  reflect  the  
compositional  structure.    The  distribution  always  centers  at  zero  with  constant  standard  
deviation.    A  desired  null  distribution  should  vary  the  location  to  reflect  the  portion  of  eventual  
correlation  attributable  to  compositionality  alone  and  vary  the  scale  to  reflect  measurement  
scale  based  on  variation  in  the  absolute  abundance.  
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Figure  SM3.1:  Compositionality  induces  spurious  correlation  and  causes  loss  of  information.  
Consider   two  possible  absolute  abundance  profiles   from  collections  of  microbial   communities  
including  taxa  b1  through  b4.  250  synthetic  samples  (A)  and  (B)  represent  absolute  abundances  
(read   counts)   that,   upon   normalization   into   relative   abundance   (C),   produce   identical   values  
from  which   it   is   impossivle   to   recover   the  original   information.  Hence   it   is   important   to  note  
that   in   even   the   best-­‐‑handled   relative   abundance   data,   there   may   be   some   correlation   that  
cannot  completely  be  recovered.    
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Figure  SM3.2:  Permutation  testing  alone  cannot  distinguish  between  true  and  spurious  
correlations  in  compositional  data.  (A-­‐‑B)  Simulated  absolute  and  relative  microbial  
abundances.  (C)  Pairwise  correlations  (vertical  red  lines)  based  on  the  relative  abundance  in  (B)  
for  each  pair  of  synthetic  microbes.  These  are  accompanied  by  permutation-­‐‑based  null  
distributions,  standard  deviations,  and  z-­‐‑test  p-­‐‑values,  all  of  which  are  highly  (and  incorrectly)  
significant  due  to  compositional  effects.  
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The  Permutation-­‐‑Renormalization  and  Bootstrap  (ReBoot)  Method  
We  propose  ReBoot:  Permutation-­‐‑Renormalization  and  Bootstrap  Method,  a  procedure  
to  construct  a  null  distribution  that  reflects  the  compositional  effect  in  the  abundance  data.  As  
shown  in  Figure  SM3.3,  the  method  starts  with  the  relative  abundance  data  and  consists  of  two  
steps:  constructing  a  compositionality-­‐‑aware  null  distribution  and  comparing  this  with  a  
bootstrap  confidence  interval  around  the  observed  correlation.    These  steps  proceed  as  follows:  
Constructing  the  compositional  null  distribution  
For  each  pair  of  microbes:  
1. Permute  the  relative  abundance  of  the  microbes  
2. Renormalize  the  permuted  abundance  by  summing  over  each  sample  and  dividing  the  
abundance  in  that  sample  by  the  sample  sum  
3. Calculate  the  correlation  between  the  renormalized  permuted  relative  abundances  of  the  
two  microbes  
4. Repeat  (1)-­‐‑(3)  N  times  to  obtain  the  compositional  null  distribution  
Constructing  the  bootstrap  confidence  interval  
For  each  pair  of  microbes:  
1. Sample  with  replacement  the  sample  indices  and  construct  a  bootstrap  resampled  
dataset  
2. Calculate  the  correlation  between  the  bootstrapped  relative  abundances  of  the  two  
microbes  
3. Repeat  (1)-­‐‑(2)  B  times  to  obtain  the  bootstrap  distribution,  which  represents  the  
confidence  interval  around  the  observed  correlation  
Finally,  compare  the  compositional  null  distribution  and  the  bootstrap  distribution  by  z-­‐‑
test  with  the  variance  pooled  from  both  distributions  using  an  equally  weighted  unbiased  least  
square  estimate.  
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Figure  SM3.3:  The  Permutation-­‐‑Renormalization  and  Bootstrap  (ReBoot)  Method.     From  the  
relative   abundance   data,  we   construct   (1)   bootstrap   confidence   interval   around   the   observed  
correlation  and   (2)   the  null  distribution   that   represent   the   correlation  due   to   compositionality  
alone.   Contrasting   the   two   distributions   through   z-­‐‑test  with   pooled   variance,   an   appropriate  
significance  level  of  the  observed  correlation  can  be  assessed.  
Intuition  
The  bootstrap  distribution  represents  the  confidence  interval  around  the  observed  
correlation,  which  will  be  wider  for  less  abundant  organisms  due  to  lower  signal-­‐‑to-­‐‑noise  ratios.  
The  permutation-­‐‑renormalization  null  distribution  represents  correlation  due  solely  to  the  
compositional  effect  (see  the  detailed  explanation  below).  The  significance  of  associations  over  
and  above  those  expected  from  compositionality  alone  can  thus  be  evaluated  by  comparing  
these  two  distributions.  The  null  hypothesis  to  be  tested  is  that  the  two  distributions  have  the  
same  mean,  making  z-­‐‑test  an  appropriate  comparison.  The  variance  pooled  with  equal  weight  
from  both  distributions  provides  an  unbiased  least  squares  estimate.  
ReBoot  method  works  well  on  simulated  data  
We  demonstrated  the  performance  of  the  ReBoot  Method  by  assessing  significance  of  
the  correlation  in  a  simulated  dataset  (described  below).    The  results  are  shown  in  Table  SM3.1,  
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where  pairwise  correlations  and  p-­‐‑values  assessed  through  various  methods  were  compared.    
In  the  simulation  data  (Figure  SM3.4A),  b1  increased  linearly  while  b2  remained  constant  in  all  
samples;  b3  also  decreased  linearly  while  b4  remained  constant  at  a  lower  abundance;  16  other  
low-­‐‑abundance  microbes  were  also  present  at  a  constant  abundance.    The  all  microbes  had  low  
abundances  and  were  affected  strongly  by  the  noise.    The  correlation  and  the  permutation  test  
p-­‐‑values  estimated  from  the  absolute  abundances  were  the  expected  values  and  were  treated  as  
the  gold  standard  against  which  we  compared  our  results.      
Pairwise  Pearson  correlations  calculated  from  the  relative  abundances  of  b1-­‐‑b2  and  b2-­‐‑
b4  pairs  differed  substantially  from  the  true  correlations  (Table  SM3.1)  due  to  the  effects  of  
compositionality  as  expected.    The  p-­‐‑values  estimated  by  a  simple  permutation  test  on  the  
relative  abundance  data  overstated  the  significance  of  the  b1-­‐‑b2  and  b2-­‐‑b4  correlations  but  
maintained  the  true  significance  of  the  b1-­‐‑b3  pair.    Using  the  permutation-­‐‑renormalization  null  
distribution  (without  the  bootstrap  distribution)  improved  the  p-­‐‑value  estimates  of  b1-­‐‑b2,  but  
the  significance  level  of  b2-­‐‑b4  correlation  was  still  overstated.    Finally,  when  the  bootstrap  
distribution  was  introduced,  the  p-­‐‑values  of  b1-­‐‑b2  and  b2-­‐‑b4  were  no  longer  significant,  
matching  the  expectation  and  the  synthetic  data'ʹs  gold  standard.    




Figure   SM3.4:   Combining   a   renormalized   permuted   null   distribution   with   a   bootstrap  
confidence   interval   adjusts   the   significance   of   associations   between   features   appropriately  
according  to  the  degree  of  compositionality  in  the  data.    A  synthetic  dataset  of  four  simulated  
microbes  was  generated  as  absolute  abundances  (A)  including  a  single  true  negative  correlation  
between  b1-­‐‑b3  and  uncorrelated  taxa  b2  and  b4.  (B)  After  normalization  to  relative  abundances,  
b2  and  b4  exhibit  spurious  correlation  mitigated  by  (C)  application  of  the  ReBoot  procedure  to  
all   pairwise   comparisons.   Blue   and   red   vertical   lines   represent   means   of   bootstrapped  
(confidence   interval  of   true  association)  and  permuted   (null  distribution  of  association  due   to  
compositionality)   distributions,   respectively.      A   z-­‐‑test   with   pooled   variance   was   used   to  
compare   the  means  of   the   two  distributions,   among  which  only   the  b1-­‐‑b3   retains   significance  
(see  Table  SM3.1),  matching  the  gold  standard.  
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Table  SM3.1:  Comparison  of  ReBoot  p-­‐‑values  to  a  synthetic  gold  standard  
Simulated  data  
We  performed  a  number  of  simulations  to  demonstrate  the  effect  of  compositional  
measurement  and  assess  the  performance  of  the  ReBoot  method.    In  the  simulations,  absolute  
abundances  of  10  to  100  microbes  were  simulated  by  adding  normally  distributed  noise  to  a  
linear  trend.    A  minimum  of  10  microbes  were  required  to  capture  a  realistic  compositional  
effect,  while  too  many  simulated  microbes  will  diminish  the  effect.    For  each  microbe,  250  
absolute  abundances  (the  same  number  as  the  HMP  subjects)  were  produced  as  a  linear  
function  of  the  subject  index  (1-­‐‑250)  with  random  noise.    The  standard  deviation  of  the  noise  
distribution  is  fixed  within  each  simulation.    The  true  correlations  between  simulated  microbes  
were  determined  by  the  correlation  of  the  noise-­‐‑free  linear  trends.    These  absolute  abundances  
were  converted  to  relative  abundances  by  sample-­‐‑wise  normalization.  
Renormalization  mitigates  the  compositional  effect  
As  discussed  above,  an  appropriate  null  distribution  should  represent  the  amount  of  
correlation  due  to  compositional  measurement  alone.    While  permutation  breaks  the  correlation  
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structure  between  pairs  of  microbes,  it  also  eliminates  compositional  correlation.    During  the  
ReBoot  procedure,  since  only  the  microbes  of  interest  are  permuted,  the  compositional  effect  is  
retained  in  the  other  microbes,  we  can  thus  reintroduce  the  compositional  structure  to  the  
permuted  vectors  by  renormalizing  the  data  so  that  each  sample  sum  is  one.    The  correlation  
structure  remaining  in  the  renormalized  permuted  data  is  the  correlation  due  to  
compositionality  alone.  
To  illustrate  that  permutation-­‐‑renormalization  recovers  the  compositional  effect,  we  
performed  a  simulation  (Figure  SM5)  in  which  high-­‐‑abundance  microbe  b1  is  increasing  with  
the  sample  index,  microbe  b2  remains  constant,  low-­‐‑abundance  microbe  b3  is  decreasing,  and  
the  other  97  microbes  are  constant  (and  thus  uncorrelated)  at  low  abundance.    The  absolute  
abundance  is  normalized  into  relative  abundance  whose  negative  compositional  (spurious)  
correlation  between  b1  and  b2  is  clearly  visible.    For  each  pair  of  microbes  (e.g.  b2-­‐‑b3  and  b1-­‐‑b2  
shown  in  Figure  SM5),  permutation  was  performed  to  break  their  correlation,  then  sample-­‐‑wise  
renormalization  was  performed.    The  correlations  between  microbes  of  interest  in  the  
renormalized  permuted  data  were  the  correlation  structure  due  to  compositionality  alone  and  
were  visible  when  plotted  with  index  ranked  by  abundance  of  the  microbes  of  interest  (e.g.  b2  
and  b1,  Figure  SM5).  
It  is  important  to  note  that  renormalization  can  only  recapture  the  compositional  effect  
in  as  much  as  one  exists  in  the  relative  abundance  data.    Some  compositional  effects  cannot  be  
removed  because  of  the  information  lost  during  the  initial  normalization,  and  in  these  cases  
ReBoot  errs  on  the  side  of  potential  false  positives,  assuming  that  correlations  greater  than  
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would  be  expected  by  chance  in  relative  abundances  were  also  significant  in  the  underlying  
hidden  absolute  abundances.    Again,  Figure  SM3.1  illustrates  such  a  case  where  it  is  impossible  
to  fully  distinguish  compositional,  spurious  correlation  from  the  original  absolute  correlations.  
  
Figure   SM3.5:   Correlation   due   to   compositionality   alone   is   retained   in   the   permutation-­‐‑
renormalization  null  distribution.     Because  permutation  alone   is   insufficient   to   represent   the  
null  distribution  of  correlation  due  to  compositionality,  we  recover  the  additional  compositional  
structure   through   renormalization.   Permutation   of   relative   abundance   breaks   all   correlation  
structure   in   the   data,   but   renormalization   of   each   column   of   permuted   data   reintroduces   the  
compositional   structure,   by   the   degree   to  which   it   is   present   in   the   remaining   non-­‐‑permuted  
features'ʹ   relative   abundances.   Correlations   that   exist   in   this   renormalized   permuted   data   are  
due  to  compositionality  alone  and  can  be  used  to  construct  an  appropriate  null  distribution.  
Bootstrap  scales  the  confidence  interval  according  to  the  overall  relative  abundances  
As  discussed  above,  normalization  reduces  the  information  about  the  absolute  
abundance  while  introducing  spurious  correlation.    It  has  been  shown  previously  [1]  that  the  
information  about  the  absolute  abundance  can  be  retrieved  through  the  variance/co-­‐‑variance  
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structure  of  the  relative  abundance.    Similarly,  because  the  noise  in  the  data  (from  sequencing)  
is  assumed  to  be  comparable  between  both  low  and  high  abundance  microbes,  normalization  
affects  the  abundance  data  differently  based  on  the  noise-­‐‑to-­‐‑signal  ratio.    In  particular,  low  
absolute  abundance  microbes  are  affected  more  strongly  by  the  noise,  thus  the  variance  of  the  
relative  abundance  is  high.    The  reverse  is  true  for  high  abundance  microbes.    The  variance  of  
the  relative  abundance  directly  affects  the  variability  of  the  correlations  between  pairs  of  
microbes,  which  can  be  observed  through  the  variance  of  the  bootstrap  distribution  of  the  
correlations  as  shown  through  simulations  below  (Figure  SM6).    Hence,  the  variability  of  the  
bootstrap  distribution  of  the  correlation  can  be  utilized  as  a  way  to  recover  information  about  
the  absolute  abundance  of  the  microbes.  
To  demonstrate  the  relationship  between  the  variability  of  the  bootstrap  distribution  and  
the  absolute  abundance,  we  performed    a  series  of  simulations  in  which  we  monitored  the  
shape  of  the  bootstrap  distribution  of  correlations  between  two  anti-­‐‑correlated  vectors  with  
increasing  levels  of  noise  (Figure  SM6).    In  particular,  for  each  simulation,  we  generated  a  pair  
of  perfectly  anti-­‐‑correlated  vectors  (one  is  <1,2,3,…,1000>  and  the  other  <1000,999,998,…,1>).    
Normally  distributed  noise  with  mean  zero  and  increasing  standard  deviations  (Figure  SM6A:  
50,  B:  100,  C:  1000,  and  D:  10000)  were  added  to  the  two  vectors,  and  a  bootstrap  correlation  
distribution  was  generated  by  bootstrap  sampling  for  each  of  the  variance  (noise)  levels.    
Although  our  simulation  holds  the  absolute  abundance  constant  and  varies  the  noise  level,  this  
is  equivalent  to  holding  the  noise  level  constant  and  varying  the  absolute  abundance  
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magnitude.    As  shown  in  Figure  SM6,  as  signal-­‐‑to-­‐‑noise  increased,  the  bootstrap  distribution  
widened,  and  the  center  shifted  toward  zero,  which  is  the  desired  characteristic.  
  
Figure  SM3.6:  The   confidence   interval  provided  by  bootstrap  assessment  of   correlations   in  
compositional  data  scales  by  the  signal-­‐‑to-­‐‑noise  ratio,  and  is  thus  informative  for  excluding  
unreliable   low-­‐‑abundance   signals   most   affected   by   compositionality.      A   series   of   pairs   of  
vectors  were  generated  with  perfect  negative  correlations  (one   is  <1,2,3,…,1000>  and  the  other  
<1000,999,998,…,1>).      Normally   distributed   noise   with   mean   zero   and   increasing   standard  
deviations   (A)   50,   B)   100,   C)   1000,   and   D)   10000)   were   added,   and   a   bootstrap   correlation  
distribution  was   generated   by   bootstrap   sampling   for   each   of   the   variance   (noise)   levels.   As  
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Filtering  based  on  bootstrap  confidence  interval  of  R2  prevents  over-­‐‑fitting  in  GBLM  
As  an  additional  consideration  unrelated  to  compositionality,  we  extended  our  
application  of  the  ReBoot  procedure  to  GBLMs  to  prevent  overfitting  of  these  high-­‐‑dimensional  
models.  It  has  been  shown  that  the  boosting  procedure  for  linear  models  can  over-­‐‑fit  in  noisy  
data  [2],  and  in  the  case  of  our  microbial  relative  abundance  data,  low  abundance  microbes  can  
have  substantially  noisy  data  and  lead  to  over-­‐‑fitting  of  GBLMs.    In  assessing  significance  of  
GBLMs,  we  produced  bootstrap  distribution  of  adjusted  R2  to  be  compared  with  the  null  
distribution,  the  adjustment  of  which  provides  a  first  step  favoring  simpler  models  with  fewer  
parameters.    However,  through  simulations,  we  observed  that  the  bootstrapped  adjusted  R2  
could  in  many  cases  remain  elevated,  making  the  bootstrap  confidence  interval  a  poor  estimate  
of  the  true  adjusted  R2  and  leading  to  potential  false  positives.  Figure  SM  illustrates  this  in  
simulations,  using  data  as  in  Figure  SM6  and  resulting  in  an  over-­‐‑fitted  linear  model  b1  ~  b3  +  
(12  other  non-­‐‑informative  terms).  In  the  over-­‐‑fitted  model,  the  bootstrap  distributions  were  not  
centered  at  the  original  R2/adjusted  R2  values,  but  overinflated.    Note  also  that  the  bias  occurs  
both  in  R2  and  adjusted  R2  estimates,  as  the  number  of  predictors  in  the  model  is  the  same  
between  the  original  model  and  the  bootstrap  models  and  penalizing  for  it  as  in  adjusted  R2  
does  not  correct  the  bias  discussed  here.  Thus,  to  avoid  including  overfit  GBLMs  in  later  
analyses,  we  retained  only  GBLMs  whose  bootstrap  90%  confidence  intervals  included  the  true  
(observed)  R2  value  assessed  on  all  training  data.  
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Figure  SM3.7:  The  bootstrap   confidence   interval   for   a   sparse   linear  model   can  be   a  biased  
estimator   of   adjusted  R2.     Here,  we   use   the   data   of  Error!  Reference   source  not   found.   In   a  
GBLM  predicting  b1  relative  abundance  by  the  model:  b1  ~  b3  +  (12  other  non-­‐‑informative,  low-­‐‑
abundance   terms).   R2   (blue)   and   adjusted   R2   (red)   based   on   the   original   data   are   shown   as  
vertical   lines   and   the   bootstrap   distributions   are   plotted   as   curves.   (A)   uses   dense   (nonzero)  
synthetic  data  and  (B)  demonstrates  the  case  when  the  auxiliary  predictors  are  sparse  (>50%  of  
the  samples  have  zero  abundance).    The  similarity  between  (A)  and  (B)  suggests  that  the  bias  is  
independent  of  the  sparsity  of  the  predictors.  In  our  application  of  GBLMs,  to  avoid  including  
overfitting,  we  thus  retained  only  models  with  bootstrap  90%  confidence  intervals  including  the  
R2  observed  from  all  training  data.  
A  strategy  to  evaluate  ReBoot  procedure  
In  Faust  et  al.  (2012),  we  have  proposed  a  procedure  to  account  for  compositionality,  the  
induction  of  spurious  correlation  by  normalization.    Called  ReBoot,  the  procedure  breaks  any  
correlation  structure  by  permutation  and  re-­‐‑introduces  the  compositional  correlation  structure  
by  re-­‐‑normalization.    Although  the  application  of  ReBoot  to  the  16S  relative  abundance  data  
from  the  Human  Microbiome  Project  yielded  biologically  sensible  microbial  co-­‐‑occurrence  
network,  a  formal  test  of  validity  and  analysis  of  the  performance  of  ReBoot  under  different  
scenario  is  still  needed.  
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To  assess  the  performance  of  ReBoot,  we  need  both  a  synthetic  (computationally  
simulated)  gold  standard  and  a  biological  gold  standard.    One  of  the  biggest  challenges  of  
simulating  relative  abundances  is  simulating  the  noise.    The  noise  present  in  microbial  
abundance  data  arises  from  two  sources:  technical  noise  and  biological  noise.    The  technical  
noise  is  a  result  of  sample  preparation  and  sequencing.    This  has  been  well  explored  in  the  
sequencing  literature  and  can  be  modeled  by  lognormal  distribution.    That  is,  in  the  absence  of  
biological  variation,  microbial  abundance  can  be  simulated  by  a  lognormal  distribution.  
Microbes  may  have  natural  variation  across  body  sites  and  across  individuals,  for  
example  Bacteroides  can  varies  from  5-­‐‑95%  in  the  stool  samples.    This  biological  variation  may  
correlate  with  variation  of  another  microbe,  hence  a  co-­‐‑occurrence.    To  simulate  this  co-­‐‑
variation  pattern,  we  may  “spike-­‐‑in”  different  pattern  of  variation.    Four  major  co-­‐‑variation  
patterns  exist:  1)  positive  co-­‐‑variation  (e.g.  the  end  product  of  metabolism  of  one  can  be  used  by  
the  second)  2)  co-­‐‑occurrence  (e.g.  two  microbes  are  susceptible  to  a  toxin  from  a  third)  3)  
negative  co-­‐‑variation  (e.g.  two  microbes  competing  for  the  same  limited  resource),  and  4)  co-­‐‑
exclusion  (e.g.  each  microbe  produces  a  toxin  against  the  other).    
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1)  Positive  co-­‐‑variation            2)  Co-­‐‑occurrence  
  
3)  Negative  co-­‐‑variation            4)  Co-­‐‑exclusion  
Figure  SM3.8:  Four  patterns  of  co-­‐‑variation:  1)  positive  co-­‐‑variation  represents  cases  where  the  
end  product  of  metabolism  of  one  can  be  used  by  the  second  2)  co-­‐‑occurrence  represents  cases  
where  two  microbes  are  susceptible  to  a  toxin  from  a  third  3)  negative  co-­‐‑variation  represents  
cases  where  two  microbes  competing  for  the  same  limited  resource,  and  4)  co-­‐‑exclusion  
represents  cases  where  each  microbe  produces  a  toxin  against  the  other.  
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Co-­‐‑variation  
We  can  simulate  the  absolute  abundances  of  a  pair  of  microbes  jointly  by  a  multivariate  
normal  distribution  and  then  add  lognormal  noise  to  the  variation  to  simulate  the  technical  
noise.    The  strength  of  the  co-­‐‑variation  can  be  directly  controlled  by  changing  the  variance-­‐‑
covariance  matrix  of  the  multivariate  normal  distribution.  
Co-­‐‑occurrence  
We  first  simulate  the  baseline  abundance  of  the  microbes  by  lognormal  distribution.    
Then  a  subset  of  samples  is  chosen  at  random.    The  abundances  of  the  pair  of  microbes  in  
question  are  elevated  jointly  by  a  fix  margin  so  as  to  create  the  high  abundance  cluster  like  that  
shown  in  Figure  1(2).    The  strength  of  the  co-­‐‑occurrence  pattern  can  be  controlled  by  the  
fraction  of  the  samples  chosen  to  have  elevated  abundances  and  the  margin  relative  to  the  total  
abundance  in  the  simulated  system.  
Co-­‐‑exclusion  
We  can  simulate  co-­‐‑exclusion  pattern  by  first  allow  one  microbe  to  vary  freely  by  
lognormal  distribution  with  high  mean,  so  as  to  allow  for  high  range  of  biological  variability.    
The  second  microbe  is  simulated  under  the  null.    Then  a  subset  of  samples  is  chosen  at  random.    
The  abundances  of  the  first  and  the  second  microbes  in  these  selected  samples  are  swapped  so  
that  in  these  samples  the  second  microbes  have  high  abundance  and  the  first  low.    The  strength  
of  co-­‐‑exclusion  can  be  controlled  by  the  mean  of  the  lognormal  of  the  first  microbes  and  the  
fraction  of  the  samples  selected.  
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Aitchinson’s  log-­‐‑ratio-­‐‑based  measure  clusters  with  Kullback-­‐‑Leibler  dissimilarity  
We  close  with  a  brief  comment  on  the  use  of  Aitchinson'ʹs  proposed  variance  of  log  ratios  









This  measure  is  zero  if  the  ratio  of  two  components  is  the  same  in  all  observed  
compositions  and  is  increasing  (without  upper  bound)  with  increasing  variance  of  the  ratio.  The  
variance  of  log  ratios  can  therefore  be  considered  as  a  dissimilarity  measure.    
We  applied  the  variance  of  log  ratios  to  the  Houston  sample  subset  and  compared  the  
1,000  highest-­‐‑  and  1,000  lowest-­‐‑scoring  relationships  to  those  obtained  with  six  other  similarity  
and  dissimilarity  measures  in  the  same  data  set.  We  found  that  the  variance  of  log-­‐‑ratios  
clustered  together  with  other  dissimilarities  in  terms  of  edge  overlap,  such  as  the  Bray  Curtis  
dissimilarity  and  the  Euclidean  distance,  but  shares  most  edges  with  the  Kullback-­‐‑Leibler  
dissimilarity  (see  Supplemental  Figure  3.6).  Because  of  its  similarity  to  Kullback-­‐‑Leibler,  we  did  
not  include  the  variance  of  log-­‐‑ratios  in  our  analysis.      
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Appendix  3B:  Supplemental  Figures  for  Chapter  3  
  
Supplemental  Figure  3.1:  Significant  co-­‐‑occurrence  and  co-­‐‑exclusion  relationships  among  the  
abundances  of  clades  in  the  human  microbiome.  The  network  displays  all  significant  
phylotype  associations  within  and  across  the  18  body  sites  sampled  by  the  HMP.  Nodes  
represent  phylotypes  (colored  according  to  the  body  site  in  which  they  occur)  whereas  edges  
represent  significant  relationships  between  phylotypes.  Edge  thickness  reflects  the  strength  of  
the  relationship,  and  edge  color  its  directionality  (green  co-­‐‑occurrence,  red  co-­‐‑exclusion).  
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Supplemental  Figure  3.2:  Markov  clustering  of  the  complete  phylotype  network.  Markov-­‐‑
clustered  network  (inflation  parameter:  1.3).  When  clustering  the  cross-­‐‑body  site  network  with  
this  inflation  parameter  giving  optimal  modularity,  the  network  splits  into  the  set  of  depicted  
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Supplemental  Figure  3.3:  Cluster  coefficients  of  association  networks  within  individual  body  
sites  and  clades.  Average  cluster  coefficients  (computed  with  tYNA  [3])  of  body-­‐‑site-­‐‑specific  
(A)  and  class-­‐‑specific  (B)  sub-­‐‑networks.  The  "ʺcliquishness"ʺ  of  each  node  within  a  body  site  or  
class  is  expressed  by  the  average  cluster  coefficient,  which  is  higher  when  the  neighbors  of  each  
node  are  also  connected  among  themselves.  It  can  be  zero  if  none  of  the  nodes  in  the  sub-­‐‑
network  has  inter-­‐‑linked  neighbors.  The  cluster  coefficient  was  computed  for  all  edges  of  a  sub-­‐‑
network  (gray  bars)  and  for  positive  (green  bars)  and  negative  edges  (red  bars)  separately.  
Strikingly,  almost  none  of  the  negative-­‐‑edge-­‐‑only  sub-­‐‑networks  had  cluster  coefficients  above  
zero.  In  the  case  of  the  negative  class  sub-­‐‑networks,  this  is  a  consequence  of  the  low  number  of  
intra-­‐‑class  negative  edges  (see  Figure  3E).  If  a  negative-­‐‑edge-­‐‑only  sub-­‐‑network  has  a  cluster  
coefficient  of  zero,  it  means  that  neighbors  of  a  node  are  either  not  interconnected  at  all  or  that  
they  are  interconnected  only  by  positive  edges.  Within  the  body  sites,  groups  of  phylotypes  
linked  by  negative  edges  likely  reflect  alternative  communities.  Members  of  these  communities  
are  linked  among  themselves  by  positive  edges.  Thus,  if  the  positive  edges  are  removed,  the  
neighbors  of  negative  nodes  are  no  longer  interlinked  and  the  average  cluster  coefficient  
becomes  zero.  The  high  positive-­‐‑edge-­‐‑only  cluster  coefficients  in  classes  correspond  well  to  the  
high  positive  intra-­‐‑edge  number  in  these  classes  (see  Figure  3E)  and  mean  that  if  one  member  of  
the  class  is  present  in  an  individual,  the  other  members  are  also  likely  present.  
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Supplemental  Figure  3.4:  Co-­‐‑exclusion  of  Tannerella  and  Streptococcus  in  the  subgingival  
plaque.  The  anaerobic  and  proteolytic  Tannerella  requires  a  lower  pO2  than  Streptococcus,  while  
Streptococcus  is  an  asaccharolytic  colonizer  of  the  tooth  surface  that  uses  sugars  as  its  primary  
source  of  carbon  [4,5].  Between  the  supragingival  and  the  subragingival  plaques,  as  well  as  
within  the  subgingival  plaques,  a  gradient  of  nutrition  and  oxygen  is  present.  The  gradual  drop  
of  the  abundance  of  Tannerella  as  the  streptococci  increase  reflects  the  continuous  nutritional  
and  oxygen  gradient  between  and  within  the  supragingival  and  the  subgingival  biofilms.    
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Supplemental  Figure  3.5:  Abundances  of  18  putative  associations  between  oral  and  gut  
microbes.  Quality  control  plots  of  the  raw  data  for  all  putatively  significant  oral/gut  microbial  
associations  showed  no  strong  evidence  for  microbial  transfer  from  the  oral  cavity  along  the  
digestive  tract  at  the  available  level  of  detection.  For  GBLM  associations,  plots  show  predictions  
from  the  full  linear  model  (x  axis)  against  observed  values  (y  axis)  with  the  line  of  unity  drawn  
as  a  guide,  with  data  from  the  two  clinical  centers  distinguishable  by  color  (orange  =  Baylor  
College,  purple  =  Washington  University).  None  of  the  significant  associations  proved  to  be  
substantially  robust  from  any  of  the  nine  oral  body  sites  to  gut  microbes.  
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Supplemental  Figure  3.6:  Repeatability  of  network  inference  using  seven  individual  
similarity/dissimilarity  measures  with  the  Houston  data  subset.  The  2,000  most  extreme  (1,000  
top-­‐‑  and  bottom-­‐‑scoring)  edges  were  computed  for  each  measure  in  the  Houston  sample  subset.  
Measure  similarity  was  then  computed  as  the  Jaccard  index  of  edge  overlap.  Abbreviations:  
KLD  =  Kullback-­‐‑Leibler  dissimilarity,  Var-­‐‑Log  =  variance  of  log-­‐‑ratios,  a  measure  recommended  
by  Aitchison  to  compute  associations  between  parts  of  compositions  [1].  
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Supplemental  Figure  3.7:  Agreement  between  association  networks  produced  by  individual  
similarity  measures  and  datasets.  Heat  map  depicting  the  edge  overlap  as  measured  by  the  
Jaccard  index  between  the  different  methods  and  sample  sets  (Houston  versus  St.  Louis)  
employed.  By  design  from  our  ensemble  of  scoring  measures,  which  were  chosen  to  capture  
different  types  of  microbial  co-­‐‑occurrences,  the  networks  are  first  grouped  by  measure  into  
correlations  (Pearson,  Spearman),  GBLMs,  and  dissimilarities  (KLD,  Bray-­‐‑Curtis).  Each  of  these  
clusters  then  differentiate  further  according  to  sample  set  (e.g.  Spearman  and  Pearson  in  
Houston  versus  Spearman  and  Pearson  in  St.  Louis).  
   228  
  
Supplemental  Figure  3.8:    Intersection  of  networks  generated  independently  for  the  Houston  
and  St.  Louis  clinical  center  sample  subsets.  Our  co-­‐‑occurrence/exclusion  network  built  on  the  
combination  of  p-­‐‑values  for  microbial  interaction  from  10  distinct  networks,  generated  by  five  
methods  in  each  of  two  sample  subsets  from  the  HMP'ʹs  Houston  and  St.  Louis  clinical  centers.  
We  examined  the  feasibility  of  treating  these  two  clinical  centers  as  replicates  rather  than  semi-­‐‑
independent  observations  by  performing  a  hard  intersection,  i.e.  applying  Simes  method  to  
each  set  of  five  methods  separately  and  retaining  only  the  edges  significant  in  both.  This  
intersection  retained  only  499  nodes  and  938  edges,  almost  all  of  which  (902,  96%)  were  
contained  in  the  complete  network.  This  represents  approximately  30%  of  the  edges  in  the  
complete  network,  with  the  remainder  made  up  of  significant  relationships  confidently  detected  
at  only  one  clinical  center.  As  the  two  clinical  centers  differed  systematically  in  minor  technical  
details  such  as  input  DNA  concentration  and  chimerism  during  16S  sequencing  [6],  treating  
these  as  non-­‐‑independent  but  non-­‐‑replicate  observations  likely  represents  a  more  complete  
model  of  the  HMP  data'ʹs  microbial  co-­‐‑occurrence  and  exclusion  networks.    
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Supplemental  Figure  3.9:  Co-­‐‑occurrence  and  exclusion  relationships  within  each  body  site,  
within  body  areas,  and  between  body  areas.  Sub-­‐‑networks  consisting  of  (A)  1,409  edges  
among  clades  within  one  body  site,  (B)  1,552  edges  spanning  body  sites  within  the  same  area  
(such  as  the  oral  cavity  or  vagina),  and  (C)  44  interactions  between  distinct  body  areas.  
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Appendix  4A:  Supplemental  Materials  for  Chapter  4  
	   	   LGRC	   Bhattacharya	   Steiling	  
COPD	  
Male	   93	   9	   52	  
Female	   71	   5	   35	  
Control	  
Male	   26	   5	   83	  
Female	   39	   12	   68	  
Tissue	  type	   Whole	  lung	   Whole	  lung	   Bronchial	  brushings	  
Gene	  expression	  platform	  
Agilent	  Whole	  Human	  




Gene	  1.0	  ST	  
Total	  no.	  of	  probes	   19,596	   54,675	   19,793	  
No.	  genes	  (probes)	  mappable	  
to	  SDCD	  genes	  
959	  (959)	   942	  (1,867)	   944	  (948)	  
No.	  genes	  (probes)	  validated	   -­‐	   264	  (321)	   225	  (226)	  
Table  SM4.1:  Validation  of  SDCD  genes  by  independent  datasets  
Validation  of  SDCD  genes  in  independent  datasets  
One  of  the  challenges  of  gene  expression  signatures  is  the  inability  to  replicate  in  
independent  datasets.  To  assess  replicabiltiy  of  SDCD  genes,  we  used  independent  gene  
expression  datasets  from  Bhattacharya  [1]  and  Steiling  [2].    Key  characteristics  of  the  datasets  
are  summarized  in  Table  SM4.1.  
The  dataset  from  Bhattacharya  et  al.  includes  31  whole  lung  samples  collected  from  
subjects  who  underwent  lobectomy  for  removal  of  a  suspected  tumor—very  similar  to  the  
LGRC  tissue  protocol.    As  before,  we  defined  COPD  cases  as  those  with  FEV1  <  70%  and  
FEV1/FVC  <  0.7  and  controls  as  those  with  FEV1  >  80%  and  FEV1/FVC  >  0.7;  this  results  in  14  
COPD  and  17  control  samples.    We  then  identified  sexually  dimorphic  and  differentially  
expressed  genes  (see  Methods);  however,  due  to  the  limited  smoking  exposure  information  in  
the  public  version  of  the  dataset  (all  subjects  were  ex-­‐‑smokers),  the  models  were  only  adjusted  
for  age.    Because  of  a  difference  in  the  gene  expression  platform,  we  used  Ensembl  gene  
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identifiers  to  map  Bhattacharya’s  expression  probes  to  the  SDCD  genes.    A  total  of  1,867  probes  
were  mapped  successfully,  corresponding  to  942  SDCD  genes.    Encouragingly,  264  (28%)  of  the  
SDCD  genes  included  in  the  Bhattacharya  dataset  meet  our  criteria  for  being  both  sexually  
dimorphic  and  differentially  expressed.    
The  dataset  from  Steiling  et  al.  contains  expression  profiles  from  bronchial  brushings  
obtained  from  current  and  former  smokers  with  (n=87)  and  without  (n=151)  COPD.    We  
similarly  mapped  probes  from  the  dataset  to  SDCD  genes  through  Ensembl  gene  identifiers  and  
were  able  to  map  948  probes,  which  correspond  to  944  SDCD  genes.    In  this  bronchial  epithelial  
brushing  dataset,  our  models  identified  225  (23%)  of  the  included  SDCD  genes.    
Description  of  databases  of  hormone  regulation  
Regulation  by  hormones,  especially  sex  hormones,  may  explain  sexually  dimorphic  
expression  patterns  of  SDCD  genes.    A  number  of  databases  for  hormone  regulation  exist.    The  
mouse  and  human  estrogen  response  element  database  (ERE  DB)  [3]  is  a  collection  of  high-­‐‑
affinity  putative  binding  sites  from  a  computational  motif  scan  of  the  human  and  mouse  
genomes.    The  androgen  responsive  gene  database  (ARGDB)  [4]  is  a  manually  curated  list  of  
human,  mouse,  and  rat  genes  with  experimental  evidence  for  regulation  by  androgen.    A  
database  of  regulatory  motifs  such  as  JASPAR  can  also  be  used  to  scan  for  potential  binding  
sites  within  a  fixed  window  around  transcription  start  sites  (TSS’s).    While  JASPAR  motif  scan  is  
unbiased  by  tissue  type  or  cell  state,  it  is  prone  to  false  positives  and  sensitive  to  the  choice  of  
window  size  and  motif  binding  strength  threshold.    Here  we  chose  a  conservative  window  size  
of  1kb  (750bp  upstream,  250bp  downstream  of  TSS’s)  and  a  stringent  p-­‐‑value  cutoff  of  1.0e-­‐‑5.      
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Enrichment  of  nuclear  receptor  targets  from  Cistrome  database  
Cistrome  (cistrome.org/NR_Cistrome/Targets.html)  is  a  large  collection  of  predicted  
hormone  response  genes  based  on  an  integration  of  ChIP-­‐‑seq  experiments  and  gene  expression  
profile.    In  addition  to  estrogen  receptor  (ESR1/2)  [5,6]  and  androgen  receptor  (AR)  [7,8]  targets,  
it  contains  regulatory  targets  for  progesterone  receptor  (PGR)  [9],  another  important  female  sex  
hormone,  vitamin  D  receptor  (VDR)  [10],  and  peroxisome  proliferator-­‐‑activated  receptor  
gamma  (PPARG)  [11].  Each  of  the  nuclear  receptors  in  the  database  has  a  number  of  regulatory  
target  lists,  each  corresponding  to  an  experimental  condition.    For  example  there  are  three  target  
lists  for  ESR1,  corresponding  to  treatments  of  MCF7  cell  line  with  estradiol  (E2)  for  4  and  24  
hours  (Table  SM4.2).    All  of  the  target  lists  correspond  to  up-­‐‑regulation  of  target  genes,  except  
for  one  list  which  corresponds  to  down-­‐‑regulation  by  ESR1.    Enrichment  analysis  proceeded  by  
Fisher’s  exact  test,  which  assess  significance  of  the  overlap  between  genes  targeted  by  hormone  
receptors  and  SDCD  genes.    Here,  hormone  receptor  targets  were  defined  by  threshold  on  
Cistrome’s  rank-­‐‑product  value  (RP-­‐‑value).    Currently  there  is  no  standard  on  an  appropriate  
cutoff  for  RP-­‐‑values.    However,  because  the  RP-­‐‑values  correspond  roughly  to  adjusted  p-­‐‑
values,  0.25  is  a  possible  cutoff.    In  fact,  we  found  that  the  0.25  RP-­‐‑value  threshold  is  
conservative  as  it  yields  slightly  fewer  than  expected  total  number  of  genes  targeted  by  estrogen  
receptors  (observed  300-­‐‑400  vs.  expected  500-­‐‑1000  genes;  personal  communication  with  Dr.  
Shirley  Liu;  Table  SM4.2A).    This  conservative  definition  of  Cistrome  targets  drives  the  p-­‐‑values  
toward  the  null  (i.e.  less  significant),  thus  increasing  our  belief  in  the  enrichment  results.  
  










p-­‐value	   Cell	  type	   Condition	  
Estrogen	  (ESR1)	   21	   278	   0.2197	   MCF7	   E2,	  4hr	  
Estrogen	  (ESR1)	   19	   282	   0.4062	   MCF7	   E2,	  24hr	  
Estrogen	  (ESR1)	   25	   309	   0.1226	   MCF7	   E2,	  24hr,	  down	  regulation	  
Estrogen	  (ESR2)	   39	   431	   0.0188	   U20S	   E2,	  16hr	  
Androgen	  (AR)	   17	   241	   0.3307	   abl	   DHT,	  4hr	  
Androgen	  (AR)	   16	   210	   0.2270	   abl	   DHT,	  16hr	  
Androgen	  (AR)	   11	   255	   0.9196	   abl	   siAR	  
Androgen	  (AR)	   19	   262	   0.0240	   LnCaP	   DHT,	  4-­‐6hr	  
Androgen	  (AR)	   27	   188	   0.0082	   LnCaP	   DHT,	  16hr	  
Androgen	  (AR)	   11	   287	   0.9706	   LnCaP	   siAR	  
Androgen	  (AR)	   18	   237	   0.2233	   LnCaP	   R1881,	  18hr	  
Androgen	  (AR)	   30	   375	   0.1172	   LnCaP	   R1881,	  48hr	  
Progesterone	  (PGR)	   18	   362	   0.5945	   MCF7	   P4,	  3hr	  
Progesterone	  (PGR)	   40	   297	   0.0005	   MCF7	   P4,	  24hr	  
PPAR-­‐gamma	   32	   371	   0.0506	   Adipocyte	   siPPARG	  
PPAR-­‐gamma	   37	   416	   0.0268	   Adipocyte	   Mature	  vs	  premature	  
Vitamin	  D	  (VDR)	   42	   546	   0.1322	   GM10855	   Calcitriol,	  36hr	  
Vitamin	  D	  (VDR)	   42	   460	   0.0136	   GM10861	   Calcitriol,	  36hr	  
  
B.  Other  databases  of  hormone  responsive  elements  
Nuclear	  Receptor	  
SDCD	  






p-­‐value	   Database	   Experiment	  
Estrogen	  (ESR1/2)	   217	   2980	   0.0470	   ERE	  DB	  [3]	   Motif	  scan	  
Estrogen	  (ESR1)	   20	   295	   0.3956	   JASPAR	  [12]	   Motif	  scan	  
Estrogen	  (ESR2)	   14	   209	   0.4100	   JASPAR	  [12]	   Motif	  scan	  
Androgen	  (AR)	   103	   1344	   0.0485	   ARGDB	  [4]	   PubMed	  manual	  curation	  
Androgen	  (AR)	   21	   206	   0.0178	   JASPAR	  [12]	   Motif	  scan	  
  
Table  SM4.2:  List  of  nuclear  receptor  regulatory  targets  and  their  enrichment  for  SDCD  
genes.  
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Sensitivity  Analysis  
Excluding  clinical  anomalies    
One  of  the  fundamental  requirements  of  a  case-­‐‑control  analysis  is  the  reliability  of  subjects’  
clinical  classification.    Heretofore  in  this  study  we  have  made  an  effort  to  adjudicate  based  on  
the  validity  of  the  clinical  diagnosis  of  the  LGRC  cohort,  excluding  samples  with  questionable  
phenotypes  from  the  analysis.    Even  so,  we  acknowledge  that  the  remaining  samples  still  have  
attributes  with  the  potential  to  affect  the  results  of  our  analysis.  For  example,  in  the  LGRC,  a  
subset  of  the  subjects  have  clinical  phenotypes  considered  atypical  of  COPD  or  control  patients,  
namely  the  controls  with  unusually  low  diffusion  capacity  (DLCO)  and  subjects  with  no  
reported  history  of  smoking  (see  Table  1).    To  assess  the  robustness  of  our  analyses,  we  
performed  sensitivity  analyses,  rerunning  our  models  (Equations  1-­‐‑4)  excluding  samples  from  
subjects  that  may  be  misclassified,  thus  assessing  the  robustness  of  the  SDCD  genes  and  their  
functional  enrichments.  
There  are  26  control  samples  with  DLCO  <  80,  24  of  which  had  gene  expression  profiles  and  
were  included  in  the  original  SDCD  analysis.    Without  the  24  control  samples  with  low  DLCO,  
the  analysis  yielded  776  genes  with  sexually  dimorphic  differential  expression,  of  which  521  
were  in  the  original  SDCD  gene  set  (overlap  Fisher’s  exact  p  =  5.58x10-­‐‑121).    Functional  
enrichment  analysis  of  these  776  genes  recapitulated  similar  themes  in  the  original  SDCD  
analysis  such  as  cell  chemotaxis  (GO:0050920,  p=0.003),  inflammatory  response  (GO:0050729,  
p=0.048),  and  ATP  metabolic  process  (GO:0006200,  p=0.006),  but  also  highlighted  new  concepts  
such  as  DNA  damage  response  (GO:0006977,  p=0.004)  and  checkpoint  (GO:0031571,  p=0.003).    	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About  15%  (N=37)  of  subjects  self-­‐‑reported  never  having  smoked  cigarettes,  32  of  which  had  
gene  expression  profiles  and  were  included  in  the  original  SDCD  analysis.  Because  cigarette  
smoking  is  an  important  risk  factor  of  COPD,  inclusion  of  never-­‐‑smokers  may  obscure  the  effect  
of  cigarette  smoking.  Thus  we  repeated  the  SDCD  expression  analysis  without  these  never-­‐‑
smokers  and  identified  2,277  SDCD  genes,  of  which  790  are  in  the  original  SDCD  gene  set  
(overlap  Fisher’s  exact  p  <  1x10-­‐‑120).    Despite  a  much  higher  number  of  identified  genes,  
functional  enrichment  results  again  reiterate  a  similar  set  of  key  biological  processes,  such  as  
cell  locomotion  (GO:0040013,  p=0.007),  immune  response  (GO:0045824,  p=0.018),  and  
inflammatory  response  (GO:0002536,  p=0.016).  Interestingly  this  analysis  again  also  highlighted  
DNA  damage  response  (GO:0006977,  p=1.95x10-­‐‑5)  and  cell  cycle  checkpoints  (GO:0031571,  
p=1.24x10-­‐‑4),  similar  to  the  results  when  excluding  the  samples  with  DLCO<80  (see  
Supplementary  Table  S7).  
Modifying  parameter  choices  
In  classifying  the  SDCD  genes  we  used  an  FDR  cutoff  of  0.25  in  each  stratified  analysis.  
We  assessed  the  appropriateness  of  this  cutoff  by  repeating  the  analysis  for  several  various  
cutoff  values.  At  each  cutoff  we  determined  the  significance  of  the  overlap  between  the  COPD-­‐‑  
and  sex-­‐‑stratified  analyses  by  Fisher’s  exact  test.    As  shown  in  Figure  SM4.1,  the  significance  of  
the  overlap  optimizes  when  the  FDR  cutoff  is  between  0.1  and  0.25  (p-­‐‑value  <  1x10-­‐‑300)  and  
quickly  reduces  beyond  cutoffs  greater  than  0.3.    Thus,  the  results  support  the  use  of  0.25  as  the  
FDR  cutoff.  
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We  next  used  functional  enrichment  results  to  evaluate  the  FDR  cutoff  choice.    For  an  
FDR  cutoff  of  0.05  (135  genes  identified)  we  found  enrichment  for  similar  functional  classes  as  
the  original  SDCD  gene  set;  for  instance  cell-­‐‑cell  signaling  (GO:0007267,  p=0.008),  hormone  
secretion  (GO:0046888,  p=0.004),  and  response  to  wounding  (GO:0009611,  p=0.025);  however,  
these  genes  are  not  enriched  for  several  key  COPD  processes  previously  found  to  be  significant  
such  as  immune  response  and  inflammatory  response  (see  Supplementary  Table  S7E).    This  
suggested  a  more  liberal  cutoff  is  beneficial  for  exploring  the  functional  impact  of  sexually  
dimorphic  gene  expression  in  COPD.  
Finally,  as  seen  in  Figure  1B  and  Supplementary  Figure  S2  many  of  the  SDCD  genes  
have  relatively  small  effect  size  as  measured  by  Δα  and  Δβ,  albeit  statistically  significant.  Since  
genes  with  a  small  effect  size  may  not  be  clinically  relevant,  we  selected  291  SDCD  genes  in  the  
top  and  bottom  5%  of  ΔβCOPD-­‐‑control  (Δβ  >  0.049  or  Δβ  <  -­‐‑0.053)  and  of  Δαmale-­‐‑female  (Δα  >  0.055  and  
Δα  <  -­‐‑0.058)  and  performed  functional  enrichment  analysis.  Consistent  with  the  analysis  using  
all  SDCD  genes,  the  results  included  cell-­‐‑cell  signaling  (GO:0007267,  p=3.58x10-­‐‑5),  regulation  of  
chemotaxis  (GO:0050920,  p=2.16x10-­‐‑4),  negative  regulation  of  hormone  secretion  (GO:0046888,  
p=0.003),  and  inflammatory  response  (GO:0006954,  p=0.004)  (see  Supplementary  Table  S7F).    
This  consistency  suggests  that  the  full  set  of  SDCD  genes  is  at  least  as  functionally  relevant  as  
the  genes  with  the  largest  effect  sizes.    The  number  of  SDCD  genes  identified  in  each  sensitivity  
analysis  is  given  in  Table  SM4.3,  and  the  lists  of  genes  and  their  functional  enrichment  can  be  
found  in  Supplementary  Table  S7.  
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Figure  SM4.1:  The  effect  of  changing  FDR  cutoff  on  the  number  of  SDCD  genes  and  the  
significance  of  the  overlap  between  COPD-­‐‑  and  sex-­‐‑stratified  analyses.  Vertical  dotted  lines  
are  at  FDR  =  0.25.  (A)  As  expected,  the  number  of  SDCD  genes  increases  as  we  relax  the  FDR  
cutoff.  (B)  The  increase,  when  plot  on  the  log  scale,  has  an  inflection  point  at  around  the  cutoff  
of  0.25.  (C)  The  significance  of  the  overlap  between  the  two  stratified  analyses  peaks  at  cutoff  









































































































● ● ● ● ● ● ● ● ●


























   239  
Sensitivity	  Analysis	  
No.	  of	  subjects	  	  
(M-­‐COPD/M-­‐Ctrl/	  
F-­‐COPD/F-­‐Ctrl)	  
SDCD	  genes	  	  
identified	  	  
in	  this	  analysis	  
No.	  overlap	  with	  	  
the	  SDCD	  genes	  (%)	  
Original	  SDCD	  analysis	   93/26/71/39	   959	   –	  
Without	  low	  DLCO	  controls	   93/14/71/27	   776	   521	  (54.33)	  
Without	  nonsmokers	   90/19/68/20	   2277	   790	  (82.37)	  
FDR	  cutoff	  of	  0.05	   –	   135	   135	  (14.08)	  
Top	  &	  bottom	  5%	  of	  Δβ	  and	  Δα	   –	   291	   291	  (30.34)	  
  
Table  SM4.3:  Number  of  SDCD  genes  identified  by  various  sensitivity  analyses  
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Appendix  4B:  Supplemental  Figures  and  Tables  for  Chapter  4  
  
Figure  S4.1:  A  summary  of  data  processing  for  three  main  data  types  in  the  LGRC.  Each  data  
type  was  initially  processed  by  LGRC  research  sites  and  further  refined  in  our  study.  
Methylation  and  genotype  data  were  generated  by  University  of  Colorado  at  Denver  while  gene  
expression  profiling  was  performed  at  University  of  Pittsburgh  Medical  Center  and  processed  
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Figure  S4.2:  Volcano  plot  shows  the  p-­‐‑values  and  differences  of  regression  coefficients  from  
the  COPD-­‐‑stratified  SDCD  analysis.  The  purple  dots  are  the  SDCD  genes.  The  vertical  red  
lines  represent  the  5th  and  95th  percentiles.  The  genes  with  large  sexual  dimorphic  effects,  as  
measured  by  the  coefficient  differences,  include  MMP3,  EDN3,  CXCL13,  TIMP4,  and  CNTN2.  
TIMP4  and  CNTN2  also  have  large  sexual  dimorphic  effect  as  measured  in  the  sex-­‐‑stratified  
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(continued)  
Figure  S4.3:  mRNA  expression  profile  of  selected  SDCD  genes  stratified  by  sex  and  COPD  
status.  (A)  CNTN2,  along  with  TIMP4,  appear  in  the  top  corner  of  the  volcano  plot  in  Figure  
4.1B,  representing  low  p-­‐‑values  and  large  effect  sizes.  (B)  MMP3  shows  the  largest  effect  size  in  
the  COPD-­‐‑stratified  analysis.  (C)  PAQR3  and  (D)  CXCL10  are  among  the  SDCD  genes  that  are  
sexually  dimorphic  in  COPD  but  not  in  control  samples.  (E-­‐‑F)  In  addition  to  MMP3,  two  
members  of  matrix  metalloproteinase  family,  MMP15  and  MMP28,  also  exhibit  sexually  
dimorphic  and  differential  expression.  
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Figure  S4.4:  Network  clustering  analysis  of  SDCD  gene-­‐‑enriched  biological  processes.  GLay  
community  analysis  of  GO  terms  (Figure  4.2A)  reveals  distinct  and  coherent  clusters  of  
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(continued)  
Figure  S4.5:  Boxplots  showing  percent  methylation  of  VMRs  proximal  to  SDCD  genes.  
Stratified  by  sex  and  COPD  status,  these  exemplify  general  patterns  of  sexual  dimorphic  
methylation.  Male  control  samples  appear  to  have  consistently  higher  level  of  methylation  
while  the  level  of  methylation  in  COPD  and  control  female  are  largely  similar.  These  genes  
included  here  are  involved  in  actin  cytoskeletal  signaling  pathway.  
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(continued)  
Figure  S4.6:  Actin  cytoskeleton  signaling  and  integrin  signaling  pathways  represented  by  
IPA.  Node  colors  represent  the  regression  coefficients:  (A,C)  male  (αmale  )  and  (B,D)  female  
(αfemale)  (green=negative,  red=positive).  The  genes  marked  by  orange  edges  are  SDCD  genes.  Full  
legend  can  be  found  in  Figure  4.4.  (A-­‐‑B)  While  most  molecules  are  similarly  expressed  between  
male  and  female,  key  growth  factors  and  signaling  molecules  appear  to  be  SDCD  genes.  Similar  
to  VEGF-­‐‑signaling  pathway,  actin,  alpha  acting,  paxillin,  and  myosin  activate  downstream  key  
events  such  as  focal  adhesion.  (C-­‐‑D)  In  integrin  signaling  pathway,  the  actin-­‐‑alpha  actin-­‐‑
vinculin-­‐‑paxillin  complex  (top  left)  corresponds  to  the  signaling  complex  of  VEGF-­‐‑activated  cell  
migration  pathway.  VEGF  and  integrin  signaling  pathways  may  form  a  signal  transduction  
cascade  potentially  impacting  sex-­‐‑specific  features  of  cytoskeletal  rearrangements  and  cell  
motility.    
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Supplemental  Tables  
These  files  are  available  at  http://www.filedropper.com/chapter4suptables  and  as  
supplemental  files  to  this  dissertation.  
Table  S4.1:  Number  of  LGRC  samples  with  various  genomic  assays.  [DOCX]  
Table  S4.2:  The  SDCD  Genes.  (A)  A  list  of  959  SDCD  genes.  (B)  Subset  of  150  SDCD  genes  that  
are  sexually  dimorphic  in  COPD  but  not  in  controls  and  (C)  their  functional  enrichment  from  
DAVID  (david.abcc.ncifcrf.gov).  [XLSX]  
Table  S4.3:  Top  SDCD  genes  that  are  related  to  COPD.  [DOCX]  
Table  S4.4:  Replication  of  SDCD  genes  by  independent  datasets.  SDCD  genes  replicated  in  
(A)  Bhattacharya  et  al.  dataset  and  (B)  Steiling  et  al.  dataset.  [XLSX]  
Table  S4.5:  Functional  enrichment  analyses  of  SDCD  genes.  (A)  Functional  enrichment  of  
SDCD  genes  based  on  Gene  Ontology.  (B-­‐‑C)  Results  from  gene  set  enrichment  analysis  (GSEA)  
using  a  list  of  all  genes  ranked  by  (B)  Δβ  COPD-­‐‑control  and  (C)  adjusted  pCOPD-­‐‑control.  Only  results  with  
p  <  0.1  are  listed.  (D)  Functional  enrichment  analysis  using  DAVID  (david.abcc.ncifcrf.gov).  (E)  
Canonical  pathway  enrichment  results  from  Ingenuity  Pathway  Analysis  (IPA,  Ingenuity  
Systems,  www.ingenuity.com).  [XLSX]  
Table  S4.6:  Regulatory  mechanisms  of  SDCD  genes.  (A)  A  list  of  variably  methylated  regions  
(VMRs)  with  evidence  for  sexually  dimorphic  differential  methylation.  For  each  SDCD  VMR,  a  
list  of  near  by  genes  within  10kb  is  given,  along  with  the  key  statistics  from  the  analysis.  (B)  
Functional  enrichment  analysis  of  the  genes  associated  with  the  sexually  dimorphic  VMRs.  (C)  
A  list  of  sexually  dimorphic  eQTL  with  the  key  statistics  from  the  male-­‐‑only  and  female-­‐‑only  
eQTL  analyses.  [XLSX]  
Table  S4.7:  Sexually  dimorphic  differential  expressed  genes  identified  in  sensitivity  analysis  
and  their  functional  enrichment.  (A)  Genes  and  (B)  their  functional  enrichment  from  the  
analysis  without  controls  with  low  diffusion  capacity  (DLCO  <  80)  (C)  Genes  and  (D)  their  
functional  enrichment  from  the  analysis  without  samples  who  self-­‐‑reported  never  having  
smoked  cigarettes.  (E)  Functional  enrichment  of  SDCD  genes  identified  by  FDR  cutoff  of  0.05.  
(F)  Functional  enrichment  of  SDCD  genes  with  effect  sizes  in  the  top  and  bottom  5%  of  Δαmale-­‐‑
female  and  ΔβCOPD-­‐‑control  (i.e.  outside  of  the  90%  confidence  interval).  [XLSX]  
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Appendix  5:  Supplemental  Figures  and  Tables  for  Chapter  5  
  
Figure  S5.1:  Overview  of  the  simulation  study.  For  each  iteration  of  the  simulation,  we  draw  
from  a  correlated  binomial  distribution  to  generate  genotypes.  Pairs  of  SNP  and  genes  were  
selected  to  be  “true”  eQTL.    Then  based  on  the  eQTL  and  genotypes,  mean  and  standard  
deviation  of  expression  for  each  gene  is  calculated.  We  use  a  multivariate  normal  distribution  to  
simulate  gene  expression  data.  Then,  eQTL  analysis  and  multiple  testing  adjustment  are  
performed,  and  eQTL  are  called  using  the  significance  level  of  0.05.  Comparing  the  called  eQTL  
and  the  simulated  eQTL  yields  specificity  and  sensitivity.  
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   252  
Selecting  number  of  co-­‐‑expression  clusters    
  
Figure  S5.2:  Height  distances  between  subsequent  cluster  joining  events  from  hierarchical  
clustering  of  LGRC  gene  expression  data.  Hierarchical  clustering  was  performed  with  1-­‐‑
|cor(X,Y)|  as  distance.  The  dendrogram  was  cut  using  the  peak  distance  (marked  in  red)  so  as  
to  maximize  the  distance  between  clusters.  This  corresponds  to  dendrogram  tree  height  of  0.4,  
which  is  used  to  define  clusters.  
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A.                  B.  
  
C.  
Figure  S5.3:  Cluster  size  distribution.  (A)  LD  blocks  range  in  size  from  one  to  several  hundred  
SNPs.  (B)  A  truncated  histogram  of  LD  block  sizes  (1  <  NSNPS  <  50).  (C)  Size  distribution  of  the  
co-­‐‑expression  clusters  identified  by  hierarchical  clustering.  
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SNP	   Gene	   eQTL	  
SNP	   Chr	   Position	   Gene	   Chr	   TSS	   Unadjusted	  P-­‐value	  
BBER-­‐adjusted	  
FDR	   Cis	  
rs2532316	   17	   44213712	   MAPK8IP1	   11	   45907202	   1.67E-­‐47	   3.58E-­‐39	   NO	  
rs2469933	   17	   44285531	   MAPK8IP1	   11	   45907202	   8.76E-­‐50	   3.54E-­‐41	   NO	  
rs2732651	   17	   44345063	   MAPK8IP1	   11	   45907202	   2.80E-­‐49	   1.13E-­‐40	   NO	  
rs17650901	   17	   44039691	   MAPK8IP1	   11	   45907202	   3.16E-­‐42	   3.33E-­‐38	   NO	  
kgp8197546	   17	   44041562	   MAPK8IP1	   11	   45907202	   7.77E-­‐42	   2.00E-­‐36	   NO	  
rs2532274	   17	   44247164	   MAPK8IP1	   11	   45907202	   3.26E-­‐46	   3.20E-­‐43	   NO	  
rs2395943	   6	   42940673	   PEX6	   6	   42946958	   4.49E-­‐44	   3.81E-­‐36	   YES	  
rs11982736	   7	   55855180	   PSPH	   7	   56119297	   5.44E-­‐49	   3.03E-­‐41	   YES	  
kgp6231899	   16	   24845143	   SLC5A11	   16	   24857162	   2.30E-­‐45	   1.06E-­‐36	   YES	  
kgp11777277	   16	   24856775	   SLC5A11	   16	   24857162	   4.72E-­‐45	   2.18E-­‐36	   YES	  
rs2550309	   16	   56434742	   AMFR	   16	   56459450	   4.88E-­‐45	   3.15E-­‐36	   YES	  
kgp11544682	   16	   56436824	   AMFR	   16	   56459450	   1.83E-­‐45	   1.18E-­‐36	   YES	  
kgp8174079	   16	   56442734	   AMFR	   16	   56459450	   4.88E-­‐45	   3.15E-­‐36	   YES	  
rs1382359	   16	   56399514	   AMFR	   16	   56459450	   4.40E-­‐46	   2.37E-­‐37	   YES	  
kgp1284210	   16	   56442066	   AMFR	   16	   56459450	   1.83E-­‐45	   1.18E-­‐36	   YES	  
kgp6813453	   16	   56395610	   AMFR	   16	   56459450	   4.40E-­‐46	   4.74E-­‐37	   YES	  
kgp2821240	   16	   56462000	   AMFR	   16	   56459450	   4.88E-­‐45	   4.77E-­‐37	   YES	  
rs4924	   16	   56396486	   AMFR	   16	   56459450	   2.30E-­‐46	   2.47E-­‐37	   YES	  
rs1478478	   16	   56402531	   AMFR	   16	   56459450	   4.88E-­‐45	   2.62E-­‐36	   YES	  
rs4251689	   8	   145741130	   LRRC14	   8	   145743376	   1.49E-­‐45	   1.20E-­‐36	   YES	  
kgp2553412	   8	   145764360	   LRRC14	   8	   145743376	   1.79E-­‐43	   6.58E-­‐37	   YES	  
rs3816732	   8	   145724275	   LRRC14	   8	   145743376	   6.59E-­‐46	   5.32E-­‐37	   YES	  
rs9071	   8	   145750506	   LRRC14	   8	   145743376	   1.61E-­‐50	   5.20E-­‐41	   YES	  
rs11601413	   11	   18421683	   LDHC	   11	   18433854	   1.99E-­‐49	   1.47E-­‐42	   YES	  
kgp3928819	   11	   18439927	   LDHC	   11	   18433854	   1.83E-­‐53	   2.96E-­‐44	   YES	  
kgp6997008	   11	   18431265	   LDHC	   11	   18433854	   2.34E-­‐48	   3.79E-­‐39	   YES	  
rs3135006	   6	   32667119	   HLA-­‐DQB1	   6	   32636160	   1.89E-­‐39	   1.85E-­‐36	   YES	  
kgp10470881	   19	   9264401	   OR7D2	   19	   9296279	   2.05E-­‐83	   1.10E-­‐80	   YES	  
kgp10544853	   19	   9250984	   OR7D2	   19	   9296279	   6.79E-­‐83	   3.91E-­‐80	   YES	  
Table  S5.1:  Top  30  eQTL  ranked  by  BBER-­‐‑adjusted  FDRs.  *  “kgp”  identifiers  designates  SNPs  
from  1000  Genome  Projects  pilot  
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MarkerName	   P.value	   PMID	   disease	  
rs10134365	   2.50E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs10769813	   8.54E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs1080879	   7.69E-­‐07	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs10861369	   9.39E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs10926189	   9.95E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs10942957	   3.15E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs10989511	   7.27E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs11210569	   4.40E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs11219732	   4.47E-­‐06	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs11588172	   9.02E-­‐06	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs11603831	   2.83E-­‐06	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs11673894	   9.71E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs11719713	   7.22E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs12193019	   2.27E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs12421122	   3.52E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs12495172	   2.79E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs12576370	   7.59E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs12577504	   8.16E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs12662524	   8.11E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs12681897	   4.84E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs12762979	   4.59E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs12772513	   6.08E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs12796185	   1.79E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs13061634	   2.76E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs1402769	   4.46E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs1432534	   8.75E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs1551133	   2.38E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs1575208	   1.46E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs158990	   5.04E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs1622472	   6.71E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs163574	   6.77E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs16903825	   2.35E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs16943236	   7.68E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs16980016	   7.95E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs17099345	   6.93E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs17161994	   9.46E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs17310770	   6.65E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs1738899	   6.09E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs1828591	   1.00E-­‐07	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs1996020	   4.86E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs200303	   7.96E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs2080798	   1.63E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	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rs2080799	   6.74E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs215864	   3.30E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs2248540	   6.99E-­‐06	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs2253023	   2.46E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs2269640	   7.54E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs239349	   3.09E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs25796	   6.43E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs2589183	   4.50E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs26566	   7.81E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs2898879	   1.35E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs2912263	   3.59E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs2963162	   1.54E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs30539	   3.38E-­‐06	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs312495	   7.60E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs32447	   6.46E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs32466	   8.31E-­‐07	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs3767943	   9.18E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs3847554	   9.03E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs3901366	   1.21E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs4148777	   9.07E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs4432437	   4.22E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs4588237	   7.66E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs4712564	   8.79E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs4739642	   6.99E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs4754595	   4.90E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs4842213	   3.77E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs4951563	   1.73E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs4974153	   9.55E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs6100861	   7.16E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs6426962	   1.94E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs6542127	   9.25E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs6706895	   7.90E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs6720264	   6.69E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs6790122	   2.93E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs6823107	   3.62E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs6852830	   6.66E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs6944889	   7.21E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs6973373	   3.32E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs7105963	   9.90E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs7233241	   7.76E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs729319	   3.36E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs732285	   4.86E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs7341022	   9.97E-­‐08	   19300482	   Chronic	  obstructive	  pulmonary	  disease	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rs735243	   2.02E-­‐07	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs7522756	   1.44E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs7524799	   6.74E-­‐06	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs7529406	   6.13E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs7727670	   8.38E-­‐08	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs7775523	   5.12E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs7988287	   4.69E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs8009673	   9.54E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs8022070	   8.10E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs8034191	   1.00E-­‐10	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs9350301	   8.93E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs935381	   7.47E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs9482826	   5.44E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs9686327	   9.84E-­‐08	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs9788469	   1.43E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs9862661	   1.57E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs9978132	   7.22E-­‐05	   19300482	   Chronic	  obstructive	  pulmonary	  disease	  
rs1051730	   2.14E-­‐05	   20173748	   Chronic	  obstructive	  pulmonary	  disease	  
rs1062980	   3.42E-­‐05	   20173748	   Chronic	  obstructive	  pulmonary	  disease	  
rs13118928	   9.30E-­‐08	   20173748	   Chronic	  obstructive	  pulmonary	  disease	  
rs13180	   2.00E-­‐08	   20173748	   Chronic	  obstructive	  pulmonary	  disease	  
rs1903003	   7.74E-­‐08	   20173748	   Chronic	  obstructive	  pulmonary	  disease	  
rs2869967	   1.80E-­‐07	   20173748	   Chronic	  obstructive	  pulmonary	  disease	  
rs7671167	   1.00E-­‐11	   20173748	   Chronic	  obstructive	  pulmonary	  disease	  
rs10065677	   7.60E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs1012036	   5.00E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs10844154	   4.80E-­‐08	   20709820	   Emphysema-­‐related	  traits	  
rs10900114	   8.40E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs1348350	   3.10E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs161981	   6.10E-­‐07	   20709820	   Emphysema-­‐related	  traits	  
rs2129590	   4.80E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs2448276	   5.20E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs261869	   8.10E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs2999399	   6.00E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs326633	   1.10E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs341672	   8.50E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs4905179	   9.80E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs641525	   5.00E-­‐07	   20709820	   Emphysema-­‐related	  traits	  
rs7905537	   8.00E-­‐07	   20709820	   Emphysema-­‐related	  traits	  
rs7911712	   3.80E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs7977375	   4.00E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs8016091	   4.10E-­‐06	   20709820	   Emphysema-­‐related	  traits	  
rs9292394	   2.00E-­‐06	   20709820	   Emphysema-­‐related	  traits	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rs8050136	   4.00E-­‐08	   21037115	   Body	  mass	  in	  chronic	  obstructive	  pulmonary	  disease	  
rs10928927	   3.00E-­‐07	   21685187	   Chronic	  obstructive	  pulmonary	  disease	  
rs114216682	   7.00E-­‐08	   21685187	   Chronic	  obstructive	  pulmonary	  disease	  
rs117607728	   4.00E-­‐07	   21685187	   Chronic	  obstructive	  pulmonary	  disease	  
rs28675338	   1.00E-­‐07	   21685187	   Chronic	  obstructive	  pulmonary	  disease	  
rs55645543	   5.00E-­‐07	   21685187	   Chronic	  obstructive	  pulmonary	  disease	  
rs56238310	   1.00E-­‐07	   21685187	   Chronic	  obstructive	  pulmonary	  disease	  
rs73717741	   3.00E-­‐07	   21685187	   Chronic	  obstructive	  pulmonary	  disease	  
rs76351433	   2.00E-­‐07	   21685187	   Chronic	  obstructive	  pulmonary	  disease	  
rs76884941	   1.00E-­‐07	   21685187	   Chronic	  obstructive	  pulmonary	  disease	  
rs77155169	   2.00E-­‐07	   21685187	   Chronic	  obstructive	  pulmonary	  disease	  
rs9296092	   6.00E-­‐07	   21685187	   Chronic	  obstructive	  pulmonary	  disease	  
rs9394152	   7.00E-­‐08	   21685187	   Chronic	  obstructive	  pulmonary	  disease	  
rs11858836	   1.00E-­‐06	   22080838	   Chronic	  obstructive	  pulmonary	  disease	  
rs13141641	   3.00E-­‐07	   22080838	   Chronic	  obstructive	  pulmonary	  disease	  
rs1964516	   2.00E-­‐09	   22080838	   Chronic	  obstructive	  pulmonary	  disease	  
rs7937	   3.00E-­‐09	   22080838	   Chronic	  obstructive	  pulmonary	  disease	  
rs2074488	   2.00E-­‐10	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs2077224	   2.00E-­‐14	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs1923539	   5.00E-­‐09	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs9951925	   2.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs13181561	   6.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs954820	   4.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs6667220	   8.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs3751143	   4.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs12149070	   8.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs17832777	   6.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs7953249	   1.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs652520	   2.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs7078012	   5.00E-­‐09	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs3741240	   1.00E-­‐26	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs2463822	   1.00E-­‐10	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs17157266	   1.00E-­‐09	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs7929679	   7.00E-­‐09	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs8048576	   9.00E-­‐13	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs728616	   2.00E-­‐12	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs3851050	   1.00E-­‐11	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs12220777	   7.00E-­‐11	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs6585424	   1.00E-­‐10	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs9266629	   4.00E-­‐10	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs1265093	   6.00E-­‐09	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs3130559	   8.00E-­‐09	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs4508864	   6.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	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rs2823743	   1.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs1124480	   9.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs903614	   3.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs7006821	   5.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs10007052	   1.00E-­‐07	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs7147624	   5.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
rs4468361	   8.00E-­‐06	   23144326	   Chronic	  obstructive	  pulmonary	  disease-­‐related	  biomarkers	  
Table  S5.2:  List  of  COPD-­‐‑associated  SNPs  from  GWASdb  
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SNP	   Chr	   Position	   Gene	   Chr	   tss	   P-­‐value	   BBER-­‐adj	  FDR	   cis	  
kgp6093110	   1	   37958339	   ODF1	   8	   103563800	   4.30E-­‐08	   6.61E-­‐05	   No	  
rs7544462	   1	   37962756	   ODF1	   8	   103563800	   4.30E-­‐08	   6.61E-­‐05	   No	  
rs2579644	   2	   120219940	   PPFIA2	   12	   82153332	   2.03E-­‐06	   8.33E-­‐04	   No	  
rs9812727	   3	   55990726	   DMRTC2	   19	   42349086	   9.28E-­‐08	   3.99E-­‐05	   No	  
rs4622984	   4	   155452233	   SOSTDC1	   7	   16570205	   4.54E-­‐07	   1.87E-­‐04	   No	  
kgp4707314	   4	   145496941	   C12orf61	   12	   62997214	   2.34E-­‐06	   9.60E-­‐04	   No	  
kgp10989644	   5	   14990914	   CLDN15	   7	   100882101	   1.01E-­‐06	   4.13E-­‐04	   No	  
kgp10447643	   6	   31095942	   C1orf105	   1	   172389828	   1.54E-­‐06	   6.31E-­‐04	   No	  
rs3815087	   6	   31093587	   PSORS1C1	   6	   31082527	   9.29E-­‐17	   1.08E-­‐09	   Yes	  
rs9263699	   6	   31093699	   PSORS1C1	   6	   31082527	   1.30E-­‐16	   1.52E-­‐09	   Yes	  
rs3130557	   6	   31094703	   VARS2	   6	   30876019	   7.15E-­‐07	   2.94E-­‐04	   Yes	  
kgp6354565	   6	   31095210	   PSORS1C1	   6	   31082527	   1.70E-­‐15	   1.98E-­‐08	   Yes	  
rs9263715	   6	   31095801	   PSORS1C1	   6	   31082527	   9.29E-­‐17	   1.08E-­‐09	   Yes	  
kgp9957759	   6	   31096561	   PSORS1C1	   6	   31082527	   1.08E-­‐13	   1.26E-­‐06	   Yes	  
rs9263719	   6	   31096575	   PSORS1C1	   6	   31082527	   4.02E-­‐13	   4.69E-­‐06	   Yes	  
rs2074488	   6	   31240431	   POU5F1	   6	   31148508	   2.70E-­‐08	   1.27E-­‐05	   Yes	  
kgp6834213	   7	   3487754	   TMEM128	   4	   4249950	   2.92E-­‐07	   1.69E-­‐04	   No	  
rs1012036	   7	   52472450	   ATP6V0A1	   17	   40610862	   4.04E-­‐07	   1.66E-­‐04	   No	  
kgp141150	   8	   2734822	   CCDC70	   13	   52436117	   9.11E-­‐08	   4.89E-­‐05	   No	  
rs11987190	   8	   2738093	   CCDC70	   13	   52436117	   9.11E-­‐08	   4.89E-­‐05	   No	  
rs4948917	   10	   45339090	   TMEM63A	   1	   226070069	   3.55E-­‐07	   3.48E-­‐04	   No	  
rs4948917	   10	   45339090	   LPA	   6	   161087407	   1.79E-­‐07	   8.82E-­‐05	   No	  
rs4948917	   10	   45339090	   ZBTB5	   9	   37465396	   6.35E-­‐08	   3.13E-­‐05	   No	  
rs4948917	   10	   45339090	   C12orf29	   12	   88427623	   3.65E-­‐08	   1.80E-­‐05	   No	  
rs4948917	   10	   45339090	   GCSH	   16	   81130008	   1.15E-­‐07	   5.65E-­‐05	   No	  
rs1830888	   10	   45339904	   ATP5A1	   18	   43684300	   4.41E-­‐07	   3.25E-­‐04	   No	  
rs4948917	   10	   45339090	   ZNF333	   19	   14800613	   9.89E-­‐08	   4.87E-­‐05	   No	  
rs10769813	   11	   7642031	   CYB5R2	   11	   7698453	   7.87E-­‐11	   5.79E-­‐08	   Yes	  
kgp9157600	   14	   104808367	   KIAA0196	   8	   126104082	   1.66E-­‐06	   7.03E-­‐04	   No	  
kgp9157600	   14	   104808367	   OR7E24	   19	   9361606	   3.83E-­‐07	   2.05E-­‐04	   No	  
kgp11359642	   15	   78813334	   CHRNA5	   15	   78857862	   8.25E-­‐15	   1.12E-­‐07	   Yes	  
rs12906951	   15	   78825562	   CHRNA5	   15	   78857862	   6.28E-­‐18	   8.53E-­‐11	   Yes	  
rs12915366	   15	   78831753	   CHRNA5	   15	   78857862	   2.93E-­‐18	   3.98E-­‐11	   Yes	  
rs12916483	   15	   78832397	   CHRNA5	   15	   78857862	   6.28E-­‐18	   8.53E-­‐11	   Yes	  
rs3813571	   15	   78832792	   CHRNA5	   15	   78857862	   6.28E-­‐18	   8.53E-­‐11	   Yes	  
kgp8874223	   15	   78833612	   CHRNA5	   15	   78857862	   6.28E-­‐18	   8.53E-­‐11	   Yes	  
rs4886571	   15	   78833758	   CHRNA5	   15	   78857862	   6.28E-­‐18	   8.53E-­‐11	   Yes	  
rs4887062	   15	   78837801	   CHRNA5	   15	   78857862	   1.71E-­‐16	   2.32E-­‐09	   Yes	  
rs8053	   15	   78841220	   CHRNA5	   15	   78857862	   5.35E-­‐18	   7.26E-­‐11	   Yes	  
rs12907966	   15	   78843051	   CHRNA5	   15	   78857862	   8.04E-­‐18	   1.09E-­‐10	   Yes	  
kgp5396992	   15	   78844386	   CHRNA5	   15	   78857862	   8.04E-­‐18	   1.09E-­‐10	   Yes	  
rs3743077	   15	   78894896	   CHRNA5	   15	   78857862	   7.65E-­‐11	   1.25E-­‐04	   Yes	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(continued)  
Table  S5.3:  eQTL  which  are  also  GWAS  SNPs.  *  “kgp”  identifiers  designates  SNPs  from  1000  
Genome  Projects  pilot  
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SNP	   Chr	   Position	   Gene	   Chr	   TSS	   P-­‐value	   BBER-­‐adj	  FDR	   cis	  
kgp386011	   4	   145659198	   TIMM17A	   1	   201924619	   5.36E-­‐07	   2.20E-­‐04	   No	  
kgp3206674	   4	   145706070	   TGM4	   3	   44916100	   1.51E-­‐06	   7.32E-­‐04	   No	  
kgp1594216	   4	   145778772	   TGM4	   3	   44916100	   1.12E-­‐06	   4.60E-­‐04	   No	  
kgp386011	   4	   145659198	   MYL3	   3	   46923659	   1.53E-­‐06	   6.28E-­‐04	   No	  
kgp386011	   4	   145659198	   COPB2	   3	   139108574	   4.45E-­‐07	   1.83E-­‐04	   No	  
kgp386011	   4	   145659198	   MED12L	   3	   150803484	   7.97E-­‐07	   3.75E-­‐04	   No	  
rs6537319	   4	   145761160	   GABRA6	   5	   160974069	   2.24E-­‐07	   9.20E-­‐05	   No	  
kgp386011	   4	   145659198	   SP8	   7	   20826505	   1.03E-­‐06	   4.80E-­‐04	   No	  
kgp1594216	   4	   145778772	   FGF19	   11	   69519410	   5.26E-­‐07	   2.16E-­‐04	   No	  
kgp3206674	   4	   145706070	   FGF19	   11	   69519410	   7.45E-­‐07	   3.33E-­‐04	   No	  
Table  S5.4:  eQTL  of  HHIP  SNPs,  an  important  COPD  GWAS  region.  *  “kgp”  identifiers  
designates  SNPs  from  1000  Genome  Projects  pilot  
  
